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iABSTRACT
Despite the recent introduction of a number of new and more potent anti-
rejection drugs, the incidence of rejection and long-term graft survival remain
unchanged. There remains a significant difference in long-term graft survival
depending on the source of the donor. The purpose of this study was to
examine gene expression in the transplanted kidney using microarray
technology to identify potential biomarkers that could be used to predict and
monitor graft function so that appropriate interventions could be made in the
event of graft dysfunction.
Over a 5 year period RNA was extracted from 144 donor kidneys that were
transplanted. The initial attempts at probe preparation and hybridization were
unsuccessful. This led to the development of a new strategy which involved the
use of state-of-the-art microarray technology which embraced the advances
realised with the completion of the human genome project. Microarray data
was analysed using J-Express and Pathway studio. Significance analysis of
microarray, hierachical clustering, gene ontology mapping and pathway
analysis was performed.
The identification of potential biomarkers that had previously been described
by other authors validated this approach. In addition novel genes were
identified that may have a role as biomarkers of graft function. Other potential
biomarkers were identified that represented cellular processes that could be
modified by therapeutic intervention thus possibly changing the clinical
outcome or allowing monitoring of the success of therapy.
Confirmation of previously described biomarkers and the identification of
novel potential biomarkers has confirmed that gene expression profiling has a
valuable role in identifying processes that are indicative of disease processes
including those involved in kidney transplantation. Furthermore with the
development of minimally invasive tests to measure these biomarkers, we can
potentially change the natural history of the disease process, and hence,
preserve graft function and possibly prolong life.
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11 INTRODUCTION
Graft Survival in Kidney Transplantation
Despite the recent introduction of a number of new and more potent anti-
rejection drugs the incidence of rejection and long-term graft survival remain
unchanged.
Figure 1 - OPTN five year graft survival (deceased donor)
Figure 1 demonstrates Kaplan-Meier Graft Survival Rates for Transplants
performed between 1995 and 2002 [1]. Figure 2 shows the equivalent data for
graft survival of living donor grafts.
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2Figure 2 - OPTN five year graft survival (living donor)
For both deceased and living donors these plots show that graft survival at 1, 3
or 5 years has remained constant between 1995 and 2002. Approximately 90 %
of deceased and 95 % of living donor grafts survive at one year. Approximately
69 % of deceased and 79% of living donor grafts survive at 5 years [1].
At the same time the number of kidney transplants performed each year
remains about the same but the demand for transplantation i.e. the number of
patients on the transplant waiting list continues to steadily rise (see figure 3).
The reduction in numbers of organs made available from deceased donors is
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3being balanced by an increasing number of living donors. Non-heart beating
donors expand the donor pool and current legislation now supports altruistic
and paired organ donation [2]. These more recent forms of donation help the
“demand and supply” mismatch but fail to make a significant impact on the
transplant waiting list.
Figure 3 - Number of deceased donors and Transplants in the UK, 1996 – 2005 and Patients on
the active and suspended transplant lists at 31 December 2005
It is therefore imperative that when organs become available for
transplantation, they are optimally matched to the recipient in an environment
that is likely to determine a favourable outcome.
1.1 Factors that influence the outcome of transplantation.
1.1.1 Donor Factors
Donor factors include a host of variables some of which are relatively constant
(e.g. gender, blood group, donor category) with others being highly dynamic
(Cold ischaemic time, age, blood pressure); there are also the unknown factors.
This study will aim to produce results that corroborate previously identified
biomarkers and hopefully discover those that are unknown or have not
4previously been implicated in the pathological processes that lead to graft
dysfunction.
I. Constant Factors
a) Age
Transplantation outcomes were analyzed in 598 patients who received renal
transplants from 1979 to 2002. In the elderly donor group (age >50), graft
survival was 92.8% at 1 year; in the younger donor group (age<50), they were
93.4% (P= 0.02). Recipient age >50 years was not found to be an independent
risk factor [3]. Pessione found results to suggest that cerebrovascular cause of
death, history of hypertension, and elevated creatinine are significant
independent donor risk factors for graft survival, whereas donor age was a
statistically significant but dependent risk factor [4]. This result is important for
the design of allocation and transplantation strategies for kidneys procured in
elderly donors. Morrissey et al found that graft survival at 1, 2, and 3 years,
censored for death with graft function, did not differ when comparing older vs.
younger donors [5]. In living donation donor age was found to have no impact
on graft survival, however, function at 3 and 12 months was reduced in the age
65+ kidneys [6].
b) Gender
Oh et al found that the ‘recipient’ gender may be more important than the
‘donor’ gender for early graft function after adult living donor kidney
transplantation. The gender-related differences in post-transplant serum
creatinine and urine creatinine of recipients were associated with the
differences in the parameters of metabolic demands of recipients rather than
with the weight of implanted kidney or with the pre-operative renal function of
the donor. The early graft function was not determined by donor gender. The
effect of recipient gender on the graft function depended on the metabolic
demands, which are higher in male recipients. The effect of recipient gender on
early graft function depended on the metabolic demands which, on average,
were higher in male recipients [7].
5c) Blood group
Generally blood group has been accepted as a barrier to transplantation that
should not be crossed. This barrier has been successfully crossed in living
donation where the use of plasmapheresis and splenectomy has been used [8,
9]. More recently Ishida et al successfully used an immunosuppressive regimen
for ABO incompatible recipients, including the use of anti-CD20 and anti-
CD25 antibodies (Rituximab and Basiliximab) as an alternative to splenectomy
[10]. With respect to rhesus status Osman et al found that the Rh(D) blood
group system was not a clinically relevant histocompatibility barrier to living
donor renal transplantation [11].
d) HLA Mismatch
The outcome of a particular allograft is also influenced by the degree of MHC
match between donor and recipient. This has been shown in the rat model
where very different outcomes occur following liver transplantation depending
on the combination of strains used. In DA to Lewis rat liver transplantation,
rapid severe acute rejection occurs, whereas Lewis to DA results in
spontaneous tolerance. These pure-bred strains are termed high and low
responders, respectively [12]. Farges et al analyzed the cell infiltrate and
cytokine expression in these two models, but found very little difference. The
cell infiltrate in each case was the same and the only noticeable difference was
a reduction in IL-4 production in the tolerant group.
HLA Class II typing in was introduced in 1980 and there were general
improvements in tissue typing techniques for transplants after 1987. Terasaki et
al found that the 0 ABDR-mismatched grafts had a projected 20-year survival
of 40%. This fell progressively by 13% for each mismatch (up to 6) [13].
II. Dynamic Factors
a) Hypertension
Pre-existing long-standing hypertension in the donor was a strong independent
variable affecting both DGF and graft function in deceased kidneys at 1 year
[14]. Compared with controls, duration of HTN was an independent risk factor
6for graft survival. 3-year graft survival rates were 75% versus 65%; relative
risk = 1.36 in the hypertensive group (P < 0.001) [15].
b) Brain-Stem death
Brain-stem death usually occurs as a result of raised intra-cranial pressure as a
consequence of an intra-cerebral bleed. It is well recognised that brain death
induces an autonomic storm inducing cytokine release. This manifests as
bradycardia, hypertension and irregular breathing in spontaneously breathing
patients (Cushing reflex), followed by tachycardia, hypertension,
vasoconstriction and high plasma concentrations of catecholamines [16-18].
This can cause renal injury and has a deleterious effect on renal function [19].
Pratschke et al postulated that antigen independent factors may influence the
rate and intensity of host response following transplant [20]. He observed that
insults occurring around the time of organ transplantation become risk factors
for allograft failure and suggested that graft injury may be programmed even
prior to transplantation. Donor risk factors such as age, cause of death, donor
management, consequences of ischemia / reperfusion injury and brain death
trigger the graft into an immunologically active state [21].
c) Cold ischaemia time (CIT)
In a rat mode Tullius et al found that donor age and duration of cold ischemia
acted in a synergistic manner. Cold ischaemic times were of particular
relevance when grafts from older donors were used [22].
d) Warm ischaemia time (WIT)
Shiroki et al found that prolonged warm ischemia caused a chronic ongoing
process, leading to late graft failure in kidneys transplant from Non-Heart
Beating donors (NHBDs). They postulated that the response to prolonged
ischemic injury may increase graft immunogenicity and promote the chronic
changes seen in chronic rejection. Kidney grafts with an extremely prolonged
WIT had significantly poorer long-term survival [23].
71.1.2 Recipient Factors
a) Age
Older patients have a lower risk of acute rejection but a poorer death-censored
graft survival. This result is not explained by any combination of patient age
with donor age, delayed graft function or immunosuppression [24].
b) Underlying cause of renal failure
The aetiology of renal failure may have an impact on the graft outcome. For
example, focal segmental glomerulosclerosis (FSGS) is a condition in which
the filter units within the kidney are damaged and lead to proteinuria. In the
more severe cases end-stage renal failure ensues leading to the need for dialysis
of a kidney transplant. The overall recurrence rate of FSGS in the transplanted
kidney is 30% and is associated with increased rate of graft loss [25-27].
c) Pre-existing medical conditions, co-morbidities and performance status
Clearly a younger transplant recipient who has had a short lived primary
disorder is more likely to have a better prognosis than a more elder recipient
with for example the long term consequences of diabetes mellitus, ischemic
heart disease. Performance status is an objective system of measuring a patients
overall fitness for any medical procedure[28]. This measure has not been used
in relation to kidney transplantation and prognosis.
d) Immunosuppression
Variable pre-dose cyclosporin concentrations may be a risk factor for graft loss
[29]. The calcineurin inhibitors are known to be nephrotoxic at high
concentrations. Long term steroid use has well documented long term sequelae.
It can be seen that poly-pharmacy associated with immunosuppression and the
treatment of concurrent conditions can all have detrimental effects on graft
function and the overall health of a transplant recipient. The analyses of the
effects are combinations of immunosuppressants and other medications and
their effect on long term graft and patient survival are outside the scope of this
study.
8e) Hypertension
Early hypertension is common after renal transplantation. Early BP control has
the potential to influence the risk of allograft rejection and delayed graft
function[30]. Early post-transplantation systolic hypertension strongly and
independently predicts poor long-term graft survival in paediatric patients[31].
There are clearly many donor, recipient and environment variables that
interplay to result in the immune response. Some of these factors have a
common influence upon the immune response that manifests itself in the form
of acute rejection; a variable phenomenon which is usually has a detrimental
effect on the function of the graft.
1.2 Acute rejection
The effector limb of rejection consists of the mechanisms concerned with
actual graft damage and ultimate destruction and may be divided into the cell-
mediated or the antibody-mediated (humoral) response.
1.2.1 Acute cellular rejection
Cell-mediated graft destruction occurs once the inflammatory cell infiltrate has
migrated into the graft. The mechanism involves CD8 + T cells which exert
their cytotoxic effects following the recognition of foreign, endogenous antigen
in association with the MHC Class-I molecule by the T-cell receptor. Toxins,
such as Fas ligand and serine esterases are released, as are a group of
molecules called ‘perforins’. The perforins polymerise and form pores in the
membrane of the target cell, enabling granzyme, a protease which lyses
cytoplasmic components, and other toxins to enter. Although the cytotoxic
lymphocytes are capable of significant damage, recruitment of other non-
specific cells, such as leucocytes and natural killer cells produces the epithelial
damage seen in organ transplant rejection (e.g. tubulitis) with similar
inflammatory changes detectable in the endothelium of the graft vasculature.
91.2.2 The humoral response
The humoral immune response is based on the maturation of B-lymphocytes
and the production of antibodies (immunoglobulins (Ig)), bi-functional
molecules which bind antigen, via their Fab region, and activate further
immune functions via their Fc region. There are five Ig isotypes (IgG, 1gM,
IgA, IgD and IgE), each consisting of heavy chains, encoded on chromosome
 DQG HLWKHU ț RU Ȝ OLJKW FKDLQV HQFRGHG RQ FKURPRVRPHV  DQG 
respectively. Each chain is composed of one variable domain, forming the
antigen binding site, and constant domains.
B-cells produce the huge variation in antibody specificity like that of the T-
cell, by the rearrangement of Ig genes at the D (diversity), J (joining) and V
(variable) regions. Following this rearrangement, the immature B-cells express
the 1gM isotype on their surface with resultant mature B-cells expressing both
1gM and IgD antibody receptors of the same specificity. These mature cells
circulate the lymphatics if they fail to interact within a few days with the
antigen for which they are specific; they are removed by the spleen. If,
however, the surface Ig receptors come into contact with antigen, the B- cell
undergoes differentiation, with T-cell help, becoming either the antibody-
producing plasma-cell (under the influence of IL-6) or a memory B-cell.
Memory cells arise under the influence of IL-5 and circulate, expressing high-
affinity antigen receptors, enabling the rapid production of antibody on future
encounter with the specific antigen. If antigen cross-links the surface Ig
receptors, the B-cells increase in size, undergo DNA synthesis and the antigen
is internalised and re-expressed as exogenous peptide in association with MHC
Class-II; the B-cell is functioning as an APC.
Antibodies which are damaging to the transplanted organ are of the cytotoxic
IgM and IgG isotypes, effective activators of the classical complement cascade.
Following antigen binding, the Fc region of the antibody binds and initiates the
soluble serum proteins of the complement cascade. These subsequently form
the C3- and C5- convertase enzymes and the final, lytic membrane attack
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complex (MAC which is similar to the perforins released by cytotoxic
lymphocytes.
In renal transplantation, antibodies specific for HLA Class I molecules are
clinically significant (see Tissue-typing and cross-matching) and reports of
antibodies specific for endothelial cell molecules causing graft loss, even
hyperacute rejection, are accumulating [32]. The role of antibodies post-
transplantation, in acute rejection, remains controversial. The established view
is that antibody is unimportant, the dominant pathway of damage being exerted
by the cytotoxic lymphocytes. However, in at least one rat combination,
antibody has been shown to b capable of causing acute rejection in the absence
of cytotoxic lymphocytes. There has also been recent data linking antibody
with a possible role in chronic rejection[33]. It has been suggested that current
immunosuppression by targeting T helper 1 responses may cause a natural
deviation of the immune response to the T helper 2 pathway and antibody
production [34, 35].
It is important, therefore, to minimise the mismatch in HLA class I and II
molecules in an attempt to diminish potential adverse reactions. This is
partially achieved with tissue typing and cross-matching.
1.3 Tissue typing and cross-matching
HLA (Human Lymphocyte Antigen)
The hypothesis that matching the HLA Class-I and Class-II status of both
donor and recipient would reduce the immunogenicity of the graft and,
therefore, the number and severity of rejection episodes, led to the introduction
of pre-transplant tissue typing. In kidney transplantation, the current practice is
to type and match for HLA-A and B (Class-I) and HLA-DR (Class-II).
Because each individual possesses two specificities for each, this means
matching for six alleles. Large population studies, have shown improved long-
term survival when five or six of the HLA antigens are matched [35]. The
benefit of matching for liver and cardiac transplantation is much less clear-cut
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and currently no prospective matching, other than blood group ABO, takes
place for these organs.
a) Lympho-Cytotoxicity Test
The basic serological test used in the tissue-typing laboratory is the lympho-
cytotoxicity test (LCT) whereby complement fixation with resultant cell lysis
indicates the presence of specific antibody or antigen. In order to determine a
tissue type, antibodies (monoclonal or polyclonal) of known specificity are
incubated with lymphocyte fractions harvested from peripheral blood. T cells,
which constitute 85% of peripheral blood lymphocytes (PBLs), are used to type
for Class-I antigens and are separated from the non-T-cell /B-cell fraction,
expressing Class-II, by either sheep red blood cell rosetting or density gradient
techniques.
b) ABO Blood Groups
In kidney transplantation ABO matching is insufficient because rapid rejection
responses due to circulating cytotoxic donor-specific HLA-antibodies can
cause an equally damaging effect. In the mid-1960s, the cross-match was
introduced into kidney transplantation whereby donor lymphocytes, harvested
either from peripheral blood lymphocytes or from the spleen, are incubated
with serum from the potential recipient. In addition to this immediate pre-
transplant test, the antibody profiles of future recipients may be constructed by
incubating sequential serum samples against a panel of HLA-typed
lymphocytes.
c) Panel-Reactive Antibody
This panel-reactive antibody (PRA) screening determines the presence and
specificity of HLA-alloantibodies and is, therefore, useful in organ allocation.
The original LCT principle is still commonly applied to both the cross-match
and PRA but sensitivity and specificity have been improved by the
development of flow-cytometric and immunoassay methods.
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These technologies, although primarily developed for the antibody assessment
of kidney transplant patients, have been used to investigate whether donor-
specific HLA antibodies are deleterious in other transplant settings. Hyperacute
rejection is rare in heart and almost unknown in liver transplantation despite 7-
33% of waiting-list patients known to harbour cytotoxic HLA-antibodies [36].
The ability of the liver to counteract the presence of cytotoxic allo-antibodies
has been shown to extend to protection of a kidney graft even in the presence
of a positive crossmatch if combined liver and kidney transplantation is
performed. The mechanism of this protection remains unknown. One
hypothesis is based on the production by the liver of a soluble form of MHC
Class I molecules, which has been postulated to play a role in protecting the
liver by swamping the recipient’s immune system with foreign antigen. This
may be one of the mechanisms that help to explain the phenomenon known as
tolerance.
1.4 Tolerance
When applied to an allograft the definition of tolerance is the co-existence of a
transplanted organ or tissue within a recipient without the need for continuous,
long-term immunosuppression. This is specific with the immune system being
otherwise unimpaired in its protective functions, but the graft is not necessarily
free of inflammatory cells. It is also durable, being unaffected by other
unrelated stimuli which may activate the immune system of the recipient.
Achieving tolerance in a clinical setting would be the ‘holy grail’ of transplant
immunology which clinicians and scientists are working There are some recent
clinical trials, which have come close to achieving it[37], and there are many
reports of tolerant patients from historical series[38].
i. Deletion
Deletion (with or without chimerism) occurs in a manner similar to the
development of self-tolerance. The term ‘chimerism’ is used to describe a state
where donor cells survive long-term in the recipient so that the recipient’s
immune system becomes unresponsive to the donor cells after deletion of the
reactive donor clone.
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ii. Co-stimulatory blockade
Blockage of co-stimulation has been reliably achieved using a variety of
monoclonal antibodies to co -stimulatory receptors or their ligands such as
CD28 and CD40 Examples include CTLA4-Ig, which binds to B7.1 and 2, and
anti-CD154 (CD40 ligand) which blocks T-cell interaction with CD40-
expressing B-lymphocytes. This T-cell mediated suppression has been shown
to be transferable to naive animals. The presence of a graft has been shown to
render the naive cells tolerant rather than simply suppressed
iii. Development of regulatory cells.
Sir Peter Medawar was awarded the Nobel Prize for his experiments
demonstrating long-term donor-specific tolerance by injection of bone marrow
into neonatal mice. After falling into disrepute as a theory in the 1980s, recent
data has convincingly shown that it is possible, in certain circumstances, to
induce the formation of suppressor cells which prevent rejection from
occurring.
Tolerance induction in experimental animal models has a long history. There
are many examples of tolerance induction in animal models by these three
methods. In order to achieve tolerance it is likely that a combination of these
methods will need to be used. Sir Peter Medawar achieved tolerance in his
initial experiments because he used neonatal animals. The transplanted bone
marrow populated the thymus together with the recipient’s native bone
marrow; leading to the elimination of donor reactive T-cell clones in the same
way that self-tolerance is achieved.
Another mechanism for tolerance induction is by overwhelming the immune
response by donor antigen. This is based on the observations in liver
transplantation where an allograft can be accepted when there is a full MHC
mismatch[39], and the ability of the liver to partially protect a kidney from
cytotoxic antibodies in a combined transplant[40]. Evidence from multiple
heart and kidney transplants in one animal suggests that the T-cell response can
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be turned off by overwhelming the system with large amounts of antigen,
leading to apoptosis of the reactive T cell clones.
One result of this extensive experience with the animal models is that it has
become clear that tolerance induction is dependent on lymphocytic infiltration
of the allograft. This has given rise to the idea that many current
immunosuppressive regimens using calcineurin blockers may actually hinder
the development of tolerance.
Tolerance reflects a modification in the host’s immune response to transplanted
tissue. Development of a tolerant state requires the otherwise immunogenic
graft to be accepted by the host by one or a combination of the mechanisms
proposed above. Factors are required, therefore, to interact between the graft
and the host in order to modify the immune response. These factors are known
as cytokines
1.5 Cytokines and chemokines
The role of the soluble mediators released by a variety of cells during rejection
was relatively under-studied for a long time because of the complexity of the
interactions involved. Much new knowledge has been gained recently by
applying new molecular techniques such as polymerase chain reaction (PCR)
and in situ hybridization to characterize the cytokines and chemokines
produced during rejection.
1.5.1 Cytokine Classification
Cytokines are small soluble proteins, and exert their effects by binding to
specific receptors on the surface of their target cells. These produce functional
changes brought about by protein synthesis. They are involved in the activation
and regulation of the immune response to a stimulus. In transplantation,
important cytokines include interleukins (e.g. IL-1, IL-2, IL-4, IL-6, IL-9, IL
10, IL-15) and the interferons (e.g. IFN-Ȗ &HUWDLQ F\WRNLQHV ZKLFK SOD\ DQ
important role in chemo-attraction, are termed chemokines (e.g.
RANTES).These can be divided into four subfamilies distinguished by
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positions of N-terminal cysteines: C, CC, CXC and CXXXC, the two important
ones being the CXC chemokines (e.g. IL-8) and the CC group (RANTES,
MCP-1, 2). The CXC chemokines induce migration of neutrophils / monocytes
/ T-lymphocytes and other cell types whereas the CC group predominantly
stimulates and attracts monocytes/ macrophages and T-cells [41]. CXXXCR1
is unique among chemokine receptors in functioning directly as a cell-cell
adhesin, CX3CR1 mRNA is expressed at highest levels in brain, but it is found
in all organs. The only known ligand is fractalkine. There is only one member
of the C family, XCR1 (also known as GPR5). The receptor is specific for the
T lymphocyte directed molecule lymphotactin. It was postulated to have a
potential role in cancer therapy due to the ability of lymphotactin to synergize
with IL-2 in producing an anti-tumour immune response [42].
1.5.2 T-cell growth factors (Interleukins)
A group of cytokines of particular interest in transplantation is the T-cell
growth factors (TCGFs) IL-2, 4, 7, 9 and 15. IL-2 is produced by activated T-
cells and causes proliferation and differentiation of both T- and B-cells. Other
immune cells, such as NK and dendritic cells, also express a receptor for IL-2
although the precise consequences of this interaction are not fully understood
IL-2 expression is regulated at the transcriptional level and is blocked by
calcineurin inhibition which is the basis by which the most effective current
immunosuppressants cyclosporin and tacrolimus prevent rejection. Stimulation
of T-cells without the ability to produce IL-2, or where the ability bas been
blocked by monoclonal antibody can result in a state of anergy or
unresponsiveness. IL-4 is produced by TH cells, basophils and mast cells and is
important for TH differentiation. IL-9 is produced by TH cells and is a potent
growth factor for cultured but not fresh primary T-cells, suggesting that its
activity may be related to the activation state of the T-cell. IL-7 has a pivotal
role in intrathymic T-cell development. IL-15 possesses very similar biological
ties to IL-2, but crucially is produced by cells other than T-lymphocytes
(activated macrophages, epithelial and endothelial cells), and is not blocked by
calcineurin inhibitors. It is regulated at both transcription and translational
levels.
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TCGFs play a critical role in regulating multiple aspects of immune activation,
which have been investigated using mice with single gene knock-out (KOs).
For example, IL-2 knock-out animals are not immunodeficient by developing
lymphoproliferation and autoimmunity. Mice lacking IL-7, which is crucial to
T-cell maturation, develop both immunodeficiency and lymphopaenia. In
contrast to IL-2, IL-15 KOs develop lymphopaenia and impaired lymphocyte
activation, it therefore appears that IL-15 is involved in the normal homeostasis
of peripheral lymphoid tissue.
There is a large degree of redundancy in the system. IL-2-deficient mice can
mount a vigorous acute rejection response, and the same applies to blockage of
IL-4, 7, and 15. IL-2 also plays an important role in priming activated T-cells
to undergo apoptosis, and therefore it may also have paradoxical role in the
acquisition of peripheral tolerance. The use of calcineurin based
immunosuppression may potentially reduce the chance of tolerance occurring.
Cytokines also regulate the production and function of each other; IL-4
antagonizes both the proliferation and differentiation of B-cells and
lymphokine-activated killer cells by IL-2. IL-10 prevents IFN-Ȗ DQG ,/-2
synthesis but this is an indirect effect through macrophages. This complicated
cross-regulation may be helpful in controlling rejection and may have a
possible role in the induction of tolerance.
Variation in the response to disease between a delayed-type hypersensitivity
and humoral response has been related to different patterns of cytokine
production. Originally demonstrated in the mouse different immune responses
have been linked to specific T-cell clones. A T-helper 1 response is
characterized by the production of IL-2, IFN-ȖDQG71)-13 and is seen when
delayed-type hypersensitivity predominates. A T-helper 2 response is
associated with IL-4, IL-5, IL-6 and IL-13 and is seen when antibody
production is predominant. The T-helper 1 cytokine profile has been associated
with acute rejection. In humans, the picture is less clear and the type of
cytokine profile that produced is dependent upon the type of stimuli and many
environmental factors surrounding each immune event. Naive T-cells have the
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ability to produce either pattern of cytokines, so that differentiation into T-
helper 1 and T-helper 2 subsets is not fixed in an individual cell. It appears that
the method of antigen presentation and the mix of other stimulatory factors
determine whether a T-helper 1 (primarily associated with cell-mediated
immunity) or a T-helper response 2 (anti-body production) occurs.
1.5.3 Chemokines
Chemokines (especially RANTES) have been shown to have an important role.
It is expressed 3 days after T-cell activation and is a chemo-attractant for
monocytes, and memory T-cells. It results in the accelerated formation of the
immune over a larger area. It has been shown to be involved in the recruitment
of monocytes and T-lymphocytes in acute rejection, being produced by
fibroblasts and tubular epithelium after activation by IL-1 and TNF-Į produced
by macrophages. There is also some evidence that it plays a role in the
development of chronic rejection as it is present in large amounts in the early
stages of chronic rejection.
Clinically, cytokine levels are difficult to interpret because their importance
lies in the local environment so that systemic levels may not accurately reflect
what is occurring locally. They are measured by ELISA (enzyme-linked
immunosorbant assay) which gives accurate serum and plasma levels in
picograms. Dallman et al demonstrated a relationship between IL-2 mRNA
expression and acute rejection in fine-needle aspiration samples from renal
allografts[43]. In general, however, studies of serum levels of a variety of
cytokines have failed to distinguish reliably between rejection and infection.
1.5.4 Cytokines that mediate and regulate innate immunity
a) Type I interferons
There are three main types of interferon that are produced by human cells:
interferon alpha, interferon beta, and. There is also an older system of
nomenclature, that divides interferons into two types: type I interferons
(interferon alpha and interferon beta) mainly produced by fibroblasts, epithelial
cells and macrophages.
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There are at least 25 sub-types of IFN-Į. They are comprised of 166 amino
acids and are mainly produced by leukocytes. Its receptor is a Type I multi-
subunit receptor.
There is only one type of IFN-ȕ which is contains166 glycosylated amino
acids. It is mainly produced by fibroblasts, epithelial cells and macrophages.
Interferon beta produced in mammalian cells is interferon beta-1a; interferon
beta-1b is produced in bacteria.
b) Interferon gamma
The receptor for IFN-ȖKDVWZRVXEXQLWVWKHOLJDQG-binding chain (the Į chain)
and the signal-transducing chain (the ȕ chain). As the ligand-binding (or Į)
chains interact with IFN-Ȗ WKH\ GLPHULVH DQG EHFRPH DVVRFLDWHG ZLWK WZR
signal transducing (or ȕ) chains which leads to activation of the Janus kinases
JAK1 and JAK2.
c) Tumour necrosis factor-Į
Tumour necrosis factor-Į (TNF- Į), also known as cachectin, There are two
TNF-receptors: TNF-RI (55kDa) and TNF-RII (75kDa), 19 ligands and 29
receptors that belong to the tumour-necrosis factor (TNF) superfamily have
been identified.
d) Interleukin 1
Interleukin 1 (IL-1) is a general name for two proteins, IL-1a and IL-1b, the
first of a small family of regulatory and inflammatory cytokines[44]. Along
with IL-1 receptor antagonist (IL-1ra) and IL-18, these molecules play
important roles in the up- and down-regulation of acute inflammation [45] .In
the immune system, the production of IL-1 is induced, generally resulting in
acute inflammation. IL-1b and TNF-a are generally thought of as prototypical
pro-inflammatory cytokines. The effects of IL-1, however, are not limited to
inflammation, as IL-1 has also been associated with bone formation and
remodelling [46]insulin secretion[47] appetite regulation[48]fever
induction[49]. IL-1 has also been known by a number of alternative names,
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including lymphocyte activating factor, endogenous pyrogen, catabolin,
hemopoietin-1, melanoma growth inhibition factor, and osteoclast activating
factor.
Human IL-1a and IL-1b are synthesized as 31-33 kDa, variably glycosylated
pro-cytokines. Although the pro-forms have no known biological activity, there
may be a regulatory interaction between the pro- and mature segments both
before and after cleavage. IL-1a and IL-1b exert their effects by binding to
specific receptors. Two distinct IL-1 receptor binding proteins, plus a non-
binding signalling accessory protein have been identified. Each have three
extracellular immunoglobulin-like domains, qualifying them for membership to
the type IV cytokine receptor family. IL-1 is expressed by many cells and has
multiple functions including local inflammation.
e) Interleukin 6
Interleukin 6 (IL-6) may be considered the prototypic pleiotrophic cytokine.
IL-6 induces cellular differentiation or expression of tissue-specific genes; it is
involved in processes such as antibody production in B cells, acute-phase
protein synthesis in hepatocytes, megakaryocyte maturation, cytotoxic T cell
differentiation, and neural differentiation of PC12 (pheochromocytoma) cells.
This is reflected in the variety of names originally assigned to IL-6, including
Interferon b2, Hepatocyte Stimulating Factor, Cytotoxic T-cell Differentiation
Factor, B cell Differentiation Factor (BCDF) and/or B cell Stimulatory Factor 2
(BSF2). Once all the activities associated with the various names for IL-6
became connected with one common gene, the name IL-6 was proposed for
this molecule A number of cytokines make up an IL-6 cytokine family.
Membership in this family is based on a helical cytokine structure consisting of
two polypeptide chains, a ligand-binding chain (IL-6R) and a non-ligand-
binding, signal-transducing chain (gp130)[50].
f) Interleukin 10
(CSIF/Cytokine Synthesis Inhibitory Factor)
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All mature IL-10 family members have an Į-helix common to their structure.
IL-10 is involved in mast cell proliferation and mediates leukocyte secretion
and chemotaxis[51]. On T cells, IL-10 inhibition of IFN-g production is
mediated indirectly by accessory cells [52]. Additional effects on T cells,
include: IL-10 induced CD8+ T cell chemotaxis[53], an inhibition of CD4+ T
cell chemotaxis towards IL-8,[51] suppression of IL-2 production following
activation[54], an inhibition of T cell apoptosis via Bcl-2 up-regulation,[55]
and an interruption of T cell proliferation following low antigen exposure
accompanied by B7/CD28 co-stimulation[56].
IL-10 has a number of related but distinct functions on B cells. In conjunction
with TNF-ȕ and CD40L, IL-10 induces IgA production in naïve (IgD+) B
cells. It is believed that TGF-ȕ/CD40L promotes class switching while IL-10
initiates differentiation and growth[57]. CD27/CD70 interaction in the
presence of IL-10 promotes plasma cell formation from memory B cells[58].
On mast cells, IL-10 induces histamine release while blocking GM-CSF and
TNF-Į release. This effect may be autocrine as IL-10 is known to be released
by mast cells in rat[59].In support of its pleiotrophic nature, IL-10 has the
opposite effects on NK cells. Rather than blocking TNF-a and GM-CSF
production, IL-10 promotes this function on NK cells[60]In addition, it
potentiates IL-2 induced NK cell proliferation and facilitates IFN-ȖVHFUHWLRQLQ
NK cells primed by IL-18[61]In concert with both IL-12 and/or IL-18, IL-10
potentiates NK cell cytotoxicity[61].
IL-10 has a distinct anti-inflammatory impact on neutrophils. It inhibits the
secretion of the chemokines MIP-1Į, MIP-1ȕ and IL-8[62]and blocks
production of the pro-inflammatory mediators IL-1ȕ and TNF-Į[63]. In
addition, it decreases the ability of neutrophils to produce superoxide, and as a
result interferes with PMN mediated antibody-dependent cellular
cytotoxicity[64].
On dendritic cells (DCs), IL-10 exhibits immunosuppressive effects.
Macrophages, although phagocytic, are poor antigen-presenting cells and IL-10
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seems to decrease the ability of DCs to stimulate T-cells (particularly Th1 type
cells) [65]. Relative to MHC type II expression, it can be down-regulated[66],
unchanged[67], or up-regulated[68]. At the regional level, IL-10 may block
immunostimulation by inhibiting Langerhans cell migration in response to pro-
inflammatory cytokines [69]. Alternatively, IL-10 blocks an inflammation-
induced DC maturation, which results in a failure of DCs to migrate to regional
nodes. The result is an immobile DC that will not stimulate T cells but will
bind and therefore eliminate pro-inflammatory chemokines without responding
to them[70]
IL-10 has a number of documented effects on monocytes. For example, IL-10
seems to reduce cell surface MHC type II expression[71] and also inhibits IL-
12 production following stimulation. The connective tissue component
Hyaluronectin, is now known to be secreted by monocytes in response to IL-
10, which may have some importance in cell migration, where hyaluronectin is
known to interrupt cell migration through the extracellular space[72].
g) Interleukin 12
IL-12, a cytokine produced by macrophages and B lymphocytes, has multiple
effects on T-cells and NK cells, including stimulation of cytotoxic activity,
proliferation, and promotion of Th1 development and IFN-gamma and TNF
production [73, 74]The pleiotropic functions of IL-12 on T cells and NK cells
include stimulation of cytotoxic activity, proliferation, and promotion of Th1
development[75].
h) Interleukin 15
Interleukin 15 (IL-15) is a novel cytokine that shares many biological
properties with, but lacks amino acid sequence homology to, IL-2. IL-15
encodes a 162 amino acid precursor protein that is cleaved to generate the 114
aa residue mature IL-15. Although the structure of IL-15 has not been
determined, it is predicted to be similar to IL-2 and other members of the four-
helix bundle cytokine family[76].
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High-affinity cell surface receptors for IL-15 have been detected on a variety of
T cells and B cells, as well as non-lymphoid cells[77]. the beta and the gamma
common chain subunits of the high-affinity IL-2 receptor complex are also
required for IL-15 signal transduction and efficient internalization [77]. IL-15R
alpha shares structural similarities with IL-2R alpha and Soluble IL-2R beta
appears to bind human IL-15 with sufficiently high affinity making it an
efficient IL-15 antagonist.
IL-15 mRNAs have been detected in a number of human tissues and cell types,
including heart, lung, liver, placenta, skeletal muscle, adherent peripheral blood
mononuclear cells, and epithelial and fibroblast cell lines. However, IL-15
mRNA is not detectable in activated peripheral blood T cells that contain high
levels of IL-2 mRNA [77, 78]. Despite high levels of IL-15 mRNA being
present in adherent peripheral blood mononuclear cells, IL-15 protein does not
appear to be detectable in culture supernatant using a sensitive ELISA.
IL-15 has biological activities similar to IL-2 and has been shown to stimulate
the growth of natural killer cells, activated peripheral blood T lymphocytes[77,
78], and B cells[79]. In addition, IL-15 has also been shown to be a chemo-
attractant for human blood T lymphocytes [80] and to be able to induce
lymphokine-activated killer (LAK) activity in NK cells.
By virtue of its activity as a stimulator of T cells, NK cells and LAK cells, IL-2
is currently in clinical trials testing its potential use in treatments for cancer and
for viral infections. Because of its similar biological activities, IL-15 should
have similar therapeutic potential.
1.5.5 Cytokines that mediate and regulate specific immunity
a) Interleukin 2
IL-2 is a monomeric, secreted glycoprotein with a molecular weight of 15 kDa.
It exists in a globular structure with four Į-helices folded in a configuration
typical of the Type I cytokine family. IL-2 was discovered in 1975 as a growth
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factor for bone marrow-derived T lymphocytes [1]. It was one of the first
cytokines to be characterized at the molecular level. IL-2 exhibits a large
number of pleiotropic effects on numerous target cells.
Cell type Primary activities of IL-2
CD4
+
T cells
Induces expansion of antigen-specific clones via both proliferative and
anti-apoptotic mechanisms.
Augments production of other cytokines
Required for differentiation to Th1 and Th2 subsets
Induces apoptosis of activated T cells via Fas/FasL signalling
(activation-induced cell death)
Involved in development of CD4
+
CD25
+
T regulatory cells (?)
CD8
+
T cells
Induces expansion of antigen-specific clones
Augments cytokine secretion
Augments cytolytic activity
Induces proliferation of memory CD8
+
cells
B cells
Enhances antibody secretion
Initiates immunoglobulin J chain transcription and synthesis
Promotes proliferation
NK cells
Promotes proliferation
Augments cytokine production
Enhances cytolytic activity
Table 1 - Primary activities of IL-2
i. T-cell activation
IL-2 exerts its effects on many cell types, the most prominent of which is T-
cell activation which rapidly leads to the de novo synthesis of IL-2. This is
followed by expression of a high affinity IL-2 receptor permitting rapid and
selective expansion of effector T cell populations activated by antigen[81]. A
major function of IL-2 is to promote proliferation of both CD4+ and CD8+ T
cells. IL-2-induced proliferation occurs via pro-proliferative signals through
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the proto-oncogenes c-myc and c-fos, in combination with anti-apoptotic
signals through Bcl-2 family members [82]. More recently, it has become clear
that, in addition to anti-apoptotic signals, IL-2 also exerts effects on cellular
metabolism and glycolysis that are necessary for long-term survival of T
cells[83].
ii. Down-regulation of immune Reponses
Paradoxically, studies in IL-2 knockout mice have revealed that perhaps the
most important activity of IL-2 is to down-regulate immune responses in order
to prevent autoimmunity. These inhibitory effects of IL-2 create a negative
feedback loop that is achieved by several mechanisms. Production of IL-2 is
quite transient and so in the absence of continued antigenic stimulation,
activated T cells die due to cytokine deprivation. Second, IL-2 initiates
apoptosis through enhancing FasL expression on activated T cells. additionally
there is good evidence that IL-2 may act during thymic development to prevent
autoimmunity, probably by influencing the development of CD4+CD25+ T
regulatory cells [84].
iii. Growth factor action
IL-2 is also a growth factor for natural killer (NK) cells together with IL-15,
which signals through an essentially identical receptor [85]. IL-2 promotes
production of NK-GHULYHG F\WRNLQHV VXFK DV 71)Į ,)1Ȗ DQG *0-CSF.
Furthermore, IL-12 and IL-2 act synergistically to enhance NK cytotoxic
activity [86].
iv. Antibody production
In B cells IL- 2 has been associated with facilitating antibody secretion. In
IgM-expressing B cells, IL-2 (along with IL-5) up-regulates expression of
heavy and light chain genes as well as inducing de novo synthesis of the
immunoglobulin J chain gene [87]. The latter is required for oligomerization of
the IgM pentamer, and represents a tightly controlled stage in B cell activation
[22]. As in T cells, IL-2 increases expression of IL-2RĮ in B cells, enhancing
their responsiveness to IL-2[88]].
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Inhibition of IL 2
Calcineurin is the target of several potent immunosuppressive drugs (including
cyclosporin A and rapamycin), which suppress T cell activity by inhibiting IL-
2 secretion.
The majority of IL-2 is derived from activated CD4+ T cells. Whereas most or
all T cells produce IL-2 immediately following antigen stimulation, only the
Th1 subset produces it in large amounts after T helper cell differentiation [43].
In addition, CD8+ T cells also secrete substantial quantities of IL-2 after
stimulation of their T cell receptors.
A number of drugs act at various points in the TCR signalling pathway to block
IL-2 production. For example, cyclosporin A (CsA) is a cyclic oligopeptide
and a potent immunosuppressant that blocks the activity of calcineurin, and
thus prevents NFAT from gaining access to the nucleus. Rapamycin and
FK506, other common immunosuppressants in clinical use, also block
calcineurin, although by a different mechanism [54], [55] and [56].
IL-2 is crucial for the maintenance of immune homeostasis. First, IL-2 is
important for the clonal expansion of most types of activated T cells. IL-2 is
vital for determining the magnitude and duration of primary and memory
immune responses. Second, IL-2 plays a central role in down-regulating
immune responses. Its absence results in severe autoimmunity due to a failure
to eliminate activated T cells [89]. Third, IL-2 opposes IL-15 in maintaining
CD8+ T cell memory responses [90]. Finally, recent studies have indicated that
a major function of the IL-2/IL-2 receptor system lies in directing development
and function of T regulatory cells [91].
A number of agents Cyclosporin A, tacrolimus (FK506) and sirolimus
(rapamycin) target IL-2 production and/or the IL-2 signalling cascade. Anti-IL-
2RĮ antibodies are also currently used in anti-rejection regimens for kidney
transplantation, by specifically blocking IL-2-mediated signalling through high
affinity receptors[92].
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b) Interleukin 4-see IL-13
c) Interleukin 5
Human IL-5 is a 134 amino acid (aa) polypeptide with a predicted mass of 12.5
kDa Although many cells contribute to the general process known as
inflammation, eosinophils are noted for their contribution to late phase allergic-
type disorders. Interleukin 5 (IL-5), is a key player in the co-ordination and
orchestration of eosinophil-based inflammatory processes[93].
d) Interleukin 13
Interleukin 13 (IL-13) is closely related to interleukin 4 (IL-4). They display
overlapping functions, and the genes for the human proteins are both found on
chromosome 5q. IL-13 is produced by activated Th0, Th1-like cells, Th2-like
cells and CD8-positive T cells. IL-13 has multiple effects on the differentiation
and functions of monocytes/macrophages. It can suppress the cytotoxic
functions of monocytes/macrophages, the production of pro-inflammatory
cytokines, and up-regulate the production of IL-1rĮ. The similarities and
overlapping functions of IL-4 and IL-13 led to interest in the components of
the IL-13 receptor (IL-13R) complex and the relationship of IL-13R to the IL-4
receptor (IL-4R). The IL-4RĮ chain plays an important role in IL-13 signalling,
despite it having a low affinity for IL-13[94].
e) Interleukin 16
Interleukin 16 (IL-16) is a pro-inflammatory cytokine that is chemotactic for
CD4+ T lymphocytes, monocytes and eosinophils. In addition to inducing
chemotaxis, IL-16 can up-regulate IL-2 receptor[95] and HLA-DR4 expression
and inhibit T cell receptor (TcR)/CD3-dependent activation[96]. 7 IL-16 is a
unique cytokine with no significant sequence homology to other well-
characterized cytokines or chemokines. IL-16 was originally identified as a
homotetramer consisting of individual 14 kDa monomers of 130 amino acids
(aa) each. The gene for IL-16 maps to chromosome 15.
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CD4 serves as a signal-transducing receptor for IL-16. Expression of CD4 is
required for mediating IL-16 functions[96]. Interaction between IL-16 and
CD4 can specifically initiate an increase in intracytoplasmic calcium and
inositol trisphosphate and translocation of protein kinase C from the cytosol to
the cell membrane. IL-16-induced functions can be inhibited by a monomeric
Fab of an anti-CD4 (OKT4) monoclonal antibody[97].
Sources of IL-16 include epithelial cells, mast cells, lymphocytes,
macrophages, synovial fibroblasts, and eosinophils. IL-16 mRNA is
constitutively expressed in both CD4+ and CD8+ cells, however, synthesis is
induced in T lymphocytes upon exposure to antigen. IL-16 may also be
secreted by activated CD8+ cells in response to histamine or serotonin.
f) Interleukin 17
IL-17 (also known as CTLA-8 (cytotoxic T cell lymphocyte-associated
antigen)) is a variably glycosylated, 20-30 kDa homodimeric polypeptide
reportedly secreted by CD4
+
activated memory (CD45
+
RO
+
) T cells.
5, 14
The
IL-17 gene codes for a 155 amino acid residue protein that consists of a 19 aa
residue signal sequence and a 136 aa residue mature segment.
It is suggested that IL-17 may be a major vehicle by which T cells
communicate with the haematopoietic system. In particular, fibroblasts, when
cultured in the presence of IL-17, are able to sustain CD34
+
haematopoietic
progenitor cells and direct their maturation towards neutrophils[98], IL-17 has
been demonstrated to induce IL-6, IL-8 and G-CSF production by fibroblasts
(and endothelium), and these three cytokines are known to impact
haematopoiesis[99].
g) Interferon-Ȗ
IFN-gamma, a 34 kDa homo-dimeric glycoprotein, is essentially restricted to
activated CD4+ Th1 T cells, CD8+ T-T cells, and NK cells[100]. For each cell
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type, IFN-gamma secretion is further restricted by the availability of IFN-
gamma-inducing cytokines such as IL-12 and TNF-alpha, which arise from
accessory cells following activation[100]. One of the most important
consequences of IFN-gamma secretion is the activation of macrophages. This
is achieved through the induction of reactive oxygen intermediates and
nitrogen monoxide (NO), which activate a variety of anti-bacterial, anti-tumour
and anti-viral responses[100]. In addition, IFN-gamma contributes to
endothelial cell activation, Th1 cell development, and up-regulation of MHC
expression on both professional APCs and non-APCs. This makes the
regulation of IFN-gamma an extremely important step in the overall scheme of
an inflammatory response[100].
h) TGF-beta
Transforming growth factor beta (TGF-beta) is a stable, multifunctional
polypeptide growth factor. Specific receptors for this protein have been found
on almost all mammalian cell types. The function of the molecule varies
depending on the cell type and growth conditions. Generally, TGF-beta is
stimulatory for cells of mesenchymal origin and inhibitory for cells of
epithelial or neuroectodermal origin. TGF-beta, (known as TGF-beta1) is only
one of a family of regulatory proteins consisting of a number of proteins
distantly related to TGF-beta 1 (30 - 40% sequence homology) and a number
of more closely related proteins (70 - 80% sequence homology).
TGF-beta1 is thought to be important in the pathogenesis of chronic allograft
nephropathy. Although the cause of CAN is not fully understood, TGF-beta1
may be one important since this cytokine promotes fibrosis by stimulating the
production of extracellular matrix components, such as collagen and
fibronectin. Sharma et al found a significant correlation between TGF-beta1
mRNA levels and renal allograft interstitial fibrosis and chronic allograft
nephropathy [101]. Low TGF-beta production in donor-recipient combinations
mismatched for TGF-beta genotype has been associated with risk for early
rejection and poorer graft function at 4 years [102]. Ochsner et al postulate that
29
tailoring immunosuppressive therapy according to the TGF-beta1 genotype
might result in improved long-term function [103].
1.6 Historical overview of the development of immunosuppresion
1.6.1 The First Kidney Transplant.
In 1954, the first successful kidney transplant between identical twins was
performed by Joseph E. Murray and J Hartwell in the Peter Bent Brigham
Hospital in Boston, USA[104]. The first successful kidney transplant in UK
was performed in Edinburgh by Sir Michael Woodruff and his team on 30th
October, 1960. However, the early years were known as “the black years” due
to the consistently high graft failure and patient mortality rates [105] .
1.6.2 Strategies to overcome the immune system.
The biological response to transplanted organs involves both the major
histocompatibility (MHC) complex, which modulates rejection, and variable
expression of chemokines and cytokines in the recipient. The overall
interaction ultimately determines the type and degree of immune
responsiveness to the foreign tissue. There have been various attempts to
suppress the immune response which have over time become more targeted.
1.6.2.1 Total body irradiation
The initial successes were in identical twins, overcoming non-identical HLA
mismatch problems and their inevitable immune responses. In order to
overcome the genetic mismatch it was soon realised that the recipients’
immune system must be overcome if a kidney allograft were to have
meaningful function. From 1956 total body irradiation followed by bone
marrow transplant was employed to reduce graft rejection. However,
irradiation could lead to destruction of the nervous system, fluid loss and
bacterial invasion, and could cause death within a few hours to days. Despite
occasional successes the irradiated recipients suffered from unacceptably high
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mortality rates. This situation obviated the need for more specific and
controllable methods of immunosuppression.
1.6.2.2 Generalised Immunosuppressive agents
In 1959, two Boston haematologists, Robert Schwartz and William Dameshek
reported that the activity of adult rabbits to beef protein could be suppressed by
the anticancer drug 6-mercaptopurine. By inhibiting RNA and DNA synthesis
it diminished maturation and proliferation of all rapidly dividing cells including
lymphoid cells. When antigen and drug were administered together, the rabbits
remained specifically non-reactive to the foreign protein even after cessation of
the agent but still responded to third party protein. This state was described as
“drug induced immunological tolerance” [105] .
1.6.2.3 Specific Immunosuppressive agents
I. Azathioprine and Corticosteroids
In 1961, Calne, Peart and Porter launched a transplantation programme using
azathioprine and corticosteroids. In April 1962, R.Y. Calne and J.E. Murray
reported the successful use of azathioprine, on a kidney transplant patient in
Boston, USA. The second half of this first batch of azathioprine was used in a
successful renal transplantation in Edinburgh in the same year. This important
development - maintenance immunosuppression with azathioprine and steroids
in combination with the treatment of rejection episodes with high doses of
steroids - remained the mainstay of clinical immunosuppressive regimes for the
next two decades.
II. Azathioprine alone
A further clinically relevant advance came from Thomas Starzl and Thomas
Marchioro, who presented their results with twenty-seven renal transplants
performed over the previous ten months[106] - twenty-five from living donors,
both related and unrelated. Starzl and Marchioro used azathioprine alone as
primary immunosuppression, but reversed the virtually inevitable acute
rejection episode in over 90 per cent of the cases with high doses of
prednisolone, and actinomycin C, an antibiotic that killed populations of white
31
blood cells. Eighteen of their patients (67%) remained alive with satisfactory
graft function.
Of the two hundred and sixteen recipients of kidney allografts performed up to
1963 in North America and Europe 52% of those receiving allografts from
related donors and 81% of those receiving allografts from non-related donors
had died. Only 4% of all allografts functioned for more than a year. In contrast
76% of identical twin (or irradiated non-identical twin) recipients were still
alive. This indicated that kidney transplantation was still experimental and not
yet a therapeutic procedure.
III. Anti-lymphocyte Serum / Anti-Lymphocyte Globulin
In parallel to the above developments, research in immunology and cell
biology was creating an alternate approach. In 1951, Sir Michael Woodruff
published a paper on his work on anti-lymphocytic serum (ALS) in the
rat[107]. He modified the technique used by Cruickshank in 1941 and
produced rabbit-anti-rat ALS induce lymphopaenia. This was a more specific
biological method to suppress the immune system by acting directly on the
lymphocytes. Work continued throughout the 1960s, and Woodruff found that
lymph drainage and administration of ALS resulted in prolonged homograft
survival in rats, where the maximum effect was achieved with treatment both
before and after graft transplantation[108]. In 1966, Sir Michael Woodruff and
colleagues showed that ALS against dog thoracic lymphocytes prolonged the
survival of whole kidney homotransplants in dogs. Sir Michael Woodruff and
his team made anti-lymphocyte globulins (ALG) and ALS in collaboration
with colleagues at the Royal School of Veterinary Science in Edinburgh.
Theses polyclonal antibodies were made in horses.
Understanding of ALG was important if it were later to be used clinically in
humans, and Keith James and Sir Michael Woodruff undertook extensive
research to establish this. The team investigated the mode of action of ALG,
the kinds of immune response which it suppressed, and the nature of the
molecular characteristics of the antibody. ALG was found to be predominantly
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of the IgG class. Furthermore, intact IgG was required to give a biological
effect. Antibody fragments, e.g. Fab, did not work since they did not fix
complement, and could not lead to complement-mediated lysis of lymphocytes
(James K, 1967). ALG also suppressed antibody formation experimentally
[109]. Suppression was dependent on the antigen, species of rat, and the timing
of antigen challenge (ALG was injected before antigen challenge to give
immunosuppression). ALG was later used in humans as an adjunct to other
immunosuppressants, and it was observed that grafts were functioning after 5
years in 4 out of 14 renal transplant patients who received ALG in addition to
azathioprine and prednisolone [110].
By 1972 advances were obvious, particularly with kidneys from living related
sources; the rate of graft survival had improved to 75 percent at one year.
Results with cadaver organs increased from 25 percent to 45 percent, a
relatively mediocre figure that was to remain static over the next decade. A few
long-surviving patients had returned to normal lives.
IV. Blood Transfusion and Low-dose steroids
Terasaki demonstrated that long-term prognosis in humans post-transplant was
directly related to the number of pre-transplant transfusions [111]. It was
thought that blood transfusion enhanced graft survival. In the process, only
frozen washed red cells were used (leukocyte-depleted). Later on, there was
more evidence that blood transfusion enhanced graft survival, possibly by
inducing tolerance. After a while, it became usual practice in Edinburgh to
transfuse 4 units of blood before transplant. It was shown that blood
transfusion together with a low-dose steroid regime increased the 3-year graft
survival rate from less than 40% to 66% [112]. Reductions in acute rejection
reduced the numerous side effects associated with high steroid intake,
including mortality and bone morbidity. However, transfusion was not without
problems, some patients became highly sensitised to transplant antigens,
making transplantation very difficult. With the discovery of more effective
anti-rejection agents, pre-transplant transfusions were abandoned.
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With slowly accumulating clinical successes and intriguing scientific findings,
a series of new strategies were initiated in hope of improving the results
further. Management of end-stage renal disease became better understood.
Tissue matching, with its potential of offering the best organ to the best
recipient, appeared full of promise, particularly as hope increased that the
dosages and toxicities of the existing immunosuppressive modalities could be
reduced. New methods of preservation and storage allowed more time to
transfer a kidney to a well-matched recipient. More effective dialysis
techniques sustained more patients as they awaited transplantation. More
institutions initiated transplant programs. Progressive understanding of the
biology of the host immune responses, and the realization that a variety of
chemical and biological agents could modulate their activity and increase the
survival of foreign organs, focused investigative efforts.
V. Cyclosporin A
In 1969 - 1970, two new strains of fungi were isolated. Only one of the strains,
Tolypocladium inflatium (Gans), could be grown in culture and a fungal
product was isolated from the culture broth. The extract, eventually
characterized chemically as a ring of eleven protein fragments, became
available for biological screening. Initial analysis was unremarkable until Jean
Borel, examined the materials pharmacological properties. He quickly
discovered that one of the metabolites isolated from the extract was markedly
immunosuppressive. Soon the influence of this factor, Cyclosporin A, on both
cellular and humoral immune activity had been established in cultured cells.
The new agent reversibly inhibited the function of T lymphocytes and was
nontoxic to several cell populations in a variety of animal species. The
selective interactions of Cyclosporin A with the host immune responses
contrasted to those other immunosuppressants available, which
indiscriminately destroyed rapidly dividing cells throughout the body.
In November 1978 the Lancet published two short papers that radically
changed the nature of clinical transplantation. In the first, a group in London
showed that treatment with a new immunosuppressive drug, Cyclosporin A,
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substantially diminished the incidence and severity of GVHD in bone marrow
transplant recipients [113]. In the second, Roy Calne and his Cambridge
associates reported that the same agent had been strikingly effective in several
patients with kidney grafts [114].
One year later they described in detail their results with thirty-four recipients of
thirty-six organ allografts, all treated with Cyclosporin A [115]. Twenty-six of
the thirty-two kidneys continued to function, as did two pancreases and two
livers. Twenty patients received no adjunctive steroids. No additional chemical
agent such as azathioprine was used in fifteen individuals. Compared to the
clinical results of the previous fifteen years, these data were unmatched.
In 1982 Calne and White reported one-year actuarial survival of 82 percent of
sixty cadaver- donor kidney grafts in fifty-nine patients, a figure far superior to
results ever achieved using older forms of immunosuppression[116].
Two international clinical controlled trials began to enrol patients. By 1983,
overall results from both multicenter trials and from individual units, had
shown an approximately 20 percent increase in one-year graft function
compared to conventional therapy, and a 10-15 graft survival percent
advantage at three and five years. Liver and heart transplantation also improved
substantially.
Cyclosporin dramatically increased the number of organs grafted and numbers
of persons demanding them. In 1976, worldwide, six scientific papers on the
subject had been published; in 1980 there were 107, and within a few years,
there were thousands.
Within a few years of the advent of Cyclosporin, additional agents were
introduced with ever-increasing frequency. By the end of the 1990s several
clinical trials were nearing completion and new agents became generally
available [117]. Improving success was paramount for recipient and physician
when faced with a rejection episode unresponsive to standard therapy and the
threat of graft loss, particularly as the relatively low number of available
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organs often meant years of waiting for a new one. The possibility of more
effective drugs encouraged clinicians interested in improving results and also
basic scientists who used the compounds as probes to examine the complexities
of molecular events occurring in activated cells. The changing face of the
increasingly powerful and competitive pharmaceutical industry hastened the
development of the new drugs. As the breadth of the field increased and
immunosuppression was discovered to be financially lucrative, the
industrialization phase of transplantation commenced.
Three new agents in particular, mycophenolate mofetil (CellCept), tacrolimus
(Prograf), and rapamycin (Sirolimus) used alone or in combination with
Cyclosporin, have improved the short-term results of organ transplantation.
VI. Mycophenolate mofetil
Mycophenolate mofetil was shown to reduce the incidence of acute rejection
episodes in the short term compared to the use of azathioprine [118]. In the
longer term when the diagnosis of chronic rejection was made and patients
were converted from cyclosporin to mycophenolate better graft function with
lower rates of graft loss was seen [119]. In an animal model mycophenolate
was shown to reduce intimal hyperplasia - one of the pathological processes
that leads to chronic allograft nephropathy [120]. Mycophenolate mofetil was
shown to improve long-term graft survival following renal transplantation in
patients with delayed graft function [121].
VII. Tacrolimus
Hariharan et al converted kidney/pancreas transplant patients from cyclosporin
to tacrolimus. Renal and pancreatic function remained stable during long-term
follow-up and with a tendency toward a lower rejection rate [122, 123].
A phase III U.S. Multicenter Trial compared tacrolimus - and Cyclosporin
(CsA)-based immunosuppressive therapy. A significant reduction in the
incidence and severity of acute rejection episodes was found among patients
maintained on tacrolimus [124]. Where there had been a progressive decrease
in renal function conversion from Cyclosporin to tacrolimus was found to
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stabilize or improve graft function [125], and was highly effective as
monotherapy (i.e. steroid free) over a ten year period [126].
VIII. Sirolimus
Two studies looking at the use of sirolimus monotherapy in order to reduce
nephrotoxicity from the chronic use of calcineurin inhibitors found a
significant reduction in histological damage and superior renal function in the
group maintained on sirolimus alone [127, 128]. Sirolimus has also been used
to prevent further deterioration in renal function caused by calcineurin inhibitor
induced chronic allograft nephropathy[129, 130].
Following the discovery of Tacrolimus, isolated from the bacterium
Streptomyces tsukubaensis [131], Calne and Starzl were in the audience during
a presentation at the Transplantation Society Congress in 1986, on the
immunosuppressive effectiveness of Tacrolimus in a rat heart-graft model.
Calne had already tested the agent and felt that it was exceptionally toxic to the
gastrointestinal tract of dogs and produced significant inflammation of small
blood vessels. He also noted that it was considerably more potent than
cyclosporin. Starzl, in contrast, was so enthused by the data that he promptly
travelled to Japan, to determine that organ allograft survival was prolonged in
treated rat, dog, monkey, and baboon recipients
The biochemical structure of the new agent was shown to be distinct from that
of cyclosporin, it bound to related but not similar protein receptors in the cell
and interfered early in the cell activation process. Thus, it blocked generation
of various lymphocyte products that mediate rejection. Starzl took on the drug
and controlled its use for months. Having rescued it from virtual oblivion
following the initial adverse reports of its toxicity, he persuaded the Food and
Drug Administration (FDA) to allow him to use Tacrolimus in selected
patients. He soon reported that the agent was strikingly effective in human
recipients of liver, small bowel, heart, pancreas, and kidneys - perhaps most
obviously in its ability to rescue liver grafts failing from rejection episodes
resistant to steroids or to anti T-cell monoclonal antibodies [132].
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As others began to use FK, and data from two large multicenter trials
eventually became available, the agent was increasingly accepted. One year
actuarial graft survival differed little from that of Cyclosporin treated hosts and
acute rejection could often be successfully reversed by conversion from
Cyclosporin to FK. Side effects, were significant, FK506 was found to be
extremely toxic to kidneys, causing some heart, liver, and multi organ
recipients to require dialysis. Up to 20 percent of liver recipients developed
mild central nervous system abnormalities. The onset of diabetes was an
unexpected problem, with one third of renal transplant patients in a large study
requiring insulin treatment [133]. Despite these adverse reactions, the use of
FK has gradually has become more routine, especially in multiorgan
transplantation.
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Development and use of Immunosuppression in Kidney Transplantation
1954 First successful identical-twin kidney transplant
1961 Kidney transplants in irradiated hosts, unacceptably high
mortality rates
1960 - 1963 Clinical use of chemical immunosuppression (azathioprine).
1963 52% of those receiving allografts from related donors and
81% of those receiving allografts from non-related donors
had died
1964 Addition of steroids to reverse acute rejection. Azathioprine,
steroids in combination mainstay of clinical
immunosuppressive regimes for the next two decades.
1972 75 percent graft survival at one year in recipients of kidneys
from living related donors. One year graft survival of
deceased donor kidneys remained at 25 percent to 45 percent
next decade.
1979 Twenty-six of the thirty-two kidneys survived in one study
where patients received cyclosporin as baseline
immunosuppression[23].
1982 82 percent 1 and 2 year graft survival.[24]
1986 Introduction of FK (tacrolimus)
1988 – 1996 One-year survival rate for grafts from living donors increased
from 88.8 to 93.9 percent, and the rate for deceased grafts
increased from 75.7 to 87.7 percent.[32]
1995 Clinical introduction of mycophenolate mofetil
1999 Rapamycin (sirolimus) trials
2003 1 year graft survival; 89.2% (deceased donor) and 94.3%
(living donor). OPTN/SRTR Data as of August 1, 2003.
Table 2 - Timeline; Development and use of Immunosuppression in Kidney Transplantation
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1.7 Immunosuppression
Mechanism of Action.
During the past 50 years, many immunosuppressive drugs have been
discovered empirically. Often their mechanisms of action were established long
after their discovery. Eventually these mechanisms were found to fall into five
groups:
I. Regulators of gene expression;
II. Alkylating agents;
III. Inhibitors of de novo purine and pyrimidine synthesis;
IV. Inhibitors of kinases and phosphatases.
V. Targeted immunosuppression - Monoclonal Antibodies
1.7.1 Regulators of gene expression
Corticosteroid is a glucocorticoid-based medication that works principally to
block T cell and APC derived cytokine and cytokine-receptor expression. The
major elements blocked are IL-1 and IL-6. Secondary effects of corticosteroids
include the blocking of IL-2, INF-gamma, and TNF-alpha. These elements,
notably IL-1, are essential for lymphocyte-APC communication. A decrease in
production effectively obstructs an APC's capacity to activate allograft-specific
lymphocytes. As a result, threat of acute rejection is reduced. Corticosteroids
have a hydrophobic structure that allows them to easily diffuse into cells and
bind to specific cytoplasmic receptors. The resulting complexes progress to the
nucleus, where they are able to inhibit the transcription of the genes of the
cytokines named above.
Corticosteroids are used in maintenance immunosuppression, and the treatment
of acute rejection. Oral, as well as intravenous routes are commonly used. A
high dose of intravenous methylprednisolone is usually given immediately
before and during the transplantation procedure. Methylprednisolone or
prednisone is often continued post-operatively for several days at high doses,
and is then tapered to a maintenance dose. The maintenance dose consists of
orally administered prednisone, and is normally 5-10 mg/day (0.1mg/kg). Side
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effects include: hypertension, hyperlipidaemia, osteoporosis, weight gain,
cushingoid appearance, opportunistic infection, glaucoma, ulcer formation,
hyperglycemia - progressing to steroid induced diabetes.
1.7.2 Alkylating agents
Alkylating agents such as cyclophosphamide are organic chemicals that
transfer alkyl groups to other molecules. Alkylation of DNA bases
preferentially suppresses immune responses mediated by B-lymphocytes.
Alkylating agents can cause pancytopaenia and haemorrhagic cystitis. They are
also mutagenic and can increase the risk of developing cancer and are not used
for the purposes of Immunosuppression in transplantation [134]
1.7.3 Inhibitors of de novo purine and pyrimidine synthesis
a) Azathioprine (Imuran®)
Azathioprine is hydrolyzed in the blood to 6-mercaptopurine. In this form as a
purine analogue and antimetabolite, it is incorporated into DNA, inhibiting
nucleotide synthesis by causing feedback inhibition in the early stages of
purine metabolism. This prevents mitosis and proliferation of rapidly dividing
cells, such as activated B and T lymphocytes. Through this action,
Azathioprine is able to block most T-cell functions and inhibit primary
antibody synthesis. Azathioprine has little effect on established immune
responses, and is therefore effective in the prevention and not the treatment of
acute rejection. Side effects include: bone marrow depletion/suppression,
thrombocytopenia, anaemia, pancreatitis, hepatotoxicity, and neoplasia [134].
b) Mycophenolate Mofetil (CellCept®)
Mycophenolate Mofetil (MMF) is and rapidly hydrolyzed in the blood to its
active form mycophenolic acid (MPA). Mycophenolic acid inhibits the enzyme
inosine monophsphate dehydrogenase (IMPDH), in the de novo pathway of
guanosine nucleotide synthesis. Rapidly dividing cells, such as activated
lymphocytes, depend on the de novo pathway for the production of purines
necessary for RNA and DNA synthesis. In this way, activated lymphocytes are
selectively inhibited, their proliferative responses slowed and apoptosis of
activated T-lymphocytes induced.
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The unique property of MMF is its lack of atherogenic and chronic nephrotoxic
adverse effects. Adverse effects are primarily gastrointestinal (e.g., nausea
and/or vomiting, diarrhoea, gastritis, duodenitis, oesophagitis, ulcers). Other
adverse events were related to bone marrow suppression (e.g., leukopaenia,
anaemia, and thrombocytopenia). MMF is normally taken orally, 0.5-1.0 g
twice daily. Side effects include: leukopaenia, thrombocytopenia, nausea,
opportunistic infection, malignancies, and gastrointestinal upset [134].
1.7.4 Inhibitors of kinases and phosphatases.
The common mechanisms of calcineurin inhibitors converge at the inhibition
of the calcineurin. This inhibition ultimately inhibits the production and
secretion of IL-2. The interaction between IL-2 and the IL-2 receptor is crucial
in the activation and differentiation of B and T cells. Therefore, halting the
rejection process at this step is highly effective at fighting rejection.
a) Cyclosporin
Cyclosporin is a small fungal cyclic peptide that binds to cyclophilin and
complexes with calcineurin. This inhibits phosphorylation of nuclear
regulatory proteins which suppresses the activation of critical cytokine genes
that promote T-cell activation (Il-2, Il-,)1Ȗ71)-Į). Calcineurin inhibitors
are used as long-term or maintenance immunosuppression. Cyclosporin is
available as an emulsion or micro-emulsions. Maintenance doses are
administered orally typically 5-10 mg/kg/day being given in two doses. This is
usually taken along with an antiproliferative agent and prednisone. Side effects
include nephrotoxicity (partially reversible), hypertension, tremor, coronary
artery disease, hirsutism, gingival hyperplasia, opportunistic infections
malignancies, hyperuricaemia, hepatotoxicity, and hypertrichosis [134].
b) Tacrolimus
Tacrolimus is a macrolide antibiotic which binds to the cytosolic protein
FKPB-121. This complex inhibits calcineurin in a similar manner to
cyclosporin. Tacrolimus is available in oral tablets and as an intravenous
formulation. A maintenance dose is usually 0.15 mg/kg/day given in two doses.
Side effects include nephrotoxicity (partially reversible), hypertension,
hyperkalaemia, hypomagnesaemia, alopecia, hyperglycemia (diabetogenic
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potential stronger than cyclosporin), opportunistic infections, and malignancies
[134].
c) Sirolimus (Rapamune®)
Sirolimus is a highly potent macrolide antibiotic that has a similar chemical
structure to tacrolimus. Sirolimus binds to the same protein as Tacrolimus:
FKBP-12. Instead of inhibiting calcineurin as tacrolimus does, this complex
inhibits mTOR (mammalian target of rapamycin). This inhibition prevents the
progression of T cells late in the cell cycle from the G1 to the S phase of the
cell cycle by blocking signalling downstream of the IL-2 receptor. Therefore it
is able to block delayed type hypersensitivity (DTH) reactions, cytotoxic t-cell
activity, and humoral responses directed against a transplanted organ.
Rapamycin inhibits kinases required for cell cycling and responses to IL-2 and
also induces apoptosis of activated T-lymphocytes. Sirolimus is taken orally, at
a dose of 2-5 mg once a day. Side effects include hypercholesterolaemia,
hypertriglyceridaemia, leukopaenia and thrombocytopaenia [134].
1.7.5 Targeted immunosuppression - Monoclonal Antibodies
Immunosuppression can be directed to block the action of cytokines in a
specific way. Anti IL-2 receptor (CD25) monoclonal antibodies against the p55
chain of the receptor (only expressed by activated and not resting T-cells) have
been used in clinical trials in combination with conventional
immunosuppression with encouraging results. Initially, the antibodies used
were mouse derived which has the disadvantage of causing a strong anti
immunoglobulin response by the patient, diminishing the effectiveness of the
treatment. However, these have now been ‘humanised’ by creating a chimeric
antibody with a mouse Fab fragment, and a human Fc portion. This has
significantly reduced the immunogenicity of the molecules. The impact in
transplantation has been the use of monoclonal antibodies in “high risk”
recipients - those with a high panel reactive antibody, those with a minor
degree of positive cross-match (e.g. to b-lymphocytes) and even those with
ABO incompatibility [10]. Prior to their use transplantation would not have
been contemplated.
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1.8 Summary
In Summary, over the last 50 years the outcome of kidney transplantation has
greatly improved. Improved graft survival is attributed to; advances in
immunosuppression, better methods of cytotoxic antibody detection and human
lymphocyte antigen matching. However, as we can see if we compare
outcomes as described by Hariharan et al and those described by The U.S.
Organ Procurement and Transplantation Network and the Scientific Registry of
Transplant Recipients we can see that the rate of improvement is dramatically
slowing and reaching its plateau.(See figure 4).
Figure 4 - U.S. Organ Procurement and Transplantation Network and the Scientific Registry of
Transplant Recipients: 1 Year Graft Survival
It seems to be the case that all known correctable and optimiseable factors have
been taken into account and the optimum graft outcome has been achieved.
The purpose of the thesis is to identify potential biomarkers and explore
unknown factors which interplay between the graft and the host in an attempt
to explain the overall graft attrition rate which remains at 6.4% per year for
deceased donor and 4.5% per year for living donor kidneys averaged over a 10
year period.
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1.9 History of Microarray
i. Array substrates
Traditional hybridisation assays were developed in the 1970’s. They used
flexible membranes as the substrate such as nitrocellulose and nylon. These
early filter based “macroarrays” only included a limited number of targeted
genes (1980’s) and constant effort was made to miniaturize the procedure to
increase the numbers of genes made available for analysis and reduce the
sample requirement, resulting in the microarray in the 1990’s (see. Figure 5)
Figure 5 - Image of microarray slide following hybridisation .It was taken from experiment 4
produced, by Genepix Pro 6.0
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ii. The microarray slide
In contrast to the filter based array the microarray utilized solid media (glass),
which enables the deposition of small amounts of biochemical material to be
placed in a precisely defined position. The non-porous surface permits the use
of small sample volumes, enabling high sample concentrations and rapid
hybridisation kinetics. The solid substrate also allows uniform surface for
attachment of the array elements. The inherent flatness and uniformity allows
parallelism, which provides a significant increase in the accuracy of array data.
Each spot represents a high-density array of oligo-nucleotides adherent to the
slide surface. The immobilized DNA selectively retrieves genes or sequences
of interest when the array is hybridised to a mixture of complimentary
sequences (the probe). The rate of hybridisation is related to concentration of
the probe and is therefore proportional to the relative abundance of mRNA in
the hybridising sample[135].
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1.10 Biomarkers
Recently attention has been directed to cytokines / chemokines in the
transplanted organs at time of transplantation. The question that has been asked
is whether specific cytokines /chemokines enhance or decrease this immune
response.
This may explain why some patients, despite receiving the same mismatched
Major Histocompatibility Complex (MHC) alleles and the same
immunosuppressive drugs have more rejection than others. Studies of these
biomarkers within organ transplants have been hampered by the lack of a
technique, which allows us to examine large numbers of these markers using
only small amounts of tissue. This situation has changed recently with the
introduction of the microarray technique, which has been shown to be useful in
screening gene expression in kidney transplant biopsies [136, 137]. The
emphasis from a traditional gene-by-gene approach has switched to looking at
complete sets of genes. The new emphasis on the complete picture rather than
on its component parts is driven by the completion of the human genome
sequencing project [138]and the advances in microarray technologies that
transform these advances into powerful research tools.
Gene Expression Profiling
At the RNA level, gene expression profiling gives us a snapshot of all the RNA
transcripts that are expressed at a time zero (pre-transplantation) if we can be
confident that mRNA levels in a renal biopsy are representative of those in the
entire kidney [2]. Further snapshots can be taken which are temporally related
to the first (e.g. 6 weeks later during acute rejection and subsequently at times
of graft dysfunction). Spatial relationships can be examined (e.g. comparing
snapshots in a number of grafts which undergo similar intra-graft events).
Further to this each snapshot can be correlated to donor and recipient
characteristics, time of biopsy, severity of rejection, immunosuppressant and
many other variables. Bioinformatics tools used to analyse these large data file
prove to be useful in identifying new biomarkers, or can confirm the results of
other experiments using ELISA or PCR.
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Tumour necrosis factor Į (TNF- Į) is an examples of a cytokines with relevant
to transplantation. Another, interleukin 10 (IL-10) has been associated with the
occurrence of acute rejection [3]. Further microarray findings support the
positive role of TGF-ȕ, as an anti-inflammatory cytokine [4, 5] but more
specifically it has been shown to inhibit B cells, T helper cells, cytotoxic T cells
and macrophages [6, 7].Border et al suggest that the overproduction of or
prolonged exposure to TGF-ȕ leads to excessive deposition of extra-cellular
membrane components, eventually leading to progressive renal scarring [8, 9].
It has also been shown to have a role in the regulation of extra-cellular matrix
(ECM) expression in relation to tissue repair and remodelling [10].
Gene expression profiling successfully identifies many genes with known
function. Of the 30,000 + genes that have been identified, only a handful have a
defined function. Therefore the next task is to define a function for each new
gene and to determine how the protein products interact at a cellular level and
fit into the bigger picture of the cytokine networks.
This study is designed to examine gene expression within the kidney allograft
at the time of transplantation, in an attempt to predict which patients will
develop rejection or graft dysfunction in the long-term. This data will also
provide information on biomarkers that can be associated to other end points
such as chronic rejection and chronic allograft nephropathy. This will enable us
to tailor anti-rejection drugs to every patient depending on their immune
response, and identify potential non-invasive biomarkers for the monitoring of
progression of these intra-graft events.
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2 METHODS
2.1 Ethical Approval
Formal ethical approval was obtained from Nottingham Research Ethics
Committee 2 (ref: C2040304), and from Research and Development at
Nottingham City Hospital. This allowed pre and post transplant biopsies and
blood samples to be taken from transplant recipients once informed consent
had been obtained.
2.2 Tissue handling
Samples were obtained during bench preparation of the kidney prior to
transplantation or during kidney biopsy following transplantation.
I. Surgical technique
The pre-implantation biopsy taken prior to either deceased or live donor kidney
transplantation was taken using a size 15 scalpel blade. An elliptical wedge of
tissue was taken with the approximate dimensions; 10mm in length, 2-3 mm
wide and 4-5 mm deep. This sample shape and size was used in order to
facilitate repair of the kidney and minimise bleeding from the biopsy site
following reperfusion. Two vertical mattress sutures using a 3/0 vicryl suture
were used to repair the defect.
The biopsy sample was placed into icy Soltran Kidney Perfusion Solution
(Baxter Health Care, UK). At the earliest opportunity the sample was flash
frozen using liquid nitrogen and then placed into a labelled sterile sample bag
and placed into the -80°C freezer.
II. Needle biopsy procedure
Following consent biopsies were taken. Following the administration of local
anaesthetic, using an aseptic technique a 16 Fr trucut biopsy needle was used to
take the samples. Depending on the clinical scenario the pathologist required
up to three cores of tissue (1-2 cores for histology and immunohistochemisry)
and a further core for this study. It was important that the biopsy specimen to
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be used for research was not placed into formaldehyde for macroscopic
assessment, as this would diminish the integrity of RNA [139]. The sample
was placed into a 1.5ml PCR tube containing 500ȝl RNAlater® and
transferred to the -80°C freezer.
III. Tissue Storage.
There was variation in tissue storage techniques at different times during the
research project. Prior to February 2004 the biopsied tissue was flash frozen in
liquid nitrogen and transferred to the -80° freezer. Between February and April
2004 the sample was temporarily stored in icy Soltran, transferred to a sterile
2.5ml plastic vial containing 750 µl RNAlater® and then placed in the -80°
freezer. After April 2004; as above (Feb – Apr 2004) except that the tissue
sample was transferred directly to a sterile 2.5ml plastic vial containing 750 µl
RNAlater® and then placed in the -80° freezer.
2.2.1 Deceased and Living Donor Biopsy Samples.
Deceased donor biopsy samples were taken following organ retrieval prior to
transplantation. Living donor biopsy samples were taken following perfusion
of the kidney with icy soltran immediately after laparoscopic donor
nephrectomy.
I. Donor and Recipient Demographics.
Tx date Donor age Donor type Recipient age
E02 12-Nov-2003 43 LD 36.2
E03 14-Oct-2003 62 DD 65.6
E04 10-Dec-2003 58 LD 28.1
E05 24-Nov-2003 45 DD 39.1
E06 7-Jan-2004 28 LD 4.1
E07 3-Nov-2003 15 DD 21.5
E08 24-Apr-2002 50 LD 32.1
E09 23-Nov-2000 29 LD 2.3
E10 12-Dec-2003 44 LD 34.4
E13 7-Dec-2001 56 DD 47.6
E14 1-Jan-2002 20 DD 35.4
E15 11-Feb-2004 44 LD 14.6
50
E16 27-Mar-2002 49 LD 22.8
E17 9-Jan-2002 61 LD 64.4
E18 15-Jan-2002 21 DD 33.2
E19 15-Jan-2004 48 DD 50.9
E20 18-Jan-2002 17 DD 14.7
E21 5-Dec-2001 56 DD 51.8
E22 14-Sep-2001 37 DD 37.4
E23 5-Oct-2001 25 DD 60.7
E24 22-Jan-2004 27 DD 5.1
E25 6-Jun-2004 27 DD 37.2
E26 21-Apr-2004 53 LD 47.2
E27 26-Apr-2004 56 DD 62.5
E28 28-May-2004 20 DD 40.2
E29 21-May-2004 33 LD 4.7
E30 19-Apr-2004 35 DD 7.7
E31 19-Apr-2004 35 DD 42.0
E32 16-Jun-2004 59 LD 58.2
E33 18-Sep-1993 unknown DD 49.9
E34 14-Dec-2003 44 DD 39.9
E35 14-May-2004 53 LD 23.2
E36 10-May-2004 53 DD 34.3
E37 17-Mar-2004 unknown DD 34.2
E38 29-Jul-2004 unknown DD 25.7
E39 17-Oct-2001 48 LD 20.6
E40 21-Nov-1999 unknown DD 17.5
E41 10-Aug-2004 unknown DD 35.1
E42 17-Aug-2004 unknown DD 56.4
E43 17-Oct-2001 48 LD 20.6
E44 31-Aug-2004 unknown DD 30.7
E45 14-Sep-2004 unknown DD 52.8
E46 12-Feb-2004 37 DD 21.0
Table 3 - Donor and Recipient age and donor type.
DD = Deceased Donor, LD = Living Donor
.
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Table 3 shows the list of experiments, the type of donor, donor age and
recipient age. 44 patients received kidney transplants, 28 were from deceased
donors and 16 from living donors.
All Adults Children
Donor DD 37 Donor DD 39 Donor DD 26
LD 47 LD 51 LD 34
Recipient DD 38 Recipient DD 41 Recipient DD 9
LD 28 LD 35 LD 6
Table 4 - Average Age in Years
The average age of donor was 37 for deceased donors and 47 for living donors
(Table 4). The average age of recipients was 38 for deceased donors and 28 for
living donors (adults) and 2.3 (children). The average age of donor was 43.6
(adults) and 30.4 (children).
2.2.2 Classification of Samples
For the purpose of this study tissue biopsies taken from patients were classified
as shown in Table 5
Donor Source Timing of Transplant Biopsy
Deceased donor Pre-implantation biopsy Post - transplantation kidney
biopsy taken for clinical
reasons any time following
transplantation
Living donor Pre-implantation biopsy Post - transplantation kidney
biopsy taken for clinical
reasons any time following
transplantation
Table 5 - Table to show category of biopsy sample subdivided into donor type and the timing
of biopsy
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Donor Source
Transplant biopsy samples were sourced from deceased donors, where the
kidney was retrieved from a person that had been diagnosed as being brain-
stem dead, or from living donors where fit and healthy people donated one
kidney to a relative or friend.
I. Timing (Pre-implantation)
The majority of samples were taken at the time of routine pre-implantation
transplant biopsy. This biopsy procedure is taken routinely in order to provide
the baseline histology of the graft on which to compare if subsequent biopsy
are required for clinical reasons. The baseline histology also gives us a very
generalised idea of the state of health of that kidney in order to give us some
idea of what function we are likely to expect from the graft. For example a
kidney from an 18 year old is more likely to perform better than a kidney from
a 65 year old in which widespread arteriosclerosis or glomerular hyalinisation
is seen.
II. Timing (Post-implantation)
Post-implantation biopsies were taken at any time following transplantation.
They were taken for clinical reasons in order to diagnose the underlying cause
of graft dysfunction. A research sample was taken when tissue excessive to the
requirements for histological diagnosis was obtained.
III. Functional Categorization of Samples
A. Early Samples
Early transplant biopsy samples were taken within 4 weeks following
transplantation. This group was sub-divided depending on the outcome (graft
function).
i. Immediate graft function
A graft functioned immediately when recipient plasma creatinine started to fall
on day 1 following transplantation and continued to do so until the recipient
plasma creatinine fell to below 150 µmol/l.
53
ii. Moderate function
A graft functioned moderately when recipient plasma creatinine started to fall
on day 1 following transplantation but failed to reach 150 µmol/l or below. If
the recipient plasma creatinine started to drop after day one but then fell to 150
µmol/l or below these were also included in moderate function group.
iii. Poor function
A graft functioned poorly when recipient plasma did not fall on day 1
following transplantation and failed to reach 150 µmol/l or below.
iv. Non-function
In a non- functioning graft no fall in recipient plasma creatinine was seen at
any time.
The pathophysiology causing graft dysfunction in the above groups was due to
one of, or a combination of acute tubular necrosis (ATN), acute rejection,
thrombosis/ischaemia, calcineurin induced nephrotoxicity or unknown cause.
B. Late transplant biopsy samples.
The purpose of distinguishing between early and late transplant biopsy samples
was to identify pathological processes that were more likely at that time; early
graft dysfunction was likely to be caused by ATN, acute rejection,
thrombosis/ischaemia or calcineurin induced nephrotoxicity and not by chronic
allograft nephropathy or chronic rejection and vice versa.
There were no late biopsies taken on transplanted grafts that originally
performed with immediate function. This will be discussed later.
C. Protocol biopsies.
Some Transplant units perform routine “protocol biopsies”. These are done as
part of that particular units management protocol or as part of a research
project. When this is the case biopsies are taken at pre-determined times (e.g.
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3, 6 and 12 months), regardless of the function of the graft. Protocol biopsies
were not part of the management protocol or research protocol in the unit
where this research took place. This fact in part explains why there were no
late biopsies taken in the immediate function group; there was no clinical need
and no routine (protocol) biopsies.
Of all 46 experiments 44 were hybridised with the same control RNA source.
Because test samples were not being hybridised together this meant that less
test sample would be lost should the hybridisation fail. Microarray data
analysis software was designed to provide normalisation of samples based
upon a common control sample. Therefore, as each test sample was hybridised
with the same control sample comparison could be made across all test
samples. The purpose of using a common control sample was to reduce inter
and intra-experimental variation so that results obtained from any one
hybridisation could be compared with any other sample using the same control.
IV. Control Sample
a) Pooled RNA control
During the development of the technique a pooled mRNA (Ambion) was used
as a quality control. This was made into probes as described earlier along with
sample RNA so that yields and quality control parameters could be compared
to ensure that the extracted sample mRNA was being processed into probes
suitable for hybridisation. These gene pooled probes were therefore not used
for any subsequent hybridisation or analysis purpose.
b) Human RNA control
The control RNA used for probe preparation for the purposes of hybridisation
was sourced from a human kidney that had been removed. It had contained a
small renal tumour. The rest of the kidney was histologically normal and the
patient had had normal renal function. The biopsy used to source the control
sample was taken from the normal part of the kidney. This was deemed to be a
far more suitable control because it was human and not manufactured. It was
tissue taken from the same part (cortex) of the same organ; kidney.
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The control sample had been immediately taken from the removed kidney and
stored in RNAlater® and therefore, experienced minimal physiological insult
compared to the biopsies taken from deceased donor kidneys. With regard to
the living donor kidneys the level of physiological insult was deemed to be
more similar the main difference being the amount of warm ischaemic time the
living donor kidney was exposed to (i.e. the amount of time the living donor
kidney was without a blood supply prior to the biopsy sample being taken and
stored in RNAlater®).
Depending on the sample quality amplified RNA would provide enough
material for between 1 and 8 hybridisations. Table 8 summarises experiments
that were grouped dependent on the source of donor kidney; deceased or living
and the clinical setting in which the biopsy sample had been taken.
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LIVING DONOR DECEASED DONOR
E04/LD/IF E05/DD/IF
E08/LD/IF E07/DD/IF
E15/LD/IF E13/DD/IF
E16/LD/IF E14/DD/IF
E17/LD/IF E21/DD/IF
E26/LD/IF E22/DD/IF Immediate Function
E29/LD/IF E23/DD/IF
E32/LD/IF E24/DD/IF
E27/DD/IF
E30/DD/IF
E36/DD/IF
E44/DD/IF
E45/DD/IF
E46/DD/IF
E35/LD/IF/AR E38/DD/STF
E19/DD/STF/#2 Moderate Function - Early
E47/DD/STF
E37/DD/BX/EARLY
E28/DD/ATN
E31/DD/ATN Poor Function - Early
E41/DD/ATN
E42/DD/ATN
E25/DD/NF Non Function - Early
E34/DD/TXNEPH
E33/DD/BX/LATE Moderate Function - Late
E40/DD/BX/ LATE
E39/LD/BX/ LATE Poor Function Late
E43/LD/BX(2)/OLD
Table 6 - Summary Table of Experiments.
Key: LD – Living Donor DD – Deceased Donor
IF – Immediate function NF - Non function
ATN – Acute tubular necrosis BX – Biopsy
STF - Slow to function TXNEPH – Transplant nephrectomy
In Table 6 the first column lists the experiments using the simple annotation E
for experiment followed by a number 2 – 47. E1 was removed from this
analysis; it was a separate experiment performed using Method B. It used two
samples from the same patient at time of transplantation and then during acute
rejection, therefore did not use the universal control. E1 was prepared up to the
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stage where data analysis could be performed but for the purpose of this thesis
it will be excluded. Instead the two test samples were hybridised with the
control sample and this is reflected by experiments 46 and 47.
E11 and E12 were experiments performed during the development of the
Method B and were performed with a different control RNA. This control
(C1B) was the original control that was being used for the first 12
hybridisations. These however, produced poor results due to technical
problems that will be discussed later. This control sample was used up in these
initial hybridisations. At this point the control sample C2A was obtained,
which had better characteristics in terms of RNA quantity and quality and it
was decided that this should be the common control sample. E11 and E12
hybridised adequately, suitable for further analysis but will also be excluded in
this thesis.
2.3 RNA extraction
All RNA extractions were performed using the RNeasy Mini Kit. The kit was
designed to isolate up to 100ȝg of RNA molecules longer than 200 nucleotides.
a) Quantification
Approximately 30 mgs of tissue was thawed. This was approximately a 3x3x3
mm
3
piece of tissue cut from the frozen wedge specimen that had been taken
pre-transplant or at subsequent biopsy. It was important to note than any tissue
not being used for RNA extraction was not allowed to defrost and was returned
to the -80q C freezer immediately.
b) Lysis
The sample was placed in a 600 µl lysis buffer containing guanidine
isothiocyanate (GITC). GITC served to denature the sample and inactivate
RNases to maximise the isolation of intact RNA. It was important to add 10 µl
of 14.3M ȕ-mercaptoethanol per 1ml of lysis buffer at this stage as it was not
included ready mixed in order to prolong the shelf life of the lysis buffer.
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c) Disruption and Homogenisation
Sample disruption and homogenisation was performed using a Rotor-stator
homogeniser. Complete disruption of cell walls and plasma membranes was
required to release the maximum quantity of RNA. Homogenisation was
necessary to reduce the viscosity of cell lysates produced by disruption. The
disrupted/homogenised sample was visually inspected to make sure that there
were no tissue fragments remaining. If there were the sample was further
homogenised until no tissue was visible. Partial homogenisation would cause
partial release of RNA. Therefore a partially homogenised sample would
contain less RNA available to bind to the RNeasy binding membrane,
significantly reducing RNA yield. The lysate was centrifuged at maximum
speed for 3 minutes. The supernatant was added to 600 µl of 70% ethanol and
mixed by pipetting. The alcohol was required to provide appropriate binding
conditions.
d) Binding and Washing
This was then applied to an RNeasy mini column (filter cartridge and 2ml
collection tube) in 700 µl aliquots and centrifuged at 10 000 rpm for 15
seconds. The flow-through was discarded following each spin. 700 µl of
binding buffer was added to the RNeasy column and centrifuged for 15
seconds at 10 000 rpm. The filter column was replaced into a new 2 ml
collection tube. The column was washed twice with 500 µl of wash buffer
which was pipetted onto the RNeasy filter column. Each time it was
centrifuged at 10 000 rpm for 15s. A further spin was performed to eliminate
the chance of alcohol contained in the wash buffer being carried over.
e) Elution
To elute the RNA, the filter was placed into fresh 1.5 ml collection tube, 30µl
RNase-free water was added and then the column was centrifuged. This was
repeated with further 50µl RNase free water.
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2.4 RNA Quality Control / Quantification techniques.
In the initial method prior to April 2004 the Pye Unicam UV2-100
Spectrophotometer was used in order to assess the quality (based on the
absorbance curve and ratio), and the quantity (calculated from the absorbance
and dilution factor.
Initial method - RNA quantity calculation.
5 µg of RNA was required in the next stage (amplification). This was
calculated using the readings acquired from the spectrophotometer in the
following formula:
40 x absorbance at 260 nm (A) x Dilution Factor = µg/ml
An example of the calculation involved in RNA quantification is shown below:
Volume of RNA sample (eluted volume) = 50 µl
Dilution = 1µl of RNA sample + 99 µl distilled water (1/100 dilution).
Measured absorbance of diluted sample in a 100 µl cuvette; A = 0.048
Concentration of RNA sample = Extinction coefficient* x A x dilution factor
= 40 x 0.048 x 100
= 192 µg /ml
Total yield = concentration x eluted volume of sample (ml)
= 192 µg /ml x 0.05 ml
= 9.6 µg
*The Extinction coefficient for RNA diluted in water. An absorbance of 1 unit at 260 nm
corresponds to 40µg RNA per ml.
5µg of sample RNA was required for cDNA synthesis and was calculated as
follows: Total yield = 9.6µg in 50µl
1µg = 50 µl
9.6
5µg = 50 x 5µl
9.6
= 26.0µl of sample
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Initial method - RNA quality analysis.
Spectorophotometric measurement gave the 260/280nm absorbance spectrum.
The 260/280nm ratio was used as mark of quality control where a ratio values
between 1.8 and 2.1 indicated a sample purity of sufficient quality to continue
with the probe preparation (Ambion).
New method - RNA quality analysis and quantification
It was imperative that accurate analysis of RNA quantity and quality was
performed to assess the suitability of the extracted RNA for further processing.
a) Nanodrop Spectrophotometer
The NanoDrop Spectrophotometer [25](see figures 6 & 7) was designed to
measure nucleic acid concentrations in sample volumes of one microlitre
without the need for cuvettes. This is achieved by the surface tension that
develops between the sample surface and the detector surface. Therefore a
continuous column is formed which completes the optical circuit.
Figure 6 - Nanodrop sample application. With the sampling apparatus open, a droplet of sample is pipetted
onto the lower measurement pedestal
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Figure 7 - Nanodrop droplet adhesion. When the sample apparatus is closed, the upper
measurement pedestal slightly compresses the droplet. Surface tension holds the sample in
place.[140]
The Nanodrop ND-1000 Spectrophotometer (Labtech, East Sussex, UK)
required only 1µl for analysis which was very important as the extracted RNA
volume was only 50µl. The developers recommended that a 1 or 2µl pipette is
used to apply the samples as a poorly calibrated 10µl pipette could introduce
volume error. Another benefit was that the test sample could be retrieved and
used to determine the integrity of the RNA i.e. used on the Agilent
Bioanalyser. This option was used at times when RNA quantities needed to be
preserved. Another useful feature of the Nanodrop was the ability to measure
Cye Dye incorporation into microarray probes prior to hybridisation. This will
be discussed later.
b) Agilent 2100 Bioanalyser
The Agilent 2100 Bioanalyser (Figure 8) (Agilent Technologies, Cheshire,
UK) has largely replaced gel electrophoresis in RNA sample quality control. It
was used in order to standardise the assessment of RNA quality. Samples were
prepared according to the manufacture’s protocol: Agilent RNA 6000 Nano
Assay Protocol [141] .
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Figure 8 - Agilent Bioanalyser
The RNA Nano LabChip was used to analyse up to 12 samples at a time and is
shown in Figure 9.
Figure 9 - Agilent Bioanalyser LabChip
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2.5 RNA Amplification – Initial method
The following method is adapted from; Protocol RNA Amplification for use
with Pan® Oligo Microarrays Version 220601E. The protocol incorporates the
use of the following kits.
x cDNA Synthesis System (Roche)
x High Pure RNA Tissue Kit (Roche)
x MEGAscript T7 Kit
2.5.1 The Eberwine principle
The principle behind the method was based on the RNA amplification protocol
developed by Dr. James Eberwine [135] . The technique utilizes an oligo(dT)
primer containing the T7 RNA polymerase promoter for synthesis of first
strand cDNA. The primer binds to the poly(A) tail at the end of mRNA (3’
end). The technique is designed to only amplify the mRNA fraction of total
RNA to produce double stranded DNA
2.5.2 cDNA Synthesis from total RNA using the cDNA Synthesis System
(Roche)
I. First strand synthesis:
AMV reverse transcriptase was used for first strand cDNA synthesis. The
initiation of the first strand synthesis depends upon hybridization of the primer
Oligo [(dT) 24 T7promotor] 65 to the mRNA, usually at the poly (A) tail
A 5 µg of (sample) total RNA was pipetted into a 0.2 ml PCR tube. 2 µl (2
ȝg/ȝl). Oligo [(dT)24T7promotor]65 primer was added and then the total volume
was made up to 21 µl. To denature the RNA the mixture was gently flicked to
mix and placed in the thermocycler set at 70°C for 10 minutes. The tube was
then placed on ice prior to prevent rebuilding before proceeding to the next
step.
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In a separate tube the following were mixed together:
x 8 µl of 5x RT buffer
x 4 µl 0.1M DTT
x 1ȝl RNase Inhibitor (25 U/µl)
x 4 µl dNTP mix (10 mM each nucleotide)
x 2 µl AMV reverse transcriptase (25 U/µl).
In practice a mastermix containing multiple amounts of each constituent was
made up. For example if 10 samples were to be prepared 80 µl of 5x RT buffer
would be used. In addition an extra 5% of each constituent was included (e.g.
84 µl 5x RT buffer) in the mastermix to allow for pipetting error.
To the sample tube (21 µl) 19 µl of the mastermix was added giving a total
volume of 40 µl. The mixture was vortexed briefly and placed in a
thermocycler at 42°C for 60 minutes. The tubes were again placed on ice prior
to continuing on to the second strand synthesis stage.
II. Second strand synthesis
In a new tube the following reagents were combined:
x 5x 2nd strand-buffer 30 µl
x dNTP-mix (10 mM each nucleotide) 1.5 µl
x 2nd strand enzyme mix 6.5 µl
x redistilled. water 72 µl
Total volume =150 µl
A mastermix containing multiples of the above quantities was used. This was
added to the first strand reaction (40 µl), vortexed and placed in the
thermocycler at 16°C for 2 hours, then placed on ice.
Functions of the 2nd strand enzyme mix:
i. RNase H inserted nicks into the RNA, providing 3‘OH-primers for
DNA polymerase I present in the enzyme mix.
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primer stretches in the direction of synthesis, which were then replaced
with new nucleotides by the polymerase activity. E.coli Ligase linked
the gaps to complete the dsDNA.
Following the incubation 20 µl (20 U) T4 DNA polymerase was added and
briefly vortexed.
iii. T4 DNA polymerase was added to remove any remaining overhanging
3‘ends on the dsDNA in order to blunt the terminal ends.
This was incubated at 16°C for 5 min and then the reaction stopped by adding
17 µl EDTA (0.2M pH 8.0).
III. Digestion of RNA
As the starting material was total RNA the protocol recommended that RNase
was added to digest any residual RNA.
x Proteinase K was then added to remove inhibitors of transcription
(RNase and restriction enzymes).
x µl (15 U) RNase I was added and incubated at 37°C for 30 minutes
followed by 5.0 µl (3U) of Proteinase K and incubated at 37°C for a
further 30 minutes.
2.5.3 Purification of dsDNA using the High Pure RNA Tissue Kit
A. Binding / Washing steps
At room temperature 10 µl ȕ-mercaptoethanol was added to 1 ml binding
buffer. As with preparation of the mastermix 10 µl ȕ-mercaptoethanol was
added to each 1 ml of binding buffer to cover all samples being prepared at that
time e.g. 100ȝl ȕ-mercaptoethanol was added to 10ml binding buffer to cover
10 samples.
i. The active ingredient in binding buffer one was guanidine-HCl which
solubilised and denatured proteins
The dsDNA reaction mix was transferred to a new 2ml reaction tube and added
to 800 µl binding buffer (containing mercaptoethanol) and 400µl absolute
ethanol and mixed well by pipetting up and down until the solution became
homogeneous.
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700 µl of the reaction mix were pipetted onto a filter column and collecting
tube which was then centrifuged at 8000rpm for 15 seconds, discarding the
flow-though. The process was repeated with the remaining 700 µl.
B. Washing steps
The column was washed once with 500 µl of wash buffer 1, and then with
twice with 500 µl and 300µl wash buffer 2. After each wash the column was
centrifuged at 8000 rpm for 15 seconds and the flow-through discarded.
i. Wash Buffer 1 (contained 4,5 M guanidine-HCl, 100 mM sodium
phosphate) removed transcription inhibitors.
ii. Wash Buffer 2 (contained 20 mM NaCl, 2 mM Tris-HCl and absolute
ethanol) purified template DNA from remaining impurities
The final spin was performed at 14000 rpm for 1minute and then repeated to
dry the column of excess alcohol.
C. Elution
The column was placed into a new reaction tube. 40 µl elution buffer
(containing nuclease-free, sterile, double distilled water) was added to the
centre of the filter and then centrifuged at 8000 rpm for 1 minute. This
procedure was then repeated with a further 40 µl elution buffer. The eluate was
combined and centrifuged at 14000rpm for 2 minutes.
The sample was immediately placed on ice. A 2 µl sample was taken at this
point to be read on the spectrophotometer (or Nanodrop). Readings of sample
concentration were taken which allowed calculation of the amount of sample
required (100ng dsDNA) to proceed to transcription and labelling.
The formula when calculating dsDNA is similar to that described previously
but here the extinction coefficient for dsDNA diluted in water is 50 i.e. an
absorbance of 1 unit at 260 nm corresponds to 50µg dsDNA per ml.
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For example,
Volume of dsDNA sample (eluted volume) = 80 µl
Dilution = 2µl of dsDNA sample + 8 µl distilled water (1/5 dilution).
Measured absorbance of diluted sample in a 10 µl cuvette; A = 0.100
Concentration of DNA sample = Extinction coefficient* x A x dilution factor
= 50 x 0.100 x 5
= 25 µg /ml Ł 25 ng/ul
To calculate volume containing 100ng:
25 ng = 1ul
1 ng = 1 µl
25
1 ng x 100 = 1 µl x 100
25
100ng dsDNA = 4µl
The volume containing 100ng dsDNA was calculated and pipetted into a 0.5
ml tube and dried in the speed vac at room temperature. It was important to
note the orientation of the collecting tube during the drying stage in the speed
vac. This was in order to visualise the dried pellet so that the reagents used in
the next step could be added directly onto it minimising the risk of losing the
pellet.
2.5.4 T7 Transcription and Labelling of dsDNA using the MEGAscript T7
Kit
The following reagents were added to 100ng of dried dsDNA:
x 10 x reaction buffer 2 µl
x ATP/CTP/GTP-mix stock solution (25mM each) 6 µl
x U-nucleotide stock solution (50mM) 2 µl
x Nuclease free water 3 µl
x Enzyme mix including T7 RNA polymerase 2 µl
x Cy3-UTP (5mM)(or Cy5-UTP) 5 µl
Total volume 20 µl
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These reagents were added to the dried dsDNA and carefully mixed again by
pipetting.
i. This stage involved reverse transcription of the dsDNA template using
T7 RNA polymerase. At the same time cyanine 3-NHS-ester or cyanine
5-NHS-ester (Cy3-UTP or Cy5-UTP) was added so that the Cye dye
was incorporated as transcription reaction occurred i.e. direct labelling.
The mixture was incubated in a water bath at 37°C for 16 hours.
2.5.5 Purification of labelled cRNA using High Pure RNA Tissue Kit
At room temperature the following reagents were added to the labelled cRNA:
x 80 µl RNase free water
x 400 µl binding buffer (containing mercaptoethanol)
x 200 µl absolute ethanol
The reagents were mixed and then transferred onto a spin column and
centrifuged at 8000 rpm for 15 seconds, and the flow through discarded.
a) Washing steps:
This was performed using the protocol as described earlier following 2
nd
strand
synthesis in order to remove unbound DNA, primers, enzymes, and salts from
the labelled cRNA.
b) Elution:
This was performed in the same way as mentioned previously giving 80 µl of
labelled cRNA. A 1µl sample was taken for spectrophotometer reading. The
labelled cRNA was then stored in the -80°C freezer in the dark.
It was important to remember when handling Cye dyes or reagents containing
them, to do it in low light levels in order to avoid degradation or bleaching of
the dye.
The concentration of labelled cRNA was measured using the
spectrophotometer and the volume of each sample containing 15 µg calculated
in the same way as described previously.
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2.5.6 Fragmentation of labelled cRNA
On ice 15 µg of labelled cRNA were combined for each sample and its control.
With the early experiments this control was made in the same in exactly the
same way as outlined above using human pooled gene RNA. The sample was
made up to 48 µl with RNase free water (*some samples required
concentrating in the speed vac). To this was added 12ȝl 5x Fragmentation
buffer.
i. cRNA products of T7 transcription are long (between 2-5 kb) and were
fragmented with fragmentation buffer.
The sample was mixed and briefly vortexed and then incubated in the
thermocycler at 94°C for 15 minutes, and then placed back on ice.
2.5.7 Purification of labelled, fragmented cRNA:
100 µl RNase free water was added to the cRNA and mixed carefully by
pipetting and then transferred onto a Microcon concentrator and centrifuged at
9000 rpm for 10 min, making sure that a small layer of liquid remained above
the membrane filter, to avoid drying out which would potentially cause
degradation of the cRNA. The filter was removed and placed upside down in
a new 1.5 ml reaction tube and eluted by centrifugation at 2500 rpm for 3 min.
2.6 Hybridization
The eluate was dried in a speed vac (maximum temp. 30°C, kept dark). The
pellet was re-dissolved in 10 µl hybridization buffer and incubated at 94°C for
3 minutes then placed on ice.
i. 10 µl was the re-suspension volume recommended to cover the printed
area of the slide under a 22mm coverslip.
The mixture was carefully transferred to the microarray slide. The principle
involved applying the sample to one corner of the coverslip in order to allow
capillary action to suck the hybridisation mix to cover the appropriate area
evenly and without bubbles. The slide was secured in a hybridization block and
incubated in a waterbath for 42 hours at 42°C.
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Washing
The slides were then washed in the following solutions preheated to 30°C for
five minutes each:
x 2x SSC, 0.1% SDS
x 1x SSC
x 0.5x SSC
The decreasing concentration of SSC used in each solution provided washes
with decreasing astringent properties. The slides were dried by placing them
securely in 50 ml Falcon tubes and centrifuging them at 1600 rpm for 2
minutes (with a swing-out rotor).
The slides were then stored in the dark ready for scanning.
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2.7 RNA Amplification – New Method.
aRNA amplification procedure using the Ambion Amino Allyl MessageAmp
TM
aRNA Kit (Amersham Biosciences, Bucks, UK) – Method B
i. This technique was based on the principle as described by Van Gelder
et al [135] using the T7 Oligo (dT) Primer to synthesize cDNA by
reverse transcription.
ii. Half quantities of reagents were used which had been found to give
good aRNA yields
2.7.1 Incorporation of aaUTP
The Amino Allyl MessageAmp aRNA Kit incorporated the modified
nucleotide, 5-(3-aminoallyl)-UTP (aaUTP) into the aRNA during in vitro
transcription. aaUTP contains a reactive primary amino group on the C5
position of uracil that can be chemically coupled to N-hydroxysuccinimidyl
ester-derivitized reactive dyes (NHS ester dyes) in a simple, efficient reaction
(see Figure 10). Once purified, the dye labelled aRNA can then be used for
microarray hybridization.
Figure 10 - Amino Allyl Labelling Reaction
Taken from Amino Allyl MessageAmpTM aRNA Kit manual (version 0503)
Figure 11 is a diagrammatic overview of the amino allyl message amp a RNA
procedure.
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Figure 11 - Amino Allyl Message Amp Procedure [142]
2.7.2 First strand cDNA synthesis
1 µg of total RNA was placed into a sterile RNase-free microfuge tube. 0.5 µl
of T7 Oligo(dT) Primer was added and the final volume made up to 12 µl with
nuclease-free water and incubated for 10 min at 70°C in a thermal cycler.
i. The (total) RNA was primed with the T7 Oligo(dT) Primer to
synthesize cDNA with a T7 promoter sequence (at the 5’ end) by
reverse transcription.
The RNA samples were centrifuged briefly (~5 sec) to collect the sample at
bottom of tube and then placed on ice.
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Sufficient reverse transcription master mix was prepared to synthesize first
strand cDNA from all of the RNA samples in the experiment. An extra 5% of
all reagents was calculated to cover pipetting error. The following reagents
were added (single reaction):
x 1 µl 10X First Strand Buffer
x 0.5 µl Ribonuclease Inhibitor
x 2 µl dNTP Mix
x 0.5 µl Reverse Transcriptase
x 0.5 µl Spike mix
The mixture was mixed by gently pipetting up and down and centrifuged
briefly to collect the master mix at the bottom of tube and placed on ice.
Lucidea Universal ScoreCard
Lucidea
TM
Universal ScoreCard
TM
was used to validate and normalize
experimental data and to compare microarray data across experiments. It
contains a set of 23 artificial genes designed from yeast intergenic regions
which function as universal references that are consistent between experiments.
Contained within the scorecard are different categories of control:
i. Calibration controls allow evaluation of the dynamic range and
sensitivity of the system.
ii. Ratio controls are used as references when measuring expression levels
(up to 2.5 orders of magnitude.
iii. Utility controls allow the efficiency of the mRNA purification process
to be assessed.
iv. Negative controls allow evaluation of signals produced by non-specific
hybridization.
4 µl of reverse transcription master mix was added to each RNA sample mixed
thoroughly and placed in the incubator set at 42°C for 2 hrs. After two hours
the tubes were centrifuged briefly and placed on ice.
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2.7.3 Second strand cDNA synthesis
Single stranded cDNA was converted using the T7 promoter primer into full
length double stranded DNA (dsDNA), the transcription template.
On ice, the following second strand cDNA synthesis reagents were added to
the reaction mix (quantities are given for a single reaction):
x 10 µl cDNA sample
x 31.5 µl Nuclease-free Water
x 5 µl 10X Second Strand Buffer
x 2 µl dNTP Mix
x 1 µl DNA Polymerase
x 0.5 µl RNase H
The mixture was mixed by gently pipetting up and down and centrifuged
briefly to collect the master mix at the bottom of tube and placed on ice. Then
the reaction tubes were incubated at 16°C for 2 hours.
2.7.4 Purification of dsDNA
i. The cDNA purification procedure removed enzymes, salts,
unincorporated dNTPs and RNA from the cDNA sample. This
eliminated the enzymatic digestion step that was used in the old
method, to degrade RNA.
Before beginning the cDNA purification, the nuclease-free water was
preheated to 50°C. One cDNA filter cartridge was firmly seated in a 2 ml wash
tube and 50 µl cDNA Binding Buffer pipetted onto the filter and incubated at
room temperature for 5 min.
ii. If a precipitate was visible in the cDNA Binding Buffer it was re-
dissolved by warming the solution to 37°C and then allowed to cool to
room temp before use.
A further 250 µl of cDNA binding buffer was added to each cDNA sample and
mixed thoroughly. This was pipetted onto the centre of a cDNA filter cartridge
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and centrifuged for 1 min at 10,000g. The flow-through was discarded and the
cDNA Filter Cartridge replaced in the 2 ml wash tube.
500 µl of cDNA wash buffer was added to each cDNA filter cartridge and
centrifuged for 1 minute at 10,000g and the flow-through discarded. The
cDNA filter cartridge was spun for an additional minute to remove trace
amounts of ethanol then transferred to a cDNA elution tube. To the centre of
the filter 9 µl of nuclease free water (preheated to 50°C) was applied. This was
incubated at room temperature for 2 min and then centrifuged for1.5 min at
10,000g. The procedure was repeated with a second 9 µl of nuclease-free water
giving ~14 µl of double-stranded cDNA.
2.7.5 In vitro transcription to synthesize aRNA
i. This was the amplification step. The amino aaUTP generated multiple
copies of amino allyl modified aRNA from the double-stranded cDNA
template.
According to the protocol the inclusion of aaUTP by in vitro transcription had
only minor effects on the reaction efficiency and yield. Additionally, since the
incorporation of aaUTP by in vitro transcription was virtually identical in
different samples, and since the dye coupling reaction was efficient and
reproducible, labelled samples should not have the biases that could result from
direct incorporation of modified nucleotides.
The following transcription reaction components were assembled (as a master
mix) at room temperature, mixed and briefly centrifuged.
x 7 µl double-stranded cDNA
x 1.5 µ aaUTP Solution (50 mM)
x 6 µl 12 µl ATP, CTP, GTP Mix (25 mM)
x 1.5 µl 6 µl UTP Solution (50 mM)
x 2 µl 4 µl T7 10X Reaction Buffer
x 2 µl 4 µl T7 Enzyme Mix
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The transcription reactions were incubated for 14 hrs at 37°C in an air
incubator. An optional DNase treatment was used to remove template cDNA
from the aRNA. 2µl DNase I was added to each reaction, gently mixed, then
centrifuged briefly o collect the reaction at the bottom of tube and incubated
for 30 min at 37°C.
2.7.6 aRNA Purification
78 µl of nuclease-free water (pre-heated to 50°C) was added to each aRNA
sample to bring the final volume to 100 µl. This was mixed thoroughly. 350 µl
of aRNA binding buffer was added to each aRNA sample, and mixed
thoroughly. 250 µl of ACS grade 100% ethanol was added to each aRNA
sample and mixed thoroughly.
The mixture was pipetted onto the centre of the filter in an aRNA filter
cartridge and centrifuged for 1 min at 10,000g. 650 µl aRNA wash buffer was
added to each aRNA Filter Cartridge and centrifuged for 1 min at 10,000g. The
flow-through was discarded and the aRNA Filter Cartridge replaced in the
aRNA collection tube and spun for an additional ~1 min to remove trace
amounts of ethanol. The filter cartridges were transferred to a fresh aRNA
collection tube and 50 µl of pre-heated nuclease-free water pipetted onto the
centre of the filter. After 2 min the tubes were centrifuged for 1.5 min at
10,000g, and the elution repeated with a further 50 µl of nuclease-free water.
The concentration of the purified aRNA was determined using the Nanodrop
Spectrophotometer before continuing to the next step: the dye coupling
reaction.
2.7.7 Amino Allyl aRNA: Dye coupling and clean-up.
5 µg aRNA was taken and concentrated to a volume of 7ȝl by one of two
methods:
i. Sodium acetate precipitation
ii. Vacuum dried
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I. Precipitation method
The appropriate volume containing 5 µg aRNA (A) was added to one-tenth of
this volume of 3M sodium (1/10A=B). To this, two times the sum of the
volumes of aRNA and Na acetate was added 100% ethanol i.e.
Volume 100% ethanol = 2x (A+B)
This was mixed and placed on ice for 20 minutes to allow the precipitation of
aRNA to occur. The tube was spun for 15 minutes to collect the precipitant as a
pellet. It was important to note the orientation of the tube/pellet. The
supernatant was removed taking care not to remove the pellet. The pellet was
washed with 200µl of 70% ethanol and the supernatant discarded. A further
200µl of 70% ethanol was added and the tube spun for 5 minutes at 10,000g
and 4°C and then the supernatant removed. The pellet was vacuum dried until
any residual alcohol had evaporated. The volume of each aRNA sample was
made up to 7 µls with nuclease free water. 9 µl of coupling buffer was added
and mixed well.
2.7.8 NHS Ester Dye Preparation:
4ȝl of DMSO was added to each vial of Cye Dye (Amersham Biosciences).
The ester dye was added to the aRNA coupling buffer mixture, mixed well and
incubated for 30 min at room temp in the dark. 4.5 µl 4M Hydroxylamine was
added, mixed and incubated for 15 min at room temp in the dark. This was to
quench the amine-reactive groups on the un-reacted dye molecules.
2.7.9 Dye Labelled aRNA Purification
The aRNA purification procedure described previously was repeated. The filter
in the aRNA Filter Cartridge generally acquired the colour of the fluorescent
dye during the purification. This was from the labelled aRNA binding to the
filter. Most of the colour disappeared when the purified aRNA was eluted.
The sample was stored at –20°C in the dark. The dye labelled aRNA will be
referred to as the Probe.
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2.7.10 Probe Preparation
For each slide to be hybridized, a sample of each labelled probe (one cy3, one
cy5) containing 40pmol of dye labelled cRNA was placed together in a 0.5 ml
tube. Nuclease free water was added to give a total volume of 48 µl. 2 µl of
Cot I DNA (to reduce non specific hybridization) and 50 µl of MWG 2x
Hybridization Buffer was added bringing the total volume to 100 µl. The
sample was kept on ice until required.
2.8 The Microarray
A. Initial Method
Custom designed microarray slides were used in the original experimental
design. These had been developed in conjunction with MWG biotech. They
contained 116 oligonucleotide spots. For reasons discussed later in section 0
(Rationale for changes in technique), the use of the slides was abandoned and
no analysis was performed on the data acquired from these slides. For these
reasons the slide design and choice of oligonucleotides will not be described or
discussed.
B. New Method
In conjunction with the Department of Immunology at Nottingham university
“in house” microarray slides were used. In contrast to the customised slide
used in the initial Method, the in house slide was manufactured on site and
contained 32488 oligonucleotides to represent the human genome and more
hypothetical genes. It was subject to vigorous quality control [143].
I. Microarray printing and rehydration
Arrays were printed using a Biorobotics Microgrid II 600. The Microgrid II
takes 108 slides in four trays, and can hold 24 x 384 well plates within its
biobank. The printing pins used were Matrix 2500 pins, which give ~80
micron diameter spots. The human array was printed with 48 pins in a 4x12
array. The slides used were Schott Nexterion A+ (gamma APS coated) with a
laser etched barcode [143].
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Once the oligonucleotide spots were printed onto the glass slide the following
protocol was used to rehydrate the spots so that they appeared as spots or discs
with an equal density of oligonucleotide throughout each spot. Sub-optimal
rehydration would lead to the spots appearing doughnut shaped.
Using powder free gloves the slides were placed array side down into the re-
hydration tray and place into the humidifier (set at approx. 70% humidity) for
5-10 min, until full hydration was achieved. The slides were snap dried by
briefly placing them onto a heating block (array side up) for 2-3 seconds and
placed back into the plastic slide holders. Then they were placed into an oven
for 3 hours at 70-80°C. Whilst the slides were heating, dishes for washing the
slides was prepared. The first was left empty; the next two filled with ultra pure
water and the final one with 95% ethanol.
To 335ml of 1-methyl-2-pyrrolidinone 5.5g of succinic anhydride was added
and dissolved. Once dissolved 15ml of 1M sodium borate (pH8) was added.
This buffered blocking solution was poured into the first glass slide dish and
the slides plunged rapidly into it vigorously shaken, keeping the tops of the
slides under the solution for approximately 1 minute.
The slides were placed onto a shaker in their dish and shook gently for 15 min.
Excess blocking solution was drained off then the slide rack transferred into the
first dish of water and gently agitated under the water for a few seconds. The
rack was quickly transferred into the second dish of water and then the ethanol
and the procedure repeated. The dish was centrifuged for 1 minute at 550 rpm.
The slides were checked to be clean and dry then stored in plastic slide holders.
II. Hybridization
Hybridization was performed using the Tecan TX100 hybridization station (see
figure 12). It was capable of hybridizing 12 microarray slides at a time. The
standard manufacturers’ protocol was used. This was a semi-automated
machine that required the use of a computer and some user input.
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Figure 12 - Tecan HS4800 Automated hybridisation station
The hybridisation was done in 9 steps taking about 4 hours. Step 1 involved the
initial wash performed at 50°C in the most astringent SSC buffer. In step 2 the
probe was injected into each sample well. Step 3 involved hybridization at
50°C. Steps 4-8 were further washes in buffers with decreasing concentration.
Finally the slides were dried at 23°C (step 9).
III. Image Acquisition - Agilent Scanner
The Agilent microarray scanner (see figure 13) is a laser-induced fluorescence
scanner designed to read microarrays deposited on standard 1 in x 3 in slides.
The scanner measures the fluorescence intensity of labelled sample nucleic
acid (DNA and RNA) bound to probe arrays. It is able to measure fluorescence
from two dyes simultaneously required for differential gene expression studies.
This technology provides for rapid, high-quality, automated, “hands-off”
scanning of microarrays.
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Figure 13 - Agilent Automated scanner
Up to 48 slides can be mounted in the scanner and then left to scan each slide
automatically, typically taking 3-4 minutes per slide. The scanner needed to be
connected to a computer with a Pentium® III 800 MHZ processor and 512 MB
RAM, running Windows® 2000 with SP2 and Internet Explorer 5.5 or later
were minimum requirements.
a) Lasers
The microarray scanner used a SHG-YAG laser (532nm) and a helium-neon
laser (633 nm). The lasers excited Cyanine-3 (Cy-3) and Cyanine-5 (Cy-5)
labelled RNA. The scanner was optimized for high signal-to noise performance
in the Cy-3 (550—610 nm) and Cy-5 (650—750 nm) emission channels, with a
wide dynamic range (four orders of magnitude) and low spectral cross-talk.
This allowed for measurement of a very broad range of gene expression levels
and for higher data confidence at lower signal levels.
b) Scanning
The laser excitation was scanned rapidly back and forth across the microarray.
Movement of the microarray in the orthogonal coordinate was accomplished by
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the slow linear stage. The dynamic/tracking auto-focus assembly kept the slide
in focus with the scan lens ensuring the microarray was always positioned in
the detection plane. These features maximise the signal-to-noise ratio by
providing superior linearity, uniformity, and noise performance while scanning
across the microarray surface.
c) Fluorescence detection
Fluorescent emissions from the labelled samples are detected using a high-
performance PMT design. Very low noise amplifiers and analogue-to-digital
converters process the PMT signal with a high signal-to-noise ratio.
IV. Feature Extraction and Analysis - Genepix Pro
The scanned image is saved as a large “raw image” TIFF (Tagged Image File
Format), or rather a multi image TIFF, which contains two separate images
scanned at 532 and 635 nanometers. One image file (containing two images) is
obtained per experiment. This is opened into genepix version 6.1. The Gal file
is then loaded onto the image see Figure 14. The GAL file contained data
relating to each spot on the array.
Figure 14 - Image of Gal file following alignment to the microarray. Only one block is shown
for detail
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Each of the 48 grids (containing 26 x 26 spots) needs to be accurately lined up
to the overlying grid containing the Gal file information. Once the grid is
aligned the option to “find irregular features” is checked. This allows the
software to pick up spots on the array which are not circular and would
otherwise be ignored; causing loss of potentially significant data. The decision
to find irregular feature is based on the fact that when an array slide is scanned
prior to hybridisation the spots are not all exactly circular. Sometimes the spot
appears irregular or doughnut shaped. This variation is due to the slight
variability in the conditions in which the array slides are processed and
hydrated (see section 2.34). This variability in appearance of spots is not
thought to affect the hybridisation process and hence the signal picked up by
the scanner and subsequently by genepix pro, as long as the “find irregular
features” box is checked.
The next stage involves genepix extracting information on each of the spots on
the array including:
x spot size and circularity
x spot intensity mean and median values.
x background intensity
x etc, etc
The resulting file known as genepix results file (GPR file) was stored. This file
contained the raw data that was compatible with microarray analysis software
packages such as J-Express Pro and Pathway Assist.
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2.9 Analysis Methods.
A. Significance Analysis of Microarrays
Significance analysis of microarrays (SAM) is a statistical testing algorithm
developed specifically for microarray data analysis. It identifies induced and
repressed genes with significantly different expression across samples [144]. It
compares 2 or more samples to the control sample where the control sample is
presumed to have a relative expression of 0. SAM takes into account the large
number of genes in microarray dataset and assigns a score to each gene on the
basis of change in gene expression relative to the standard deviation of
repeated measurements [144]. During SAM the data for each gene are
permutated and a test statistic delta value is computed for both the original and
permuted data for each gene[144] . SAM was used to identify significant genes
based on differential expression between groups of samples created depending
on clinical scenario and the control sample. For example, one could look at
differential gene expression between deceased and living donor kidneys that
have immediate function compared to the control. SAM is useful in that it
gives an estimate of the False Discovery Rate (FDR) which is the proportion of
genes likely to have been identified by chance as being significantly
differentially expressed. SAM has an interactive interface which allows the
distribution of the test statistic to be altered and allows the threshold for
statistical significance to be set (through the tuning parameter delta) so that for
example we allow a FDR of 0.05 – the genes identified have a 5% chance of
being discovered by chance. If very large numbers of genes are identified at
this level the FDR can be reduced e.g. to 0.01, i.e. the genes identified have a
1% chance of being discovered by chance. SAM generates a plot of the
observed versus expected delta values where delta is the vertical distance (in
graph units) from the solid line of the slope (which represents observed =
expected).
B. Hierarchical Clustering
Hierarchical clustering was described by Johnson in 1967 [145]. Each sample
(gene) is assigning to its own cluster. The closest (most similar) pair of clusters
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are merged into a single cluster, so that there is one less cluster. Distances
(similarities) are computed between the new cluster and each of the old
clusters. This process is repeated until all items are clustered into a single
cluster of size N. The last step can be done in different ways. In single-link
clustering the shortest distance between a member of one cluster and another
cluster is computed. In complete-link clustering the longest distance between
one cluster and another cluster is measured. In average-link clustering, the
average distance between each member of one cluster and each members of
another is calculated. Average link clustering was used in this analysis.
C. Gene Ontology.
Gene ontology is a collaborative research tool developed to construct and use
ontologies to facilitate the biologically meaningful annotation of genes and
their products[146, 147] . Traditional methods e.g. hierarchical clustering,
analyse data on a gene by gene basis and require time-consuming literature
searching. GO annotations have already assigned biological function to genes.
Genes are subsequently grouped by process e.g. Apoptosis, mitosis glucose
transport etc. Therefore, genes involved in the same process with similar /
different expression patterns are examined. GO terms are organised and related
in a hierarchical manner.
GO captures information about the:
i. function of gene products
ii. where and when it acts
iii. its regulators and what it regulates
GO terms are divided into three parts:
A. Cellular component (CC)
B. Molecular function (MF)
C. Biological process (BP)
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Cellular Component, describes locations, at the levels of sub cellular structures
and macromolecular complexes. Examples of cellular components include ‘cell
membrane and nucleus, with several subtypes of these complexes represented.
Molecular Function, describes activities, such as catalytic or binding activities,
at the molecular level. GO molecular function terms represent activities rather
than the entities that perform the actions and do not specify in what context the
action takes place. Examples of individual molecular function terms are the
broad concept ‘catalytic activity’ and the more specific ‘hydrolase activity’,
which represents a subtype of catalytic activity.
Biological Process, describes biological goals accomplished by one or more
ordered molecular functions. High-level processes such as ‘cell death’ have
both subtypes, such as ‘apoptosis’, and sub processes, such as ‘release of
cytochrome c from mitochondria ’.
D. Pathway Studio
Pathway studio is an updated version of the software application. Pathway
assist comes with a database of molecular networks assembled from scientific
papers [148].
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3 RESULTS
3.1 Rationale for change in initial experimental design
The original experiment design involved the use of customised MWG Biotech
array slides which are described in section 2.34. The RNA was handled and the
probes were processed using the protocol described in section 2.5 (RNA
Amplification – Initial Method). RNA was extracted from the 28 tissue
samples taken between March 2001 and May 2002 using the RNeasy Mini
Kit. The quantity and quality of RNA produced was measured using a Pye
Unicam spectrophotometer. The analysis reading was given in graphical form,
of the 260/280nm absorbance spectrum and the calculated 260/280nm ratio
were used as quality control at the different steps of probe preparation. An
example is shown in figure 15. Ideal ratios should be between 1.8 and 2.1. Less
than 1.8 can indicate too much protein contamination and above 2.1 may imply
degradation.
Figure 15 - reading from Sample 4 shows the typical spectrophotometric curve
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It shows a good clean curve suggesting that the RNA is not significantly
degraded or contaminated. However, the absorbance (y-axis) is very low
suggesting that the quantity of RNA is very low in this sample. For this sample
the absorbance was 0.062 and 0.039 at 260 and 280nm respectively. The
resulting ratio was 1.589 which, unlike the curve suggests that this sample is of
poor purity. The low reading and apparent poor quantity / quality of the
samples might have arisen from poor calibration of the spectrophotometer.
However, similar results were obtained before and after servicing and
calibration of the equipment (see Table 7 & Table 8).
Sample No. Elute (ul) 260 280 Ratio Spec DF
1 50 0.017 0.011 1.513 70
2 50 0.034 0.023 1.469 70
3 50 0.057 0.034 1.67 70
4 50 0.085 0.052 1.644 70
Table 7 - Spectrophotometer readings taken following mRNA extraction using a 100µl cuvette
prior to calibration
Sample No. 260 280 Ratio Quantity in ul to=5ug Conc (ug/ul)
1 0.009 0.006 1.589 138.9 36.0
2 0.020 0.013 1.563 62.5 80.0
3 0.048 0.030 1.569 26.0 192.0
4 0.062 0.039 1.589 138.9 248.0
Table 8 - Spectrophotometer readings taken following transcription mRNAĺGV'1$ with
100µl cuvette following calibration
This finding raised the possibility that the RNA quantity and quality was
genuinely low in all of the samples. A second possibility which would account
for the low readings was the need to use a x100 dilution factor with the cuvette.
Whilst other users had found the machine reasonably reliable, they were using
much larger quantities of sample material. This suggested that the degree of
dilution was beyond the spectrophotometer accuracy limits. We next used a
cuvette which required much smaller sample volumes allowing the use of a
smaller dilution factor.
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Sample No. 260 280 Ratio Conc (ug/ul)
1 0.202 0.103 1.964 40.4
2 0.409 0.202 2.024 81.8
3 0.870 0.448 1.942 174.0
4 1.261 0.630 2.000 242.0
Table 9 - Spectrophotometer readings taken using the 10µl cuvette
The readings shown in Table 9 indicated that that use of this lower dilution
factor gave different results. As expected the absorbance was higher. More
importantly the A260 /A280 ratios were higher, between 1.96 and 2.02 which
indicating that the purity of the RNA was good enough to continue with probe
preparation.
This assessment of sample quality was applied to the full set of samples and
again following transcription to dsDNA. Sample quality was assessed (see
section – 2.12) and not processed further if the curve was not smooth or had
any abnormal peaks. Examples are given in Table 10.
Sample No. 260 280 Ratio Conc(ug/ul) Yield(ug/ul)
1 0.097 0.080 1.202 24.3 1.94
2 0.062 0.048 1.294 15.5 1.24
3 0.100 0.082 1.218 25.0 2.00
4 0.094 0.071 1.333 23.5 1.88
Table 10 - Sample readings following transcription to dsDNA
The control and test sample readings of the dsDNA were similar to those
shown in Table 10 i.e. having a ratio of 1.2 to 1.3. The low ratio suggested that
there was a problem at some stage in the protocol. However, controls
performed using the control RNA or DNA samples supplied with each kit gave
similar results, and previous use of the above protocol by another researcher
had given similar spectrophotometer readings and yields of DNA and RNA,
and had been successful when used to make probes for microarray.
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Therefore, test hybridisations were carried out using the samples that had been
made using Cye labelled probes synthesised using the MEGAscript T7 Kit.
Following hybridisation the array slides were transported appropriately to
MWG Biotech for scanning. However, the slides showed no evidence of
hybridisation.
The initial technique involved using a single channel microarray i.e. only one
sample. Normalisation of the sample data was to be performed using statistical
techniques. The starting concentration of dsDNA was not measured raising the
possibility that much larger quantities of dsDNA were being hybridised leading
to a “positive” result.
It may have been the case that the quantity or quality of sample being used was
insufficient to hybridize successfully to the microarray slide, or hybridization
may have occurred but too inadequate to be detected in the scanner. As part of
the problem solving process it was thought prudent to test the integrity of the
microarray slides.
Advice was sought from MWG Biotech. At their suggestion two samples with
spectrophotometer readings to suggest that the starting RNA and final
amplified dye labelled dsDNA (probe) was good in quantity and quality.
Sample No. 260 280 Ratio Conc(ug/ul) Yield(ug/ul)
14 1.11 0.58 1.90 2.23 22.3
16 1.65 0.92 1.80 1.51 33.1
Table 11 – Spectrophotometer readings of samples sent to
MWG for quality testing and hybridisation
MWG performed quality control using the Agilent Bioanalyser and Nanodrop
spectrophotometer. They found the probes to be good quality and so performed
the hybridisation under their laboratory conditions. No evidence of
hybridisation was found on the slides. Their next suggestion was to send some
sample RNA for them to make a probe. This was also unsuccessful.
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In order to exclude error arising from the use of reagents past their shelf life
new kits were purchased and fresh reagents made.
Tissue that had been optimally extracted had now been used. New RNA
extraction, transcription and amplification kits, had been used and MWG
Biotech had quality control tested and repeated the experiments with no
positive outcome. It seemed increasingly likely that the array slides may have
deteriorated despite being stored as recommended by the manufacturer (in the
dark at 5-8°C). MWG suggested testing more of the slides with their own
probes which were “tried and tested”.
In parallel to those developments, a review of the literature on RNA quality
and tissue storage highlighted the use of RNAlater as a well recognised and
accepted storage media. All new tissue samples were stored in it from this
point on
There were clearly fundamental problems with the experiment. Potentially the
probe preparation process was not at fault and the array slide had deteriorated.
However, during the fault finding process it became apparent that microarray
technology had progressed. Microarray experiments were capable of
representing the entire human genome and new bio analytical software was
designed to work most efficiently with dual channel experiments.
It was recognised that single channel microarray experimentation would
require additional biostatistical processing in order to analyse gene expression
patterns. This would have involved normalisation of data being based only on
sets of housekeeping genes built into the slide. The current trend in microarray
analysis was to use dual channel microarray (test sample and control sample
are labelled with different coloured dyes). Also, there had been much
development in biostatistical software packages (e.g. Genepix Pro, J-Express)
that were optimised for dual channel experiments using a control sample.
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These facts led to the implementation of a new technique using two channels,
(dye labelled test sample and a dye labelled control sample) hybridised onto a
microarray slide containing oligonucleotide spots to represent the entire human
genome.
In summary the change in methodological technique to method B was made for
to a number of reasons. Logistic difficulties were encountered when seeking
technical support form MWG Biotech. Hybridized slides had to be sent away
for scanning, which was time consuming and highly expensive. The original
customised array slide that had been developed by in conjunction with MWG
Biotech contained a small number of oligonucleotides, not suitable for
analysis; the aim of which was to identify changes in gene expression, and
biological processes at a cellular level. Microarray technology had developed
to a point where the entire human genome could be represented on one array
slide. Method B was being developed at the Department of Immunology. Up to
date, industry standard hardware was available for use and technical advice
was at hand.
3.2 Qualitative and quantitative analysis - comparison of initial
and new method.
All RNA extracts were tested on the Nanodrop spectrophotometer and Agilent
Bioanalyser and a record of material suitable for further processing was made.
144 RNA extract were tested in this way resulting in only 46 deemed suitable
for probe preparation.
The following are examples of readings of samples taken on the Nanodrop and
Agilent machines to demonstrate good samples and samples which show
varying degrees of denaturement. Figure 16 and Figure 16 demonstrate a good
yield and good 18S and 28S peaks. Note the ratio in height between the peaks
and the background and the control spike (of the RNA ladder) shown at 24
seconds.
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Figure 16 - Nanodrop reading demonstrating good yield
Figure 17 - Agilent reading demonstrating good 18S and 28S peaks
Nanodrop reading demonstrating good yield Agilent reading demonstrating
good 18S and 28S peaks. The example shown in Figure 18 and Figure 19 is of
a sample that is not as good in quality or concentration as the upper example
but acceptable for probe preparation [149].
Figure 18 - Nanodrop reading demonstrating poorer yield
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Figure 19 - Agilent reading demonstrating poorer but acceptable 18S and 28S peaks
In Figure 20 and Figure 21 it can be clearly seen in that this sample contained
very little RNA. The trace from the Nanodrop shows a characteristic pattern
suggestive of RNA degradation.
Figure 20 - Nanodrop reading demonstrating minimal yield
Figure 21 - Agilent reading demonstrating RNA degradation
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In the example shown in Figure 22 and Figure 23 there is very little if any RNA
and it only contains degraded material.
Figure 22 - Nanodrop reading demonstrating no yield
Figure 23 - Agilent reading demonstrating loss of RNA
The minigel shown in figure 23 is an example of RNA that had been extracted
from tissue that had not been stored in RNA later. Samples 43 and 44 have
identifiable 18S and 28S bands, however, there are also a lot of background
bands that suggest degradation. It is an example of electrophoresis performed
on samples that had been stored without the use of RNA later.
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Figure 24 - Minigel demonstrating degraded RNA extracted from tissue not stored in RNA later
In contrast all of the samples apart from samples 15 and 16 show clean well
demarcated 18S and 28S bands indicating preserved RNA. All of these samples
had been stored using RNAlater®. The trace from samples 15 shows a poorly
demarcated, wide central band indicating poor sample quality. Sample 15 was
taken from a deceased sourced kidney that did not function; its blood supply
had thrombosed, therefore, this sample would represent necrotic tissue. Sample
16 shows signal across the entire range indicating RNA degradation. This
sample was taken from a living donor kidney and not stored in RNAlater®; its
electrophoretic trace suggesting that significant RNA degradation had taken
place.
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3.3 Data quality control: visualisation, processing, filtering and normalisation
Genepix 6.1
Genepix 6.1 was used. A new experiment was created by opening the Spotpix
suite. The Genepix results files (gpr files) were added. The corresponding jpeg
image file was then added to each experiment. The data channels were
automatically detected (F635 Median – B635 and F532 Median – B532). The
option to combine in array replicates was chosen. This meant that
oligonucleotides were represented on the slide more than once then the median
value of the expression data was calculated. Resultant data was outputted on a
logarithmic scale (log10).
Quality Control
I. Background
Figures 26 and 27 are taken from J-Express. It shows the (log10) intensity of
background signal from the red channel (B635) and the green channel (B532).
Figure 27 - (log10) intensity of background signal from the red channel (B635)
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Figure 28 - (log10) intensity of background signal from the green channel (B532)
Figure 27 reveals the distribution to be fairly uniform apart from areas seen in
blocks 1 and 5. Smears for example, shown in block 19 were used to identify
areas of the array which needed closer scrutiny. These areas were inspected at
high magnification and if the smear was judged to be artefact the spots were
highlighted to be excluded from analysis.
II. Flagged spots, landing lights and the scorecard.
The quality control view was also used to visualise the distribution of spots
flagged up as “not found” by genepix. Removal of flagged spots was done to
improve the normalization and ratio estimates in microarrays. The flagged spots
are shown in red in figure 28.
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Figure 29 - Flagged spots that are not found by J-Express are shown in red.
Figure 29 shows that the flagged spots were reasonably evenly distributed
indicating that the microarray hybridisation had been uniform i.e. there were no
particular areas of the slide that had not hybridised. Interestingly it can be seen
that flagged spots within each of the 48 squares were distributed in the upper
third of the slide. Control and hypothetical genes are printed in the upper third
of each grid.
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Figure 30 - Spots in red are seen as straight lines at the top of each grid. They represent landing
lights and the scorecard.
Figure 29 shows the QC image when the flag value (-75) was used to identify
the landing lights and scorecard spots. Landing lights were always seen as 4
green spots in the corner of each grid. They were used to guide the gal file to
line up each spot with its representative information (gene name and position
on the slide). The scorecard was a series of spots on the top row of each grid.
The scorecard was the mixture of oligonucleotides added to the probe mix and
show up as increasingly bright spots. They were used as a quality control
measure to confirm that each Cye dye colour is correctly represented on the
slide and it also provided a calibration scale.
III. Processes: Filters, Normalisation and visualisation
Using the “add process” button filtering parameters, normalisation and
visualisation plots were added and edited (see figure 30).
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Figure 31 - Processes and filters used and applied to all samples
IV. String Filters
String Filters identified and removed scorecard spots (pjt.*), unnamed spots,
landing lights and arabidopsis (control) spots. Value filters were used to remove
very low level intensity spots and a small number of (over)saturated spots. One
Way Filters removed irregular spots (circularity), spots flagged by GenePix as
“not found”, spots where the foreground intensity was no different to the
background intensity (F532 Median – B532<=0) for both channels. The one
way filter %> B635+2SD <80, removed all spots where less than 80 % of the
foreground pixels were above 2x the standard deviation of the background.
Basically, this removed spots which had an intensity very close to the
background intensity and therefore could not be differentiated. The figure of
80% was chosen as some of the arrays were noticed to have very high
background level, and hence spots were being included in the data which had a
signal intensity no different to the background. Increasing to 80% removed
most of these spots.
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Each stage was visualised using “Plot” to see the data that had been filtered -
see figures 31-35.
Figure 32 - Spotpix view showing the mask, i.e. all spots that have been detected in genepix.
A= small spot, B = normal size hollow intensity spot, C = up-regulated spot,
D = equally expressed spot, E= down-regulated spot.
Figure 31 demonstrates what Genepix sees as potential spots prior to filtering.
It looked for all spots in the grid and highlighted them. The arrow labelled A
points to an obviously small spot which we hoped to remove. It was not
necessary to use a filter based on spot size as these spots were removed by the
value filter <100 (see figure 34). Spot B was a spot of normal size, however, its
intensity was no different to the overall background slide intensity and was
removed by any of the latter 4 one way field filters shown in figure 30. Spot C
was a spot that we were interested in and is shown in red. It represents a gene
that was up-regulated in the sample compared to the control sample. Spot D is a
spot that was expressed equally in the test versus control sample. Spot E is a
spot that was down-regulated in the test versus control sample.
E
D
C
B
A
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Figure 33 - Spotpix view demonstrating the remaining circled spots that are left following
removal of spots flagged by genepix. Box A - spots filtered. Box B = unfiltered unwanted
spots.
In figure 32, box A contains an area of the slide where all spots were filtered
out. It can be seen that there are still a large number of small, irregular or low
intensity spots that are close to the background. Box B demonstrates an area
where all of the spots contained within it are unwanted. The value filter was
used to remove spots where either one or both channel intensities was less than
100 and was effective in removing these spots, see figure 33. In practical terms
this filter removed spots which had very low intensities that were no different
to the slide background being neither positively nor negatively expressed in that
sample and therefore of no interest. Other filter options could have been used
to remove for example, small spots of less than 50 um (the average spots
diameter being around 75 um). However, the intensity value filter proved to be
effective alone.
A
B
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Figure 34 - Spotpix view highlighting only those spots that have been left following filtering
stages suitable for further analysis. Box B = spots filtered by intensity value filter.
C1 and C2 = remaining spots / artefact.
Figure 33 shows the same box B as shown in figure 32 following filtering. It
can be seen that the unwanted spots were removed. It was noticed that there
remained a few small spots labelled C1 and C2. It was not possible to remove
every unwanted spot and artefact. However, only spots that had a faint light
ring around them were recognised by genepix. Therefore, the remaining spots
and artefacts were not included in the extracted data and so had no consequence
on subsequent analysis.
B
C1
C2
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The histogram in figure 34 demonstrates pre-normalised data that had been
filtered using the processes shown in Figure 30. The plot is log10 foreground -
background intensity (median value of pixels making up a spot) of 532nm
green channel vs. log10 foreground - background intensity of the 635 nm (red)
channel. Each dot represents a gene.
Figure 35 - Plot view highlighting pre-normalised filtered data (violet spots).
Filtered (out) spots are shown in red. The plot is of the difference between foreground and
background intensity at 532 nm vs. the difference between foreground and background
intensities in the 635 nm channel.
A = Marginal spots, B = landing lights, scorecard, C = Filtered data, D = Filtered out data
In Figure 34 the group of spots encircled A were saturated spots that would
potentially skew the data if included in the dataset and were removed by the
intensity value filter. Group B contains landing lights and scorecard spots.
Group C contains filtered data that was used in subsequent analysis. The line of
best fit shown in red can be seen to be below x = y. The data was therefore seen
to be skewed. This occurred due to the variability in hybridisation across the
experiments. The plot was the difference between foreground and background
intensity at 532 nm vs. the difference between foreground and background
intensities in the 635 nm channel. If one channel’s background e.g. 532nm
predominated the overall appearance of the slide would have been green. In
order to correct for these differences so that spot intensities were shown in
proportion to the background, Lowess Global Normalisation was performed.
A
C
B
D
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V. Lowess Global Normalisation (locally weighted scatter plot smoothing)
This normalisation technique was used to correct for differences in dye binding,
background and image scanner settings that potentially affected dye intensity
measurements [150]. Should the discrepancies not be corrected then this was
likely to lead to the data being unfit for analysis. The histogram in Figure 35
shows the filtered data shown in Figure 34 following Lowess Normalisation.
Figure 36 - Plot view highlighting normalised filtered data (violet spots). Additional spots are
seen to be filtered out following normalisation.
The data can now be seen to be shifted in order to correct for the above
mentioned potential discrepancies that would otherwise lead to inaccurate
analysis. Interestingly additional spots labelled A are seen to have been filtered
out that were not visible in the pre-normalised dataset.
A
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3.4 Data Analysis
Sample numbers were a limiting factor in the overall scope of analysis. The
above mentioned analyses were performed on the following groups of samples
(scenarios).
A. Deceased Donors (Immediate function) versus Living Donors (Immediate
function).
B. Deceased Donors (Immediate function) vs. all Non-immediately
functioning donor kidneys (Moderate / Poor / Non-function)
C. Deceased Donors (Immediate function) vs. Deceased donors: moderate /
poor /non-function
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3.4.1 Deceased Donors (Immediate function) versus Living Donors
(Immediate function).
The purpose of this analysis was to identify genes to highlight differences in the
two groups that were as a result of brain-stem death (autonomic storm) and
prolonged cold ischaemia in the deceased donor kidney compared to the living
donor kidney.
3.4.1.1 Significance Analysis of Microarrays.
Gene expression in the two groups was compared using SAM which allows
genes which are significantly up or down-regulated in the test groups compared
to the control group to be identified with a false discovery rate of 5%.
Figure 37 - SAM graph for genes differentially expressed in the Deceased donor compared to
the Living Donor samples, (False discovery rate = 0 and delta = 1.375). Green dots represent
down-regulated genes and red dots up-regulated genes in the deceased versus living donor
dataset (with respect to the control sample).
In Figure 36 the two faint lines represent the region in which genes have not
been significantly differentially expressed at the chosen FDR 5%. The red dots
shows those genes that are significantly up-regulated and the green genes show
significantly down-regulated genes (with respect to the control sample). The
genes whose plot values are represented in black are considered non-significant
at the FDR of 5%. The same control sample was used for each sample so we
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assume that differentially expressed genes in one deceased donor group are up
or down-regulated in comparison to the living donor group. Genes that were
expressed equally are not shown or analysed further.
Using a false discovery rate FDR of 5% identified 1802 genes. An FDR of 1%
identified 606 genes and an FDR of 0% (delta = 1.375) 190 genes. The
following analyses were performed using the larger dataset (1802 genes), in
order to prevent the analysis from becoming too narrowed and in the case of
gene ontology and pathway analysis; to allow a wider diversity of system and
pathways to be identified. The following list of genes identified by SAM and
the hierarchical clustering heatmap are based on the 190 genes (FDR 0%)
dataset.
Table 12 contains the list of genes identified by SAM (FDR 0%) that were
expressed at higher levels in the deceased group versus the living donor group.
SAM detected 190 genes, 143 were down-regulated and 47 were up-regulated.
The fold change refers to the amount of expression in the first set of samples
compared to the expression in the second, e.g. for NM003810 (tumour necrosis
factor (ligand)) expression in the deceased donor group was 81.68 times more
than in the living donor group.
Genbank ID Description Fold
Change
NM_003810 Homo sapiens tumour necrosis factor (ligand) super family,
member 10 (TNFSF10), mRNA.
81.68
NM_021983 Homo sapiens major histocompatibility complex, class II, DR
beta 4 (HLA-DRB4), mRNA
23.44
NM_005851 DOC-1 related protein (DOC-1R). 22.1
NM_002668 Intestinal membrane A4 protein (Proteolipid protein 2). 14.68
NM_003651 Homo sapiens cold shock domain protein A (CSDA), mRNA 12.31
NM_017867 Homo sapiens chromosome 4 open reading frame 27 (C4orf27),
mRNA
8.13
NM_018147 Fas apoptotic inhibitory molecule 1. 7.63
NM_005567 Galectin-3 binding protein precursor (Lectin galactoside-
binding soluble 3 binding protein) (Mac-2 binding protein)
(Mac-2 BP) (MAC2BP) (Tumour-associated antigen 90K).
7.53
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NM_004748 Homo sapiens cell cycle progression 1 (CCPG1), transcript
variant 1, mRNA
7.52
NM_144990 Homo sapiens schlafen-like 1 (SLFNL1), mRNA 7.26
NM_030922 Homo sapiens non imprinted in Prader-Willi/Angelman
syndrome 2 (NIPA2), transcript variant 1, mRNA
7.09
NM_006276 Splicing factor, arginine/serine-rich 7 (Splicing factor 9G8).
[Source:Uniprot/SWISSPROT;Acc:Q16629]
7.04
NM_022350 leukocyte-derived arginine aminopeptidase
[Source:RefSeq_peptide;Acc:NP_071745]
6.84
NM_002027 Protein farnesyltransferase/geranylgeranyltransferase type I
alpha subunit (EC 2.5.1.58) (EC 2.5.1.59) (CAAX
farnesyltransferase alpha subunit)
6.19
NM_006947 Homo sapiens signal recognition particle 72kDa (SRP72),
mRNA
6.08
NM_006708 Lactoylglutathione lyase (EC 4.4.1.5) (Methylglyoxalase)
(Aldoketomutase) (Glyoxalase I) (Glx I) (Ketone-aldehyde
mutase) (S-D- lactoylglutathione methylglyoxal lyase).
5.13
NM_003342 Ubiquitin-conjugating enzyme E2 G1 (EC 6.3.2.19) (Ubiquitin-
protein ligase G1) (Ubiquitin carrier protein G1) (E217K)
(UBC7). [Source:Uniprot/SWISSPROT;Acc:P62253]
5.13
NM_001797 Cadherin-11 precursor (Osteoblast-cadherin) (OB-cadherin)
(OSF-4). [Source:Uniprot/SWISSPROT;Acc:P55287]
5.07
NM_032905 Splicing factor 45 (45kDa splicing factor) (RNA binding motif
protein 17). [Source:Uniprot/SWISSPROT;Acc:Q96I25]
5.04
NM_014740 Probable ATP-dependent helicase DDX48 (DEAD-box protein
48) (Eukaryotic initiation factor 4A-like NUK-34) (Nuclear
matrix protein 265) (hNMP 265) (Eukaryotic translation
initiation factor 4A isoform 3).
4.99
NM_002571 Glycodelin precursor (GD) 4.82
NM_025207 FAD synthetase isoform 2
[Source:RefSeq_peptide;Acc:NP_958800]
4.79
NM_024618 Homo sapiens NLR family member X1 (NLRX1), transcript
variant 1, mRNA
4.75
NM_001788 Septin 7 (CDC10 protein homolog).
[Source:Uniprot/SWISSPROT;Acc:Q16181]
4.71
NM_021628 Epidermis-type lipoxygenase 3 (EC 1.13.11.-) (e-LOX-3).
[Source:Uniprot/SWISSPROT;Acc:Q9BYJ1]
4.66
NM_000173 Homo sapiens glycoprotein Ib (platelet), alpha polypeptide
(GP1BA), mRNA
4.65
NM_006848 Delta-interacting protein A (Hepatitis delta antigen interacting
protein A). [Source:Uniprot/SWISSPROT;Acc:Q15834]
4.17
NM_030967 Homo sapiens keratin associated protein 1-1 (KRTAP1-1),
mRNABottom of Form
4.13
NM_006931 Homo sapiens solute carrier family 2 (facilitated glucose
transporter), member 3 (SLC2A3), mRNA
4.05
NM_020401 Nuclear pore complex protein Nup107 (Nucleoporin Nup107)
(107 kDa nucleoporin).
[Source:Uniprot/SWISSPROT;Acc:P57740]
4.03
NM_002576 Serine/threonine-protein kinase PAK 1 (EC 2.7.1.37) (p21-
activated kinase 1) (PAK-1) (P65-PAK) (Alpha-PAK).
[Source:Uniprot/SWISSPROT;Acc:Q13153]
3.99
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NM_002932 Homo sapiens regulator of mitotic spindle assembly 1
(RMSA1), mRNA
3.82
NM_002663 Phospholipase D2 (EC 3.1.4.4) (PLD 2) (Choline phosphatase
2) (Phosphatidylcholine-hydrolyzing phospholipase D2)
(PLD1C) (hPLD2).
[Source:Uniprot/SWISSPROT;Acc:O14939]
3.81
NM_001345 Diacylglycerol kinase, alpha (EC 2.7.1.107) (Diglyceride
kinase) (DGK- alpha) (DAG kinase alpha) (80 kDa
diacylglycerol kinase).
[Source:Uniprot/SWISSPROT;Acc:P23743]
3.71
NM_000458 Hepatocyte nuclear factor 1-beta (HNF-1beta) (HNF-1B)
(Variant hepatic nuclear factor 1) (VHNF1) (Homeoprotein
LFB3) (Transcription factor 2) (TCF-2).
3.67
NM_015660 GTPase, IMAP family member 2 (Immunity-associated protein
2) (hIMAP2). [Source:Uniprot/SWISSPROT;Acc:Q9UG22]
3.61
NM_014433 Rhabdoid tumour deletion region protein 1.
[Source:Uniprot/SWISSPROT;Acc:Q9UHP6]
3.55
NM_000434 Sialidase 1 precursor (EC 3.2.1.18) (Lysosomal sialidase) (N-
acetyl- alpha-neuraminidase 1) (Acetylneuraminyl hydrolase)
(G9 sialidase).
3.4
NM_014916 Homo sapiens lemur tyrosine kinase 2 (LMTK2), mRNA 3.21
NM_012127 Cip1-interacting zinc finger protein (Nuclear protein NP94).
[Source:Uniprot/SWISSPROT;Acc:Q9ULV3]
3.12
NM_021216 Endothelial zinc finger protein induced by tumour necrosis
factor alpha (Zinc finger protein 71) (ZNF47).
[Source:Uniprot/SWISSPROT;Acc:Q9NQZ8]
2.95
NM_020298 Sulfonylurea receptor 2.
[Source:Uniprot/SWISSPROT;Acc:O60706]
2.91
NM_005215 Netrin receptor DCC precursor (Tumour suppressor protein
DCC) (Colorectal cancer suppressor).
[Source:Uniprot/SWISSPROT;Acc:P43146]
2.78
NM_005381 Nucleolin (Protein C23).
[Source:Uniprot/SWISSPROT;Acc:P19338]
2.37
NM_003991 Homo sapiens endothelin receptor type B (EDNRB), transcript
variant 2, mRNA
2.19
Table 12 - Table of - genes expressed at a higher level identified by SAM. FDR = 0%
Deceased donors versus Living donors. The right hand column indicates the fold change; the
gene is up-regulated in the deceased group in comparison to the living donor group by x fold.
Only 45 genes are shown as the other two are hypothetical genes
Two genes NM 021983 and NM 0038 were seen to up-regulated by 23 and 82
times in the deceased donor group compared to the living donor group.
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Table 13 contains the list of genes expressed at a lower level, identified by
SAM (FDR 0%) that were in the deceased group compared to the living donor
group.
GenBank ID Description Fold
Change
nm_024774 glutamine and serine rich 1 (predicted) -235.423
nm_004646 nephrosis 1 homolog, nephrin (human) -160.492
nm_001254 cell division cycle 6 homolog (S. cerevisiae) (predicted) -92.774
nm_016827 8-oxoguanine DNA-glycosylase 1 -89.555
nm_032630 similar to cyclin-dependent kinase 2-interacting protein
(predicted)
-72.186
nm_001487 biogenesis of lysosome-related organelles complex-1, subunit 1
(predicted)
-71.208
nm_006032 similar to Copine-6 (Copine VI) (Neuronal-copine) (N-copine) -61.66
nm_004003 carnitine acetyltransferase -41.927
nm_024811 similar to RIKEN cDNA 5730453I16 -41.127
nm_019899 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 -39.396
nm_003220 transcription factor AP-2, alpha (predicted) -38.949
xm_049237 RIKEN cDNA 2310022K01 gene -36.527
af118078 PRO1848 protein -34.702
nm_032592 similar to 2610203E10Rik protein (predicted) -32.526
nm_007372 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 (predicted) -32.24
nm_016292 TNF receptor-associated protein 1 -31.553
nm_002027 farnesyltransferase, CAAX box, alpha -29.756
nm_012127 CDKN1A interacting zinc finger protein 1 (predicted) -29.736
nm_025146 Mak3 homolog (S. cerevisiae) (predicted) -27.593
nm_003849 succinate-CoA ligase, GDP-forming, alpha subunit -26.52
nm_012088 6-phosphogluconolactonase (predicted) -26.035
nm_016627 similar to X83328 protein -25.334
nm_017984 zinc finger, CW-type with PWWP domain 1 (predicted) -23.386
nm_023948 motile sperm domain containing 3 -22.682
nm_033058 ring finger protein 29 -22.328
nm_003991 endothelin receptor type B -21.214
nm_002273 keratin complex 2, basic, gene 8 -19.263
nm_004493 hydroxyacyl-Coenzyme A dehydrogenase type II -19.234
nm_018457 similar to RIKEN cDNA 1110020C13 -17.08
nm_015660 GTPase, IMAP family member 2 -15.793
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nm_000789 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 -15.622
nm_004551 NADH dehydrogenase (ubiquinone) Fe-S protein 3 (predicted) -15.236
bc012493 similar to RIKEN cDNA E330009J07 gene (predicted) -15.007
nm_006003 ubiquinol-cytochrome c reductase, Rieske iron-sulfur
polypeptide 1
-14.533
nm_033640 SCAN domain containing 2 -13.666
nm_001797 cadherin 11 -13.309
nm_005866 opioid receptor, sigma 1 -12.431
nm_032383 Hermansky-Pudlak syndrome 3 homolog (human) (predicted) -11.978
nm_020549 choline acetyltransferase (predicted) -11.963
nm_005215 deleted in colorectal carcinoma -11.326
nm_020979 adaptor protein with pleckstrin homology and src homology 2
domains
-11.128
nm_014916 similar to lemur tyrosine kinase 2 -10.748
nm_024029 Yip1 domain family, member 2 -10.573
nm_014138 transmembrane protein 29 -10.469
nm_005809 peroxiredoxin 2 -10.325
nm_016730 folate receptor 1 (adult) -10.303
nm_032445 similar to MEGF11 protein -10.252
nm_013945 similar to paired box gene 7 isoform 1 (predicted) -10.115
nm_018355 zinc finger protein 415 -10.089
nm_005851 similar to DOC-1 related protein -10.025
nm_044472 cell division cycle 42 homolog (S. cerevisiae) -9.792
nm_005083 U2 small nuclear RNA auxillary factor 1-like 1 -9.669
nm_003260 transducin-like enhancer of split 2, homolog of Drosophila
E(spl)
-9.343
nm_001859 solute carrier family 31 (copper transporters), member 1 -9.334
nm_003611 similar to Ofd1 protein (predicted) -8.95
nm_020630 ret proto-oncogene -8.828
nm_033297 NACHT, leucine rich repeat and PYD containing 12 (predicted) -8.448
nm_000281 pterin 4 alpha carbinolamine dehydratase/dimerization cofactor
of hepatocyte nuclear factor 1 alpha (TCF1) 1
-8.398
nm_014960 arylsulfatase G -8.384
nm_012228 methionine sulfoxide reductase B2 -8.365
nm_020552 T-cell leukemia/lymphoma 6 -8.308
nm_018838 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12
(predicted)
-8.15
nm_006848 similar to Delta-interacting protein A (Hepatitis delta antigen
interacting protein A) (predicted)
-7.932
115
nm_014232 vesicle-associated membrane protein 2 -7.856
nm_005013 nucleobindin 2 -7.854
nm_002446 mitogen activated protein kinase 10 -7.751
nm_002436 membrane protein, palmitoylated -7.557
nm_018060 isoleucine-tRNA synthetase 2, mitochondrial (predicted) -7.086
nm_001152 solute carrier family 25 (mitochondrial carrier; adenine
nucleotide translocator), member 5
-6.796
nm_004905 peroxiredoxin 6 -6.778
nm_018249 CDK5 regulatory subunit associated protein 2 -6.705
nm_001183 ATPase, H+ transporting, lysosomal accessory protein 1 -6.581
nm_003776 mitochondrial ribosomal protein L40 -6.537
nm_003685 KH-type splicing regulatory protein -6.531
nm_004548 similar to NADH-ubiquinone oxidoreductase PDSW subunit
(Complex I-PDSW) (CI-PDSW)
-6.511
nm_018237 similar to cell division cycle and apoptosis regulator 1
(predicted)
-6.347
nm_003334 similar to ubiquitin-protein ligase (EC 6.3.2.19) E1 - mouse -6.071
nm_020414 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 -6.067
nm_144990 similar to hypothetical protein 4933406A14 -5.778
nm_013996 tachykinin 1 -5.724
nm_024308 similar to Hypothetical protein MGC18716 -5.661
nm_003477 hypothetical protein LOC311254 -5.554
nm_005601 natural killer cell group 7 sequence -5.42
nm_025107 myc target 1 (predicted) -5.381
nm_002931 ring finger protein 1 -5.315
nm_000528 mannosidase 2, alpha B1 -5.287
l38593 solute carrier family 11 (proton-coupled divalent metal ion
transporters), member 1
-5.283
nm_022785 similar to RIKEN cDNA 4931407K02 (predicted) -5.237
nm_006774 similar to indolethylamine N-methyltransferase -5.194
af258584 similar to hypothetical protein FLJ20003 (predicted) -5.125
nm_005918 malate dehydrogenase, mitochondrial -5.121
nm_022805 small nuclear ribonucleoprotein N -5.038
nm_016504 mitochondrial ribosomal protein L27 (predicted) -5.031
nm_020677 similar to RIKEN cDNA 1110025F24 (predicted) -4.841
nm_003969 ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast)
(predicted)
-4.798
nm_021947 serine racemase -4.721
nm_004568 serine (or cysteine) peptidase inhibitor, clade B, member 6a -4.72
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nm_002051 GATA binding protein 3 -4.689
nm_022095 zinc finger protein 335 -4.683
nm_006012 similar to Putative ATP-dependent Clp protease proteolytic
subunit, mitochondrial precursor (Endopeptidase Clp)
-4.521
nm_004870 mannose-P-dolichol utilization defect 1 -4.484
nm_014940 MON1 homolog b (yeast) (predicted) -4.46
nm_133371 similar to myozenin 3 -4.253
nm_000086 ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-
Vogt disease)
-4.236
nm_024622 similar to RIKEN cDNA 5330408N05 gene (predicted) -4.081
nm_005956 methylenetetrahydrofolate dehydrogenase (NADP+ dependent),
methenyltetrahydrofolate cyclohydrolase,
formyltetrahydrofolate synthase
-4.071
nm_000383 autoimmune regulator (autoimmune polyendocrinopathy
candidiasis ectodermal dystrophy) (predicted)
-4.059
nm_002501 nuclear factor I/X -4.053
nm_013325 ATG4 autophagy related 4 homolog B (S. cerevisiae) -4.006
nm_000121 erythropoietin receptor -3.994
nm_057092 FK506 binding protein 2 (predicted) -3.914
nm_032261 similar to Putative protein C21orf56 homolog -3.846
nm_003975 SH2 domain protein 2A -3.836
nm_021979 heat shock 70kDa protein 2 -3.803
nm_024051 similar to C44B7.7 -3.736
nm_015492 similar to DKFZP434H132 protein -3.633
nm_003950 coagulation factor II (thrombin) receptor-like 3 -3.533
nm_000297 similar to polycystic kidney disease 2 (predicted) -3.499
nm_004360 cadherin 1 -3.49
nm_000173 similar to glycoprotein 1b, alpha polypeptide -3.276
nm_006708 glyoxylase 1 -2.962
nm_022459 exportin 4 (predicted) -2.764
nm_014433 rhabdoid tumor deletion region gene 1 -2.654
Table 13 - Table of - genes expressed at a lower level identified by SAM. FDR = 0%.
Deceased donors versus Living donors. The right hand column indicates the fold change; the
gene is down-regulated in the deceased group in comparison to the living donor group by x
fold.
In tables 12 and 13 more genes are shown to be down-regulated in the deceased
versus living donor group, with a greater fold change in expression values.
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3.4.1.2 Hierarchical clustering
In order to visualise the data shown in tables 12 and 13 and to potentially
differentiate trends of up or down-regulation in genes across samples or groups
of samples, hierarchical clustering was performed on the dataset deceased vs.
living donor (0% FDR). Hierarchical clustering was performed in J-Express
using WPGMA (weighted pair group method with arithmetic mean) [145]. In
order to potentially highlight groups of genes that were only found in one or
other group (e.g. deceased donors), samples were also included in the clustering
algorithm.
Figure 38 Hierarchical clustering of significantly differentially expressed genes identified by
SAM (FDR 0%). Red column labels represent living donors and blue column labels represent
deceased donors. . Group A refers to genes that were down-regulated in the deceased versus
living donor group. Group B refers to genes that were up-regulated in the deceased donors
group (compared to the living donor group)
B
A
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In figure 37 hierarchical clustering reveals two main groups of genes labelled A
and B. Cluster A represents genes that were down-regulated in the deceased
donor group compared to the living group. Group B represents genes that were
up-regulated in the deceased versus living donor group.
a) Hierarchical clustering: up-regulated genes
Table 14 gives the list of genes that were upregulated in the deceased donor
group.
Accession Description
NM_015660 GTPase, IMAP family member 2 (Immunity-associated protein 2) (hIMAP2).
[Source:Uniprot/SWISSPROT;Acc:Q9UG22]
NM_020298 Sulfonylurea receptor 2. [Source:Uniprot/SWISSPROT;Acc:O60706]
NM_005381 Nucleolin (Protein C23). [Source:Uniprot/SWISSPROT;Acc:P19338]
NM_012127 Cip1-interacting zinc finger protein (Nuclear protein NP94).
[Source:Uniprot/SWISSPROT;Acc:Q9ULV3]
NM_021216 Endothelial zinc finger protein induced by tumor necrosis factor alpha (Zinc
finger protein 71) (ZNF47). [Source:Uniprot/SWISSPROT;Acc:Q9NQZ8]
NM_005215 Netrin receptor DCC precursor (Tumor suppressor protein DCC) (Colorectal
cancer suppressor). [Source:Uniprot/SWISSPROT;Acc:P43146]
NM_014433 Rhabdoid tumor deletion region protein 1.
[Source:Uniprot/SWISSPROT;Acc:Q9UHP6]
NM_002571 Glycodelin precursor (GD) (Pregnancy-associated endometrial alpha-2
globulin) (PEG) (PAEG) (Placental protein 14) (Progesterone-associated
endometrial protein) (Progestagen-associated endometrial protein).
[Source:Uniprot/SWISSPROT;Acc:P09466]
NM_025207 FAD synthetase isoform 2 [Source:RefSeq_peptide;Acc:NP_958800]
NM_002663 Phospholipase D2 (EC 3.1.4.4) (PLD 2) (Choline phosphatase 2)
(Phosphatidylcholine-hydrolyzing phospholipase D2) (PLD1C) (hPLD2).
[Source:Uniprot/SWISSPROT;Acc:O14939]
NM_006848 Delta-interacting protein A (Hepatitis delta antigen interacting protein A).
[Source:Uniprot/SWISSPROT;Acc:Q15834]
NM_021628 Epidermis-type lipoxygenase 3 (EC 1.13.11.-) (e-LOX-3).
[Source:Uniprot/SWISSPROT;Acc:Q9BYJ1]
NM_002576 Serine/threonine-protein kinase PAK 1 (EC 2.7.1.37) (p21-activated kinase 1)
(PAK-1) (P65-PAK) (Alpha-PAK).
[Source:Uniprot/SWISSPROT;Acc:Q13153]
NM_001345 Diacylglycerol kinase, alpha (EC 2.7.1.107) (Diglyceride kinase) (DGK-
alpha) (DAG kinase alpha) (80 kDa diacylglycerol kinase).
[Source:Uniprot/SWISSPROT;Acc:P23743]
NM_001788 Septin 7 (CDC10 protein homolog).
[Source:Uniprot/SWISSPROT;Acc:Q16181]
119
NM_006708 Lactoylglutathione lyase (EC 4.4.1.5) (Methylglyoxalase) (Aldoketomutase)
(Glyoxalase I) (Glx I) (Ketone-aldehyde mutase) (S-D- lactoylglutathione
methylglyoxal lyase). [Source:Uniprot/SWISSPROT;Acc:Q04760]
NM_000458 Hepatocyte nuclear factor 1-beta (HNF-1beta) (HNF-1B) (Variant hepatic
nuclear factor 1) (VHNF1) (Homeoprotein LFB3) (Transcription factor 2)
(TCF-2). [Source:Uniprot/SWISSPROT;Acc:P35680]
NM_002668 Intestinal membrane A4 protein (Differentiation-dependent protein A4)
(Proteolipid protein 2). [Source:Uniprot/SWISSPROT;Acc:Q04941]
NM_014740 Probable ATP-dependent helicase DDX48 (DEAD-box protein 48)
(Eukaryotic initiation factor 4A-like NUK-34) (Nuclear matrix protein 265)
(hNMP 265) (Eukaryotic translation initiation factor 4A isoform 3).
[Source:Uniprot/SWISSPROT;Acc:P38919]
NM_000434 Sialidase 1 precursor (EC 3.2.1.18) (Lysosomal sialidase) (N-acetyl- alpha-
neuraminidase 1) (Acetylneuraminyl hydrolase) (G9 sialidase).
NM_020401 Nuclear pore complex protein Nup107 (Nucleoporin Nup107) (107 kDa
nucleoporin). [Source:Uniprot/SWISSPROT;Acc:P57740]
NM_003342 Ubiquitin-conjugating enzyme E2 G1 (EC 6.3.2.19) (Ubiquitin-protein ligase
G1) (Ubiquitin carrier protein G1) (E217K) (UBC7).
[Source:Uniprot/SWISSPROT;Acc:P62253]
NM_005567 Galectin-3 binding protein precursor (Lectin galactoside-binding soluble 3
binding protein) (Mac-2 binding protein) (Mac-2 BP) (MAC2BP) (Tumor-
associated antigen 90K). [Source:Uniprot/SWISSPROT;Acc:Q08380]
NM_022350 leukocyte-derived arginine aminopeptidase
[Source:RefSeq_peptide;Acc:NP_071745]
NM_006276 Splicing factor, arginine/serine-rich 7 (Splicing factor 9G8).
[Source:Uniprot/SWISSPROT;Acc:Q16629]
NM_002027 Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit
(EC 2.5.1.58) (EC 2.5.1.59) (CAAX farnesyltransferase alpha subunit) (Ras
proteins prenyltransferase alpha) (FTase-alpha) (Type I protein geranyl-
geranyltransferase alpha subunit)
[Source:Uniprot/SWISSPROT;Acc:P49354]
NM_032905 Splicing factor 45 (45kDa splicing factor) (RNA binding motif protein 17).
[Source:Uniprot/SWISSPROT;Acc:Q96I25]
NM_001797 Cadherin-11 precursor (Osteoblast-cadherin) (OB-cadherin) (OSF-4).
[Source:Uniprot/SWISSPROT;Acc:P55287]
NM_018147 Fas apoptotic inhibitory molecule 1.
[Source:Uniprot/SWISSPROT;Acc:Q9NVQ4]
NM_005851 DOC-1 related protein (DOC-1R).
[Source:Uniprot/SWISSPROT;Acc:O75956]
NM_021983 HLA class II histocompatibility antigen, DR-W53 beta chain precursor.
[Source:Uniprot/SWISSPROT;Acc:P13762]
Table 14 - Hierarchical clustering of significantly differentially expressed genes identified by
SAM (FDR 0%) that were up-regulated in the deceased versus living donor group
b) Hierarchical clustering: down-regulated genes
Table 15 gives the list of genes that were downregulated in the deceased donor
group.
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Accession Description
NM_000025 Beta-3 adrenergic receptor (Beta-3 adrenoceptor) (Beta-3 adrenoreceptor).
NM_000086 CLN3 protein (Battenin) (Batten disease protein).
NM_000121 Erythropoietin receptor precursor (EPO-R).
[Source:Uniprot/SWISSPROT;Acc:P19235]
NM_000281 Pterin-4-alpha-carbinolamine dehydratase (EC 4.2.1.96) (PHS) (4-alpha-
hydroxy-tetrahydropterin dehydratase) (Phenylalanine hydroxylase-
stimulating protein) (Pterin carbinolamine dehydratase) (PCD) (Dimerization
cofactor of hepatocyte nuclear factor 1-al
NM_000297 Polycystin 2 (Autosomal dominant polycystic kidney disease type II protein)
(Polycystwin) (R48321). [Source:Uniprot/SWISSPROT;Acc:Q13563]
NM_000383 Autoimmune regulator (Autoimmune polyendocrinopathy candidiasis
ectodermal dystrophy protein) (APECED protein).
[Source:Uniprot/SWISSPROT;Acc:O43918]
NM_000528 Lysosomal alpha-mannosidase precursor (EC 3.2.1.24) (Mannosidase, alpha
B) (Lysosomal acid alpha-mannosidase) (Laman) (Mannosidase alpha class
2B member 1). [Source:Uniprot/SWISSPROT;Acc:O00754]
NM_001183 Vacuolar ATP synthase subunit S1 precursor (EC 3.6.3.14) (V-ATPase S1
subunit) (V-ATPase S1 accessory protein) (V-ATPase Ac45 subunit) (XAP-
3). [Source:Uniprot/SWISSPROT;Acc:Q15904]
NM_001254 Cell division control protein 6 homolog (CDC6-related protein) (p62(cdc6))
(HsCDC6) (HsCDC18). [Source:Uniprot/SWISSPROT;Acc:Q99741]
NM_001398 Delta3,5-delta2,4-dienoyl-CoA isomerase, mitochondrial precursor (EC
5.3.3.-). [Source:Uniprot/SWISSPROT;Acc:Q13011]
NM_001487 Biogenesis of lysosome-related organelles complex-1, subunit 1 (BLOC-1
subunit 1) (GCN5-like protein 1) (RT14 protein).
[Source:Uniprot/SWISSPROT;Acc:P78537]
NM_001626 RAC-beta serine/threonine-protein kinase (EC 2.7.1.37) (RAC-PK-beta)
(Protein kinase Akt-2) (Protein kinase B, beta) (PKB beta).
[Source:Uniprot/SWISSPROT;Acc:P31751]
NM_001859 High-affinity copper uptake protein 1 (hCTR1) (Copper transporter 1)
(Solute carrier family 31, member 1).
[Source:Uniprot/SWISSPROT;Acc:O15431]
NM_001963 Pro-epidermal growth factor precursor (EGF) [Contains: Epidermal growth
factor (Urogastrone)]. [Source:Uniprot/SWISSPROT;Acc:P01133]
NM_002051 Trans-acting T-cell specific transcription factor GATA-3.
[Source:Uniprot/SWISSPROT;Acc:P23771]
NM_002273 Keratin, type II cytoskeletal 8 (Cytokeratin 8) (K8) (CK 8).
[Source:Uniprot/SWISSPROT;Acc:P05787]
NM_002436 55 kDa erythrocyte membrane protein (p55) (Membrane protein,
palmitoylated 1). [Source:Uniprot/SWISSPROT;Acc:Q00013]
NM_002446 Mitogen-activated protein kinase 10 (EC 2.7.1.37) (Mixed lineage kinase 2)
(Protein kinase MST). [Source:Uniprot/SWISSPROT;Acc:Q02779]
NM_002931 Polycomb complex protein RING1 (RING finger protein 1).
[Source:Uniprot/SWISSPROT;Acc:Q06587]
NM_003220 Transcription factor AP-2 alpha (AP2-alpha) (Activating enhancer- binding
protein 2 alpha) (AP-2 transcription factor) (Activator protein-2) (AP-2).
[Source:Uniprot/SWISSPROT;Acc:P05549]
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NM_003260 Transducin-like enhancer protein 2 (ESG2).
[Source:Uniprot/SWISSPROT;Acc:Q04725]
NM_003477 Pyruvate dehydrogenase protein X component, mitochondrial precursor
(Dihydrolipoamide dehydrogenase-binding protein of pyruvate
dehydrogenase complex) (Lipoyl-containing pyruvate dehydrogenase
complex component X) (E3-binding protein) (E3BP) (proX).
NM_003611 Oral-facial-digital syndrome 1 protein (Protein 71-7A).
[Source:Uniprot/SWISSPROT;Acc:O75665]
NM_003685 Far upstream element binding protein 2 (FUSE binding protein 2) (KH type
splicing regulatory protein) (KSRP) (p75).
[Source:Uniprot/SWISSPROT;Acc:Q92945]
NM_003776 39S ribosomal protein L40, mitochondrial precursor (L40mt) (MRP-40)
(Nuclear localization signal containing protein deleted in velocardiofacial
syndrome) (Up-regulated in metastasis).
[Source:Uniprot/SWISSPROT;Acc:Q9NQ50]
NM_003849 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial precursor
(EC 6.2.1.4) (Succinyl-CoA synthetase, alpha chain) (SCS-alpha).
[Source:Uniprot/SWISSPROT;Acc:P53597]
NM_003975 SH2 domain protein 2A (T cell-specific adapter protein) (TSAd) (VEGF
receptor-associated protein) (SH2 domain containing adapter protein).
[Source:Uniprot/SWISSPROT;Acc:Q9NP31]
NM_004003 Carnitine O-acetyltransferase (EC 2.3.1.7) (Carnitine acetylase) (CAT)
(Carnitine acetyltransferase) (CrAT).
[Source:Uniprot/SWISSPROT;Acc:P43155]
NM_004360 Epithelial-cadherin precursor (E-cadherin) (Uvomorulin) (Cadherin-1)
(CAM 120/80). [Source:Uniprot/SWISSPROT;Acc:P12830]
NM_004493 3-hydroxyacyl-CoA dehydrogenase type II (EC 1.1.1.35) (Type II HADH)
(Endoplasmic reticulum-associated amyloid beta-peptide binding protein)
(Short-chain type dehydrogenase/reductase XH98G2).
NM_004548 NADH-ubiquinone oxidoreductase PDSW subunit (EC 1.6.5.3) (EC
1.6.99.3) (Complex I-PDSW) (CI-PDSW).
[Source:Uniprot/SWISSPROT;Acc:O96000]
NM_004551 NADH-ubiquinone oxidoreductase 30 kDa subunit, mitochondrial precursor
(EC 1.6.5.3) (EC 1.6.99.3) (Complex I-30KD) (CI-30KD).
[Source:Uniprot/SWISSPROT;Acc:O75489]
NM_004568 Placental thrombin inhibitor (Cytoplasmic antiproteinase) (CAP) (Protease
inhibitor 6) (PI-6) (Serpin B6). [Source:Uniprot/SWISSPROT;Acc:P35237]
NM_004870 Mannose-P-dolichol utilization defect 1 protein (Suppressor of Lec15 and
Lec35 glycosylation mutation homolog) (SL15).
[Source:Uniprot/SWISSPROT;Acc:O75352]
NM_004905 Peroxiredoxin 6 (EC 1.11.1.-) (Antioxidant protein 2) (1-Cys peroxiredoxin)
(1-Cys PRX) (Acidic calcium-independent phospholipase A2) (EC 3.1.1.-)
(aiPLA2) (Non-selenium glutathione peroxidase) (EC 1.11.1.7) (NSGPx) (24
kDa protein) (Liver 2D page spot 40
[Source:Uniprot/SWISSPROT;Acc:P30041]
NM_005326 Hydroxyacylglutathione hydrolase (EC 3.1.2.6) (Glyoxalase II) (GLX II).
[Source:Uniprot/SWISSPROT;Acc:Q16775]
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NM_005601 Protein NKG7 (Natural killer cell protein 7) (G-CSF-induced gene 1 protein)
(Protein GIG-1). [Source:Uniprot/SWISSPROT;Acc:Q16617]
NM_005809 Peroxiredoxin 2 (EC 1.11.1.-) (Thioredoxin peroxidase 1) (Thioredoxin-
dependent peroxide reductase 1) (Thiol-specific antioxidant protein) (TSA)
(PRP) (Natural killer cell enhancing factor B) (NKEF-B).
NM_005866 opioid receptor, sigma 1 isoform 3
[Source:RefSeq_peptide;Acc:NP_671514]
NM_005918 Malate dehydrogenase, mitochondrial precursor (EC 1.1.1.37).
[Source:Uniprot/SWISSPROT;Acc:P40926]
NM_005956 C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) [Includes:
Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5);
Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9);
Formyltetrahydrofolate synthetase (EC 6.3.4.3)].
NM_006012 Putative ATP-dependent Clp protease proteolytic subunit, mitochondrial
precursor (EC 3.4.21.92) (Endopeptidase Clp).
[Source:Uniprot/SWISSPROT;Acc:Q16740]
NM_006032 Copine VI (Neuronal-copine) (N-copine).
[Source:Uniprot/SWISSPROT;Acc:O95741]
NM_006774 Indolethylamine N-methyltransferase (EC 2.1.1.49) (Aromatic alkylamine
N-methyltransferase) (Indolamine N-methyltransferase) (Arylamine N-
methyltransferase) (Amine N-methyltransferase).
NM_007372 DEAD box polypeptide 42 protein
[Source:RefSeq_peptide;Acc:NP_987095]
NM_012088 6-phosphogluconolactonase (EC 3.1.1.31) (6PGL).
[Source:Uniprot/SWISSPROT;Acc:O95336]
NM_012228 Methionine-R-sulfoxide reductase B (EC 1.8.4.-) (CGI-131).
[Source:Uniprot/SWISSPROT;Acc:Q9Y3D2]
NM_013247 Serine protease HTRA2, mitochondrial precursor (EC 3.4.21.-) (High
temperature requirement protein A2) (HtrA2) (Omi stress-regulated
endoprotease) (Serine proteinase OMI).
NM_013325 APG4 autophagy 4 homolog B isoform b
[Source:RefSeq_peptide;Acc:NP_847896]
NM_013945 Paired box protein Pax-7 (HUP1).
[Source:Uniprot/SWISSPROT;Acc:P23759]
NM_014138 transmembrane protein 29 [Source:RefSeq_peptide;Acc:NP_054857]
NM_014232 Vesicle-associated membrane protein 2 (VAMP-2) (Synaptobrevin 2).
[Source:Uniprot/SWISSPROT;Acc:P63027]
NM_014940 HSV-1 stimulation-related 1 [Source:RefSeq_peptide;Acc:NP_055755]
NM_014960 Arylsulfatase G [Source:RefSeq_peptide;Acc:NP_055775]
NM_016292 Heat shock protein 75 kDa, mitochondrial precursor (HSP 75) (Tumor
necrosis factor type 1 receptor associated protein) (TRAP-1) (TNFR-
associated protein 1). [Source:Uniprot/SWISSPROT;Acc:Q12931]
NM_018060 mitochondrial isoleucine tRNA synthetase
[Source:RefSeq_peptide;Acc:NP_060530]
NM_018249 CDK5 regulatory subunit associated protein 2 (CDK5 activator-binding
protein C48). [Source:Uniprot/SWISSPROT;Acc:Q96SN8]
NM_018355 zinc finger protein 415 [Source:RefSeq_peptide;Acc:NP_060825]
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NM_018838 13kDa differentiation-associated protein
[Source:RefSeq_peptide;Acc:NP_061326]
NM_020414 ATP-dependent RNA helicase DDX24 (DEAD-box protein 24).
[Source:Uniprot/SWISSPROT;Acc:Q9GZR7]
NM_020677 HSCARG protein [Source:RefSeq_peptide;Acc:NP_065728]
NM_021947 Serine racemase (EC 5.1.1.-). [Source:Uniprot/SWISSPROT;Acc:Q9GZT4]
NM_021979 Heat shock-related 70 kDa protein 2 (Heat shock 70 kDa protein 2).
[Source:Uniprot/SWISSPROT;Acc:P54652]
NM_022095 Zinc finger protein 335. [Source:Uniprot/SWISSPROT;Acc:Q9H4Z2]
NM_022785 CAP-binding protein complex interacting protein 1 isoform b
[Source:RefSeq_peptide;Acc:NP_942153]
NM_023948 motile sperm domain containing 3
[Source:RefSeq_peptide;Acc:NP_076438]
NM_024811 pre-mRNA cleavage factor I, 59 kDa subunit
NM_025107 myc target 1 [Source:RefSeq_peptide;Acc:NP_079383]
NM_025146 Mak3 homolog [Source:RefSeq_peptide;Acc:NP_079422]
NM_032261 Putative protein C21orf56. [Source:Uniprot/SWISSPROT;Acc:Q9H0A9]
NM_032383 Hermansky-Pudlak syndrome 3 protein.
[Source:Uniprot/SWISSPROT;Acc:Q969F9]
NM_032445 MEGF11 protein [Source:RefSeq_peptide;Acc:NP_115821]
NM_032592 1-aminocyclopropane-1-carboxylate synthase
NM_033640 SCAN domain-containing protein 2.
NM_133371 myozenin 3 [Source:RefSeq_peptide;Acc:NP_588612]
XM_034819 PREDICTED: zinc finger protein 629
[Source:RefSeq_peptide;Acc:XP_034819]
XM_049237 PREDICTED: KIAA0841 [Source:RefSeq_peptide;Acc:XP_049237]
Table 15 - Hierarchical clustering of significantly differentially expressed genes identified by
SAM (FDR 0%) that were down-regulated in the deceased versus living donor group.
Groups A and B are analysed in more detail in the pathway analysis section.
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3.4.1.3 Gene Ontology
a) Cellular processes
Gene Ontology mapping using the SAM dataset (FDR of 5%) identified the
following cellular processes that were differentially expressed:
Figure 39 - The figure shows a GO-tree map of Cellular Processes based on deceased donor
versus living donor (SAM FDR 5%) dataset
Fig. 42
Fig 40
Fig 41
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In figure 38 the red numbers in each term shows the number of genes in the
dataset that correspond to the particular GO-term. The blue numbers represent
the total number of genes corresponding to the GO-term and other terms
downwards in the tree. The green number shows the difference between the
blue and the red number, hence this is the number of genes annotated to nodes
further down the line i.e. children nodes.
The following figures are representations of the go-terms (cell) membrane,
intracellular and nucleus. For each term they show the breakdown into each
sub-component of that term. It gives a quick visual representation of where the
differentially expressed genes are situated.
Figure 40 Cellular Components
Figure 39 depicts the number of cellular components that were differentially
expressed. Within the term “cell” (627 components), shown in Figure 39 the
sub-term “cellular membrane” is shown, in figure 40.
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Figure 41 Processes involved the cell membrane
Most of the differentially expressed processes at the cell membrane level are
shown in Figure 41 to be intrinsic to the cell membrane or plasma membrane.
Figure 41 represents the intracellular processes that were differentially
expressed within the cell membrane. Most processes are seen to involve the
cytoplasm and nucleus.
Figure 42 Intracellular processes
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b) Molecular function
Gene Ontology mapping using the SAM dataset (FDR of 5%) identified the
following molecular functions that were differentially expressed:
Figure 43 - GO-tree map of Molecular Function based on the deceased donor versus living
donor (SAM FDR 5%) dataset
Fig 45
Fig 44
Fig 46
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In Figure 44 the Go tree map for Molecular function is shown with its various
components represented as a pie chart. Within molecular function the sub-terms
binding and catalytic activity contained the majority of differentially expressed
genes.
Figure 44 - Significantly differentially expressed genes involved in the term molecular
functions
“Binding” is shown in grey in figure 43 and is broken down into its constituent
components shown in figure 44. The processes protein binding, nucleotide
binding and ion binding contain the majority of differentially expressed
processes.
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Figure 45 Breakdown of molecular binding
Catalytic activity was the other main category of processes that were shown to
be differentially expressed in the dataset. Catalytic activity is further
categorized in the figure 45.
Figure 46 Catalytic processes
Hydrolase, oxidoreductase and transferase activity can be seen to contain the
majority of differential expressed processes.
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c) Biological Processes
Gene Ontology mapping using the SAM dataset (FDR of 5%) identified the
following biological processes that were differentially expressed:
Figure 47 - GO-tree map of Biological Processes based on the deceased donor versus living
donor (SAM FDR 5%) dataset.
Fig 46
Fig 47
Fig 48
Fig 49
Fig 50
Fig 51
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In figure 46 the Go tree map for Biological processes is shown with its various
components represented as a pie chart. Under biological processes and within
the sub-term cellular processes, cell communication and cell physiological
processes contained the greatest numbers of differentially expressed genes and
are shown in figure 47.
Figure 48 Cellular Processes – Breakdown
Within cell communication, signal transduction processes are further broken
down and represented in figure 48 below.
Figure 49 Signal Transduction
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Figure 49 and 48 demonstrates that intracellular signalling and cell surface
receptor linked signal transduction processes were the majority processes to be
differentially expressed within cellular processes.
Figure 50 Cellular physiological processes
The second main group of differentially expressed processes under biological
processes was cellular physiological processes. This group is broken down into
its constituent components in figure49, cellular metabolism predominates.
The second main group of differentially expressed processes under biological
processes was physiological processes. Under this term response to stimulus,
immune response and (primary) metabolism terms contained the majority of
differentially expressed genes and are shown in Figures 50, 51 and 52.
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Figure 51 - Response to Stimulus
In figure 50 responses to biotic stimuli are seen to contain the largest number of
differentially expressed genes.
Figure 52 Immune responses
Differentially expressed genes were fairly equally distributed in the sub-terms
antigen presentation, immune cell activation, innate immune response and
antigen presentation in figure 51. A list of those genes is shown in table 16.
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Accession Description
NM_021983 HLA class II histocompatibility antigen, DR-W53 beta
chain precursor.
NM_002121 HLA class II histocompatibility antigen, SB beta chain
(Clone PHA- beta) (Fragment).
NM_000491 Complement C1q subcomponent, B chain precursor.
NM_021155 CD209 antigen (Dendritic cell-specific ICAM-3-grabbing
nonintegrin 1)
NM_002120 HLA class II histocompatibility antigen, DO beta chain
precursor (MHC class II antigen DOB).
NM_004951 EBV-induced G-protein coupled receptor 2 (EBI2).
NM_006084 Transcriptional regulator ISGF3 gamma subunit (IFN-
alpha responsive transcription factor subunit).
NM_002818 Proteasome activator complex subunit 2 (Proteasome
activator 28-beta subunit) (PA28beta).
NM_005849 immunoglobulin superfamily, member 6
NM_005776 Cornichon homolog (TGAM77) (UNQ155/PRO181).
NM_033554 HLA class II histocompatibility antigen, DP alpha chain
precursor (HLA-SB alpha chain) (MHC class II DP3-
alpha).
NM_005218 Beta-defensin 1 precursor (BD-1) (hBD-1) (Defensin, beta
1).
NM_025239 programmed cell death 1 ligand 2.
NM_001710 Complement factor B precursor (EC 3.4.21.47) (C3/C5
convertase) (Glycine-rich beta glycoprotein).
NM_015254 Kinesin-like protein KIF13B (Kinesin-like protein
GAKIN).
NM_017413 Apelin precursor (APJ endogenous ligand).
NM_001300 Core promoter element-binding protein (Kruppel-like
factor 6) (B-cell derived protein 1).
NM_001212 Complement component 1, Q subcomponent binding
protein, mitochondrial precursor (Glycoprotein gC1qBP).
Table 16 - Significantly differentially expressed genes involved in the GO term Immune
response
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Under the sub-term metabolism, the majority processes that were differentially
expressed were associated with nucleotide metabolism (figure 52).
Figure 53 Primary metabolism
Figure 54 Breakdown of the chemical
reactions involving nucleobases,
nucleosides, nucleotides and nucleic acids
Figure 55 Breakdown of transcription,
DNA-dependent
Processes involving nucleobases, nucleosides, nucleotides and nucleic acids
are further broken down into their constituent components in Figure 53. Most
of those transcription components were DNA dependant regulation
transcription processes demonstrated in Figure 54.
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From this pathway numerous relations between genes were found that related to
many cellular processes. An example is shown in table 17. This lists gene
expression terms that were identified in the pathway shown in figure 56
Relation Journal Link
FOS --+> ICAM1 http://atvb.ahajournals.org/cgi/content/full/19/9/2078
FOS --+> CCL2 http://atvb.ahajournals.org/cgi/content/full/19/9/2078
SMAD3 ---| CCL2 http://circres.ahajournals.org/cgi/content/full/94/5/601
SMAD3 ---> MYOG http://embojournal.npgjournals.com/cgi/content/full
SMARCA4 ---| FOS http://mcb.asm.org/cgi/content/full/19/4/2724
FOS ---> TIMP1 http://www.jbc.org/cgi/content/full/271/2/774
ELK1 --+> FOS http://www.jbc.org/cgi/content/full/275/21/16064
FOS --+> EGF http://www.jbc.org/cgi/content/full/276/48/45320
SMARCA4--+>CYP1A1 http://www.jbc.org/cgi/content/full/277/14/11821
TFAP2A ---> ICAM1 http://www.jbc.org/cgi/content/full/278/48/47498
SMAD4 ---> SMAD3 http://www.pnas.org/cgi/content/full/96/22/12442
ATF4 --+> BCL2
CCL11 --+> VCAM1
CCL11 ---> ICAM1
CCL2 ---> ICAM1
ATBF1 ---| AFP
Table 17 - Gene expression terms identified by SAM (FDR 5%) in the pathway built using all
significantly differentially expressed genes.
Interactions which have been previously described are shown as hyperlinks.
Further pathway analysis was performed on the dataset produced by SAM
(FDR = 5%). The following pathways were found to contain genes that were
significantly differentially expressed in the dataset and of interest and relevance
to kidney transplantation:
i. Death Receptor Pathway
ii. DR3 / DR4 Pathway
iii. Epidermal Growth Factor
Signalling
iv. IFN-ĮȕȖ(*)
v. Inhibition of Apoptosis
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Name Description LocusLink ID
STAT1 signal transducer and activator of
transcription 1
20846, 98183, 6772, 25124, 99845,
68723, 445332, 320846
BCL2 B-cell leukaemia/lymphoma 2 319577, 596, 320732, 98734
ATF4 activating transcription factor 4 11911, 79255, 468
Fli1 Friend leukaemia integration 1 2313, 315532, 14247
WT1 Wilms tumour 1 294807, 213439, 7490, 319408,
TNFRSF10A tumour necrosis factor receptor
superfamily, member 10b (predicted)
21933, 364420, 8797
PSEN1 presenilin 1 29192, 19164, 5663
HIPK3 homeodomain interacting protein
kinase 3
83617, 10114, 15259
PDCD8 programmed cell death 8 83533, 26926, 15459, 9131
CYC1 cytochrome c-1 (predicted) 1537, 300047, 105730, 66445
FADD Fas (TNFRSF6)-associated via death
domain
266610, 14082, 8772, 414082,
114082
PEA15 phosphoprotein enriched in astrocytes
15
364052, 17177, 18611, 29891,
8682
BAG1 Bcl2-associated athanogene 1
(predicted)
12017, 297994, 573
TJP1 tight junction protein 1 (predicted) 101244, 7082, 107526, 21872,
DFFA DNA fragmentation factor, alpha
subunit
13347, 1676, 114214
SIVA Cd27 binding protein (predicted) 362791, 30954, 10572, 220525
RHEB RAS-homolog enriched in brain 26954, 6009, 19744
NFYA nuclear transcription factor-Y alpha 4800, 106471, 18044, 29508
BFAR bifunctional apoptosis regulator 67118, 304709, 106253, 106390,
Table 21 - Expanded Pathway
Table 21 lists those differentially expressed genes present in the expanded
pathway shown in figure 60 that were in the dataset.
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In Figure 63 both clusters of genes are compared to the literature using
Medscan and the search terms ‘transplantation’ and ‘inflammation’. The figure
shows the interactions between genes identified and there cellular interactions
described in the literature.
Figure 63 – Relations of identified genes to the search terms inflammation and transplantation.
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3.4.2 Deceased Donors (Immediate function) versus all donors (Deceased
and Living) with Moderate / Poor / Non-function
The purpose of this sub-analysis was to potentially identify genes potentially
involved in processes that were inherent to the graft or occurred at the time of
biopsy prior to the process becoming apparent clinically.
3.4.2.1 Significance Analysis of Microarrays
SAM analysis was performed and identified 109 significantly differentially
expressed genes .These are shown in table 22; unidentified and hypothetical
genes are excluded.
ID Description
NM_001010 40S ribosomal protein S6 (Phosphoprotein NP33).
[Source:Uniprot/SWISSPROT;Acc:P62753]
NM_000991 60S ribosomal protein L28. [Source:Uniprot/SWISSPROT;Acc:P46779]
NM_000998 60S ribosomal protein L37a. [Source:Uniprot/SWISSPROT;Acc:P61513]
NM_001885 Alpha crystallin B chain (Alpha (B)-crystallin) (Rosenthal fiber component)
(Heat-shock protein beta-5) (HspB5).
[Source:Uniprot/SWISSPROT;Acc:P02511]
NM_002372 Alpha-mannosidase II (EC 3.2.1.114) (Mannosyl-oligosaccharide 1,3-1,6-
alpha-mannosidase) (MAN II) (Golgi alpha-mannosidase II) (Mannosidase
alpha class 2A member 1). [Source:Uniprot/SWISSPROT;Acc:Q16706]
NM_178510 ankyrin repeat and kinase domain containing 1
[Source:RefSeq_peptide;Acc:NP_848605]
NM_017413 Apelin precursor (APJ endogenous ligand).
[Source:Uniprot/SWISSPROT;Acc:Q9ULZ1]
NM_001686 ATP synthase beta chain, mitochondrial precursor (EC 3.6.3.14).
[Source:Uniprot/SWISSPROT;Acc:P06576]
NM_006476 ATP synthase g chain, mitochondrial (EC 3.6.3.14) (ATPase subunit G).
[Source:Uniprot/SWISSPROT;Acc:O75964]
NM_001697 ATP synthase oligomycin sensitivity conferral protein, mitochondrial
precursor (EC 3.6.3.14) (OSCP).
[Source:Uniprot/SWISSPROT;Acc:P48047]
NM_005178 B-cell lymphoma 3-encoded protein (Bcl-3 protein).
[Source:Uniprot/SWISSPROT;Acc:P20749]
NM_021211 Buster1 transposase-like protein [Source:RefSeq_peptide;Acc:NP_067034]
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NM_016395 butyrate-induced transcript 1 [Source:RefSeq_peptide;Acc:NP_057479]
NM_005956 C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) [Includes:
Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5)
NM_001780 CD63 antigen (Melanoma-associated antigen ME491) (Lysosome-associated
membrane glycoprotein 3) (LAMP-3) (Ocular melanoma-associated antigen)
(OMA81H) (Granulophysin). [Source:Uniprot/SWISSPROT;Acc:P08962]
NM_018491 COBW domain containing 1 [Source:RefSeq_peptide;Acc:NP_060961]
NM_001866 Cytochrome c oxidase polypeptide VIIb, mitochondrial precursor (EC
1.9.3.1). [Source:Uniprot/SWISSPROT;Acc:P24311]
NM_006360 dendritic cell protein [Source:RefSeq_peptide;Acc:NP_006351]
NM_022365 DnaJ homolog subfamily C member 1.
[Source:Uniprot/SWISSPROT;Acc:Q96KC8]
NM_031208 fumarylacetoacetate hydrolase domain containing 1
[Source:RefSeq_peptide;Acc:NP_112485]
NM_015710 Glioma tumour suppressor candidate region gene 2 protein (p60).
[Source:Uniprot/SWISSPROT;Acc:Q9NZM5]
NM_014367 growth and transformation-dependent protein (E2IG5), mRNA
[Source:RefSeq_dna;Acc:NM_014367]
NM_016292 Heat shock protein 75 kDa, mitochondrial precursor (HSP 75) (Tumour
necrosis factor type 1 receptor associated protein) (TRAP-1) (TNFR-
associated protein 1). [Source:Uniprot/SWISSPROT;Acc:Q12931]
NM_004499 Heterogeneous nuclear ribonucleoprotein A/B (hnRNP A/B) (APOBEC-1
binding protein 1) (ABBP-1). [Source:Uniprot/SWISSPROT;Acc:Q99729]
NM_001859 High-affinity copper uptake protein 1 (hCTR1) (Copper transporter 1)
(Solute carrier family 31, member 1).
[Source:Uniprot/SWISSPROT;Acc:O15431]
NM_018951 Homeobox protein Hox-A10 (Hox-1H) (Hox-1.8) (PL).
[Source:Uniprot/SWISSPROT;Acc:P31260]
NM_006774 Indolethylamine N-methyltransferase (EC 2.1.1.49) (Aromatic alkylamine N-
methyltransferase) (Indolamine N-methyltransferase) (Arylamine N-
methyltransferase) (Amine N-methyltransferase).
[Source:Uniprot/SWISSPROT;Acc:O95050]
NM_080730 intermediate filament-like protein MGC:2625 isoform 3
[Source:RefSeq_peptide;Acc:NP_542769]
NM_031959 Keratin-associated protein 3-2 (Keratin-associated protein 3.2) (High sulfur
keratin-associated protein 3.2).
[Source:Uniprot/SWISSPROT;Acc:Q9BYR7]
NM_018269 membrane-type 1 matrix metalloproteinase cytoplasmic tail binding protein-1
[Source:RefSeq_peptide;Acc:NP_060739]
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NM_020191 Mitochondrial 28S ribosomal protein S22 (S22mt) (MRP-S22) (GK002).
[Source:Uniprot/SWISSPROT;Acc:P82650]
NM_004279 Mitochondrial processing peptidase beta subunit, mitochondrial precursor
(EC 3.4.24.64) (Beta-MPP) (P-52).
[Source:Uniprot/SWISSPROT;Acc:O75439]
NM_023948 motile sperm domain containing 3 [Source:RefSeq_peptide;Acc:NP_076438]
NM_025107 myc target 1 [Source:RefSeq_peptide;Acc:NP_079383]
NM_004551 NADH-ubiquinone oxidoreductase 30 kDa subunit, mitochondrial precursor
(EC 1.6.5.3) (EC 1.6.99.3) (Complex I-30KD) (CI-30KD).
[Source:Uniprot/SWISSPROT;Acc:O75489]
NM_004546 NADH-ubiquinone oxidoreductase AGGG subunit, mitochondrial precursor
(EC 1.6.5.3) (EC 1.6.99.3) (Complex I-AGGG) (CI-AGGG).
[Source:Uniprot/SWISSPROT;Acc:O95178]
NM_002490 NADH-ubiquinone oxidoreductase B14 subunit (EC 1.6.5.3) (EC 1.6.99.3)
(Complex I-B14) (CI-B14). [Source:Uniprot/SWISSPROT;Acc:P56556]
NM_002489 NADH-ubiquinone oxidoreductase MLRQ subunit (EC 1.6.5.3) (EC
1.6.99.3) (Complex I-MLRQ) (CI-MLRQ).
[Source:Uniprot/SWISSPROT;Acc:O00483]
NM_024824 nuclear protein UKp68 isoform 3 [Source:RefSeq_peptide;Acc:NP_997544]
NM_003611 Oral-facial-digital syndrome 1 protein (Protein 71-7A).
[Source:Uniprot/SWISSPROT;Acc:O75665]
NM_000582 Osteopontin precursor (Bone sialoprotein 1) (Secreted phosphoprotein 1)
(SPP-1) (Urinary stone protein) (Nephropontin) (Uropontin).
[Source:Uniprot/SWISSPROT;Acc:P10451]
NM_006406 Peroxiredoxin 4 (EC 1.11.1.-) (Prx-IV) (Thioredoxin peroxidase AO372)
(Thioredoxin-dependent peroxide reductase A0372) (Antioxidant enzyme
AOE372) (AOE37-2). [Source:Uniprot/SWISSPROT;Acc:Q13162]
NM_004905 Peroxiredoxin 6 (EC 1.11.1.-) (Antioxidant protein 2) (1-Cys peroxiredoxin)
(1-Cys PRX) (Acidic calcium-independent phospholipase A2)
NM_020422 promethin [Source:RefSeq_peptide;Acc:NP_065155]
NM_000954 Prostaglandin-H2 D-isomerase precursor (EC 5.3.99.2) (Lipocalin-type
prostaglandin D synthase) (Glutathione-independent PGD synthetase)
NM_002792 Proteasome subunit alpha type 7 (EC 3.4.25.1) (Proteasome subunit RC6- 1)
(Proteasome subunit XAPC7). [Source:Uniprot/SWISSPROT;Acc:O14818]
NM_006849 Protein disulfide-isomerase A2 precursor (EC 5.3.4.1) (PDIp).
[Source:Uniprot/SWISSPROT;Acc:Q13087]
NM_003950 Proteinase activated receptor 4 precursor (PAR-4) (Thrombin receptor- like
3) (Coagulation factor II receptor-like 3).
[Source:Uniprot/SWISSPROT;Acc:Q96RI0]
149
NM_020975 Proto-oncogene tyrosine-protein kinase receptor ret precursor (EC 2.7.1.112)
(C-ret). [Source:Uniprot/SWISSPROT;Acc:P07949]
NM_025234 recombination protein REC14 [Source:RefSeq_peptide;Acc:NP_079510]
NM_015952 RWD domain containing protein 1 (CGI-24) (PTD013).
[Source:Uniprot/SWISSPROT;Acc:Q9H446]
NM_021947 Serine racemase (EC 5.1.1.-). [Source:Uniprot/SWISSPROT;Acc:Q9GZT4]
NM_013376 SERTA domain-containing protein 1 (Transcriptional regulator interacting
with the PHD-bromodomain 1) (TRIP-Br1) (CDK4-binding protein
p34SEI1) (SEI-1). [Source:Uniprot/SWISSPROT;Acc:Q9UHV2]
NM_004175 Small nuclear ribonucleoprotein Sm D3 (snRNP core protein D3) (Sm-D3).
[Source:Uniprot/SWISSPROT;Acc:P62318]
NM_005827 solute carrier family 35, member B1
[Source:RefSeq_peptide;Acc:NP_005818]
NM_014426 Sorting nexin 5. [Source:Uniprot/SWISSPROT;Acc:Q9Y5X3]
NM_017455 stromal cell derived factor receptor 1 isoform a
[Source:RefSeq_peptide;Acc:NP_059429]
NM_003849 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial precursor
(EC 6.2.1.4) (Succinyl-CoA synthetase, alpha chain) (SCS-alpha).
[Source:Uniprot/SWISSPROT;Acc:P53597]
NM_004711 Synaptogyrin-1. [Source:Uniprot/SWISSPROT;Acc:O43759]
NM_006430 T-complex protein 1, delta subunit (TCP-1-delta) (CCT-delta) (Stimulator of
TAR RNA binding). [Source:Uniprot/SWISSPROT;Acc:P50991]
NM_014138 transmembrane protein 29 [Source:RefSeq_peptide;Acc:NP_054857]
NM_013262 Ubiquitin ligase MYLIP (EC 6.3.2.-) (Myosin regulatory light chain
interacting protein) (MIR) (BM023).
[Source:Uniprot/SWISSPROT;Acc:Q8WY64]
NM_014709 ubiquitin specific protease 34 [Source:RefSeq_peptide;Acc:NP_055524]
NM_003945 Vacuolar ATP synthase subunit H (EC 3.6.3.14) (V-ATPase H subunit)
(Vacuolar proton pump H subunit) (V-ATPase M9.2 subunit) (V-ATPase 9.2
kDa membrane accessory protein).
[Source:Uniprot/SWISSPROT;Acc:O15342]
NM_001183 Vacuolar ATP synthase subunit S1 precursor (EC 3.6.3.14) (V-ATPase S1
subunit) (V-ATPase S1 accessory protein) (V-ATPase Ac45 subunit) (XAP-
3). [Source:Uniprot/SWISSPROT;Acc:Q15904]
Table 22 - Significantly differentially expressed genes identified by SAM (FDR 5%) in the
deceased donor immediate function vs. non-immediately functioning kidneys
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3.4.2.2 Hierarchical clustering
Hierarchical clustering of genes identified in table 22 is shown in Figure 64.
Figure 64 - Hierarchical clustering of significantly differentially expressed genes identified by
SAM. Green column labels represent deceased donors (immediate function) and blue column
labels represent all donors (non-immediate function)
Hierarchical clustering did not reveal any distinct groups or clusters within
genes or samples. The data was therefore analysed using gene ontology
mapping to see how the identified genes were distributed in terms of cellular
function.
3.4.2.3 Gene Ontology
The following Gene Ontology components were identified from the dataset and
are mapped in Figure 65.
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Figure 65 – The figure shows a GO tree map of the dataset Deceased donors (immediate
function) vs. Non-immediately functioning donor kidneys (Moderate / Poor / Non-function)
The following intracellular processes and molecular functions were
significantly differentially expressed and are shown in Figure 66 and Figure 67.
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Figure 66 Pie Chart representing cellular processes (intracellular)
Figure 67 - Molecular function
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Within the dataset Deceased donors (immediate function) vs. Non-immediately
functioning donor kidneys (Moderate / Poor / Non-function) the following
biological and cellular physiological processes were significantly differentially
expressed and are shown in Figure 68 and Figure 69.
Figure 68 - Biological processes
Figure 69 - Cellular physiological processes
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In Figure 65 it can be seen that there are a number of unknown genes or genes
that have not been ascribed a function. These are shown in table 23.
GENE ID DESCRIPTION (CELLULAR PROCESSES UNKNOWN)
NM_016292 Tumour necrosis factor type 1 receptor associated protein) (TRAP-1)
(TNFR- associated protein 1).
NM_003611 Oral-facial-digital syndrome 1 protein (Protein 71-7A).
GENE ID DESCRIPTION (BIOLOGICAL PROCESSES UNKNOWN)
NM_016292 (Tumour necrosis factor type 1 receptor associated protein) (TRAP-1)
(TNFR- associated protein 1).
NM_003611 Oral-facial-digital syndrome 1 protein (Protein 71-7A).
NM_015710 Glioma tumor suppressor candidate region gene 2 protein (p60).
NM_020191 Mitochondrial 28S ribosomal protein S22 (S22mt) (MRP-S22) (GK002).
Table 23 - Genes found to be significantly differentially expressed in the cadaveric donor
immediate function vs. all non-immediately functioning kidneys (SAM FDR 5%) dataset
classified as no cellular or biological function by Gene ontology
3.4.2.4 Pathway analysis
The 109 significantly differentially expressed genes were analysed further in
pathway studio 5. The following significantly differentially expressed genes
that interacted directly with one another are shown in table 24.
Name Description LocusLink ID
RET ret proto-oncogene 5979, 24716, 19713
SPP1 secreted phosphoprotein 1 25353, 100557, 20750, 100728
BCL3 similar to B-cell leukaemia
/lymphoma 3
101615, 12051, 680611, 112051,
101481, 292700, 602
PTGDS prostaglandin D2 synthase 25526, 5730, 19215
CRYAB crystallin, alpha B 25420, 1410, 12955
HOXA10 Homeobox protein A10 312338, 221882, 15395, 3206
PRDX6 peroxiredoxin 6 9588, 94167, 23804, 320807
CD63 CD63 antigen 967, 98116, 98099, 29186, 12512
DNAJC1 DnaJ (Hsp40) homolog, subfamily
C, member 1
70841, 291369, 319395, 13418,
98831, 64215
Table 24 - Direct interactions between significantly differentially expressed genes in the
Deceased donor (immediate function) vs. Non-immediately functioning donor kidneys
(Moderate / Poor / Non-function) .
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3.4.3 Deceased Donors (Immediate function) vs. Deceased donors: moderate
poor /non function.
The purpose of this sub-analysis was to look for genes that were significantly
differentially expressed that would indicate processes that were up or down-
regulated in either group. An upregulated process in the deceased donor group
with immediate function would be deemed “protective”. A downregulated
process in this group may be thought to have on otherwise damaging role.
Conversely an upregulated process in the deceased group with poor or non-
function would be deemed as “damaging” whereas a downregulated process
may have a protective role.
3.4.3.1 Significance Analysis of Microarrays
Only eight genes were identified with a 0% FDR and a represented in Figure
71.
Figure 71 –SAM plot of DD (IF) vs. DD : moderate / poor function /non function
(early and late onset), (FDR 0%).
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The genes identified in the SAM plot Figure 71 are shown in red and are
therefore upregulated in the immediately functioning group compared to the
poor or non-functioning group. These genes are listed in table 25 and may
therefore be thought to have a protective role.
Accession Description
NM_014138 Homo sapiens transmembrane protein 29
NM_016292 Homo sapiens TNF receptor-associated protein 1 (TRAP1)
NM_000954 Homo sapiens prostaglandin D2 synthase 21kDa (brain)
(PTGDS),
NM_000462 Homo sapiens ubiquitin protein ligase E3A (human papilloma
virus E6-associated protein, Angelman syndrome) (UBE3A)
NM_002372 Homo sapiens mannosidase, alpha, class 2A, member 1
(MAN2A1)
NM_002490 Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 6, 14kDa (NDUFA6), nuclear gene encoding
mitochondrial protein.
AK023297 Homo sapiens cDNA FLJ13235 fis, clone OVARC1000304,
highly similar to PROTEIN MOV-10
NM_018011 Homo sapiens hypothetical protein FLJ10154 (FLJ10154)
Table 25 - DD (IF) vs. DD : immediate / poor function /non function (early and late) (FDR
0%). Genes shown are upregulated in the immediately functioning group and potentially have a
protective role.
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3.4.3.2 Hierarchical clustering
Figure 72 - Hierarchical Clustering: Deceased Donors (Immediate function) versus Deceased
Donors
(Moderate / Poor / Non-function)
Hierarchical clustering (Figure 72) shows a degree of sample clustering which
is to be expected. Genes are clustered into much smaller clusters. This would
fit with the SAM analysis as few genes were shown to be differentially
expressed and so unlikely to be clustered together in relation to the rest of the
dataset.
3.4.3.3 Gene Ontology / Pathway Analysis
As only a few genes were identified with SAM analysis no further analysis was
performed using gene ontology or pathway analysis.
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4 DISCUSSION
During this study period a set of 43 kidney biopsy samples were analysed for
gene expression using a microarray using the complete human genome from
RNA to Cye dye labelled probes. All 43 samples were hybridized successfully
with a healthy control kidney sample. For the purpose of data analysis the
samples were grouped depending on clinical scenario and donor type. In the
main analysis comparing immediately functioning kidneys of deceased vs.
living donors 1802 genes were found to be significantly differentially
expressed. With a false discovery rate of 0, 190 genes were found to be
differentially expressed of which 143 were negatively expressed and 47 were
positively expressed.
A proportion of the differentially expressed genes already have a biological
function assigned to them and some of these genes have potential as
biomarkers. Such biomarkers have the potential to act as surrogate markers of
graft function or could be used to monitor the immune reactivity of the graft or
recipient. The adverse effects of some of the genes may be modified by the use
of pharmaceuticals Other biomarkers have been shown to be modifiable by the
use of pharmaceuticals. Other genes were identified that were significantly
differentially expressed, however, their gene sequence and biological function
have not yet been confirmed. Biomarkers identified by this study, therefore,
have the potential to improve the monitoring and treatment of kidney transplant
recipients which may improve the long term graft and patient survival.
Between the period December 2000 to May 2005 196 donor samples were
assessed for their suitability for microarray analysis. Using good samples,
quality controls checks were repeated and also performed by MWG. Despite
this, the initial methodology, probes made using small but apparently sufficient
amounts of good quality RNA, failed to hybridise.
As a result of these initial studies a new methodology was adopted. The recent
application of genome wide microarray analysis along with a newer ‘tried and
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tested’ methodology was therefore, employed. Compared to the initial methods
there were differences in the new method which offered several advantages.
The development of a reliable methodology began with the tissue handling and
storage technique. The Agilent Bioanalyser confirmed that tissue stored in
RNAlater® was more stable than when RNAlater® was not used. The minigel
trace of samples demonstrated that the 18 and 28S RNA bands were clearly
demarcated indicating RNA was preserved in the majority of samples stored
using RNAlater®. Of the one hundred and ninety six kidney biopsy samples
that were taken between December 2000 and September 2005 and were
quantitatively and qualitatively, forty seven samples were found to be suitable
for microarray and 43 were used for analysis. Of the 47 samples 35 had been
initially stored in RNAlater®. Only 10 of the remaining 149 samples not
stored initially in RNAlater® were suitable for microarray. These findings
confirmed the need to use RNAlater® for storing tissue samples in order to
preserve RNA and prevent significant degradation. These findings concur with
other authors findings that use of RNAlater® improves RNA quality and
quantity in stored tissue [151].
In the initial method a simple scheme was proposed for the Cye Ester
fluorescent dye labelling of samples. For deceased samples the control sample
was to be labelled with Cy5 dye and the control samples of living donor
samples were labelled with Cy3 fluorescent dye. Since the original
experimental design aimed to compare two samples taken from the same
recipient at different times the pre-implantation biopsy was labelled with Cy3
and the post-transplantation biopsy with Cy5. Due to the nature of
transplantation the supply of samples fitting this design was extremely limited.
Further to this, the quality of these samples prior to the use of RNAlater® was
poor, and so this scheme was not applied.
The initial methodology proposed to compare samples taken from the same
kidney at different times. E1 was an experiment of this type. It became
apparent that the supply of follow-up biopsies taken from the same kidney was
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going to be extremely limited. For this reason the data from E1 was not used in
the analysis. However, the samples used in E1 were not wasted. The RNA from
these samples had already been coupled to their respective dye depending on
donor type and so when the use of a control sample was employed in the new
strategy the complimentary dye was used. Data analysis software had the
ability to take into account which dyes the test or control sample has been
coupled to in the initial method direct labelling experiments. In J-express “dye
swapping” is a feature that was used to compensate for this [152-154]. The
purpose of dye swap recognition was to take into account the slightly increased
affinity for Cy3 over Cy5 dye, potentially in the case of a deceased donor
experiment, giving falsely elevated spot intensities for the deceased channel.
Living donor experiments could therefore appear to have reduced spot
intensities i.e. reduced induction / suppression of genes. Dye swapping
corrected for these slight differences in cye dye affinity. The new method used
indirect labelling for cye dye incorporation in which there is equal labelling
and no bias, therefore, dye swapping was not performed.
There were technical differences between the initial method and the new
method that had a number of beneficial implications. The amount of total RNA
required in new method was 1ȝg compared to 5µg in the initial method. This
allowed for the potential analysis of a larger number of samples where the
RNA yield following extraction was very low (i.e. < 5µg). It also allowed
hybridisations to be repeated if they had failed. In the initial method several
samples were never analysed because all of the extracted RNA was used in the
hybridisation, which failed.
There were differences between the initial and new strategies in reverse
transcription and dye coupling. In the initial method reverse transcription
began at the 3’ end of RNA and was performed separately to dye labelling. In
the new method antisense RNA (aRNA) was produced compared to sense
RNA and dye coupling occurred between the amino allyl modified UTP
residues on the RNA and the amine reactive dyes; the initial method produced
unmodified aRNA. There was likely to be a difference in the efficiency of
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transcription. For the few templates that were transcribed more or less
efficiently than other templates in the initial compared to new method, the
amplification bias had been shown by the manufacturer to be typically
equivalent [155-157]. Even though the aRNA amplification procedure may
not have generated exactly the same number of aRNA molecules from each
template (sample), amplification had been shown by the manufacturer to be
reproducible from reaction to reaction making it possible to compare the
expression profiles of different amplified RNA samples [155-157].
The manufacturer had compared RNA polymerase activity in the two methods.
They found that it was not affected by either the concentration of individual
templates in a complex mixture or by the sequences of the template molecules
being transcribed [157], and was shown not to significantly distort the relative
abundance of individual mRNA sequences within an RNA population [155-
157].
The incubation at the amplification / transcription stage was done in air
incubator in the new method (c.f. water bath) which made the possibility of
condensation formation in the reaction tubes much less likely. The initial
method was, therefore, more likely to produce condensation (an observation
that was made) potentially affecting the concentration of the reaction mix
during amplification. This could then cause variation in the yield across the
batch of samples being incubated at the same time, adding error to the
experiment. This hypothesis was not formally investigated because no probes
made using the initial technique were successfully hybridized. This fact does
however suggest that condensation formation in the reaction may have
significant detrimental effects on probe integrity. All incubation stages in the
new method were carried out in an air incubator.
Data filtering and Normalisation
It was important to ensure that the data was handled appropriately in order to
achieve quality data that was interesting and relevant. There is no defined
protocol to follow when handling microarray data. It is up to the researcher to
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decide on the best methods / parameters for filtering and normalisation. From
the same raw dataset it is possible, therefore, to obtain different resulting
datasets depending on which filtering parameters are used. Filtering parameters
were set in order to exclude poor quality data, artefact and background ‘noise’.
Filters were set to extract data representing significant changes in gene
expression i.e. above two fold change, between groups. Gene filtering,
therefore, excluded genes that did not change. It is possible that if genes
involved in a process that is genuinely positively or negatively expressed, are
filtered out e.g. because the differential expression was less than two-fold; then
the overall process / pathway could be overlooked because only a few genes
are identified within it.
Arbitrary cut-off values were made when setting the filtering parameters.
These were based on recommendations made by other laboratory workers’
experience of the technique and based on the J-express user guide [158]. The
value filters were used to exclude data with extreme expression values deemed
to be artefactual. The values that were set were based upon the expression
values and therefore potentially could have excluded good data with high
expression values. The other filters based upon recommendations [158] also
had the theoretical potential to exclude some good expression data, an
unavoidable reality of microarray analysis.
Another potential limiting factor was overall number of samples that were used
in data analysis. Relatively small numbers of samples fitting a specific clinical
scenario e.g. follow-up biopsy meant that that particular clinical scenario could
not be analysed as separate experiment, thus smaller groups of donor samples
were grouped together for analysis.
Due to the nature of the experiment tissue samples were not abundant. From an
overall pool of 196 potential donor samples only 47 were suitable for analysis
and 43 used for analysis. The small quantities of starting RNA limited the
number of experiments and did not allow replicate experiments to be
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performed. To some extent the latter point is compensated by the intra-
experimental replication of probes i.e. duplicates on the microarray slide.
Another drawback of having limited tissue samples was this did not allow for
any further analysis techniques to validate expression levels such as
quantitative real-time PCR. The aim of the study, however, was not to measure
exact gene expression levels, but to look for novel genes, groups of genes or
pathways that could be further investigated and validated by RT-PCR. In
contrast to other quantitative studies this study had many potential clinical
scenarios to investigate and compare to the common control which would
hopefully produce biologically and clinically relevant data.
In spite of the limitations this study generated a large number of data points
which allowed further analysis in relation to clinical parameters.
.
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4.1 Clinical scenarios
Data was analysed following normalisation using Significance analysis of
microarrays (SAM) and Hierarchical clustering. The resulting datasets were
then used in Gene Ontology Mapping and Pathway Analysis to investigate the
distribution of significant genes and hence which biological processes were
being activated or repressed. The main analyses were performed depending on
clinical scenario:
A. Deceased Donors (Immediate function) versus Living Donors (Immediate
function)
B. Deceased Donors (Immediate function) versus all Donors (Moderate / Poor
/ Non-function)
C. Deceased Donors (Immediate function) versus Deceased Donors (Moderate
/ Poor / Non-function)
Significance analysis of microarrays (SAM) is a statistical testing algorithm
which identifies induced and repressed genes with significantly different
expression across samples [144]. It compares 2 or more samples normalised to
the control sample. SAM was used to identify significant genes based on
differential expression between groups of samples created depending on the
clinical scenario.
Hierarchical clustering is a technique in which each gene is assigning to its
own cluster [145]. The closest (most similar) pair of clusters is merged into a
single cluster, so that there is one less cluster. Distances (similarities) are
computed between the new cluster and each of the old clusters. This process is
repeated until all items are clustered into a single cluster of size N.
Gene ontology is a collaborative research tool developed to construct and use
ontologies to facilitate the biologically meaningful annotation of genes and
their products [159]. GO annotations have already assigned biological function
to genes which are subsequently grouped by process e.g. Apoptosis and are
166
organised and related in a hierarchical manner. Therefore, genes involved in
the same process with similar / different expression patterns are examined.
Pathway analysis applies microarray data e.g. from SAM analysis and overlays
this data onto a database of molecular networks assembled from scientific
papers. It is a tool to visualise data in a biological sense and to see which
processes significant genes are involved in and how they interact with each
other and other processes. Another application of pathway analysis involves
the use of Medscan. The Medscan tool was useful for exploring and visualising
data. It uses a dataset (e.g. from SAM) and looks for publications relating it to
user defined search terms. The resulting pathway is built and each link can be
clicked on, to link the investigator to those publications.
4.1.1 Deceased Donors (Immediate function) versus Living Donors
(Immediate function).
We know that deceased donor kidneys have higher rates of graft dysfunction
and failure in the long term [160]. The purpose of this analysis, therefore, was
to identify genes and processes that have the potential to explain this
phenomenon. The main issues were to examine the differences between grafts
from the two donor sources to see if there are any processes that differentiated
between the two groups.
The mechanisms underlying the differences in outcome include the following:
1) The damage caused to the deceased donor kidney by brainstem death is
likely to reduce the number of functional nephrons This may manifest
itself as a graft that has reduced function from the outset or it may have
normal function initially which deteriorates at a faster than expected rate.
2) Brain-stem death, hypoxia and warm and cold ischaemia may cause
activation of pathological processes that cause damage to the graft. This
may occur immediately and result in a poorly functioning graft or may
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occur over time, accumulating, resulting in chronic allograft nephropathy;
a known cause of graft dysfunction, deterioration and loss.
SAM detected 190 differentially expressed genes of which 143 were down-
regulated and 47 were up-regulated. More genes were down-regulated
suggesting that the consequences of brain stem death / ischaemic damage are as
a result of the down-regulation of protective cellular functions.
4.1.1.1 Upregulated Genes.
A set of genes was upregulated in the deceased donor group compared to the
living donor group. The amount of up-regulation was represented as the fold
change. In this set of genes the range of fold change was between 2.2 and 81.7
times. At a cellular level the majority of genes functioned at the cell and
plasma membrane, within the cytoplasm, mitochondria and within the nucleus.
Molecular functions involving binding, transporter and catalytic activity and
biological processes involving cellular physiological and communication
processes contained the majority of up-regulated genes.
Deceased donor kidneys have been shown to have a poorer 10 year graft
survival rate [160]. Although the rate of graft survival has improved for both
groups there still remains a clinically significant difference in graft survival
and this depends on whether or not the kidney graft was sourced from a living
or deceased donor.
Long-term graft failure can be secondary to chronic allograft nephropathy
(CAN), recurrent renal disease and death from another cause with a functioning
graft. CAN is secondary to a combination of chronic rejection, chronic
cyclosporine toxicity, and/or donor kidney disease[161]. The genes that were
identified therefore potentially indicate processes that were up-regulated in the
deceased donor kidneys and not the living donor kidneys, i.e. damaging
processes. These genes may also represent genes that were up-regulated, but to
a lesser degree (of fold change) in the living donors, or represent genes that
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were down-regulated in the living donors and, as a result of data normalisation,
the actual value was expressed as a positive value.
The first explanation (genes up-regulated in deceased donors) is more likely;
however, the actual values or ratios given for each gene are not necessarily
important, it is the identification of the process that may be of potential clinical
relevance.
The following genes of known function which may be relevant to
transplantation were up-regulated in deceased donors.
i. Homo sapiens major histocompatibility complex, class II, DR beta 4 (HLA-
DRB4)
HLA-DRB4 was positively expressed 22.3 times more in the deceased donor
samples. HLA-DRB4 mRNA belongs to the HLA class II beta chain
paralogues [162]. It is a class II heterodimeric molecule which consists of an
alpha and a beta chain anchored to the cell membrane. It plays a central role in
the immune system by presenting peptides derived from extracellular proteins.
Class II molecules are expressed in antigen presenting cells (B-lymphocytes,
dendritic cells and macrophages). Within the DR molecule the beta chain
contains all the polymorphisms specifying the peptide binding specificities.
Typing for these polymorphisms is routinely done for bone marrow and kidney
transplantation.
HLA-DRB4 has been shown to have an association with Type 1 diabetes
mellitus, the insulin gene, and CTLA4[163]. It has an associated with the
development of vitiligo an autoimmune condition affecting the skin [164]. It
has also been shown to have an association with sinonasal polyposis [165].
The clinical significance of these findings is that there is an auto-immune
element that is more likely to be induced in the deceased donor group. Chronic
allograft nephropathy is a condition that causes long term deterioration in graft
function and graft loss and represents cumulative and incremental damage to
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nephrons from time-dependent immunologic and non-immunologic causes
[166].
Interestingly tacrolimus immunosuppression is more commonly given to living
donor recipients and has been shown to be more diabetogenic than cyclosporin
[167]. The finding that HLA-DRB4 is upregulated in the deceased donors
would suggest that there should be a higher incidence of diabetes among this
group. This hypothesis is however, complicated by the fact that many deceased
donors are converted to tacrolimus when they exhibit evidence of progressive
deterioration in renal function [125]. Further analysis of the diabetic status of
patients was outside of the scope of this study.
Patients who developed new onset diabetes after transplantation have been
shown to have a remission rate of 42% following conversion from tacrolimus
to Cyclosporin. Renal graft and patient survival rates were equivalent to the
group that remained on tacrolimus. There was no increase in the rate of chronic
rejection[168] .
The clinical implication of these findings is that if HLA-DRB4 expression is
seen to be high then cyclosporine immunosuppression would be the preferred
choice of immunosuppression, over the long term, for both deceased and living
donor recipients.
ii. Homo sapiens tumour necrosis factor (ligand) superfamily, member 10
(TNFSF10), mRNA.
This gene was up-regulated by 81.7 fold. The protein encoded by this gene is a
cytokine that belongs to the tumour necrosis factor (TNF) ligand family and is
also known as Tumour necrosis factor (TNF) related apoptosis-inducing ligand
(TRAIL). This protein binds to several members of TNF receptor superfamily.
It preferentially induces apoptosis in transformed and tumour cells, but does
not appear to kill normal cells although it is expressed at a significant level in
most normal tissues[169]. Song et al performed immunohistochemical staining
of rejected compared with normal renal tissue. TRAIL was strongly expressed
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both in the cell membrane and plasma of renal proximal and distal convoluted
tubules of rejected tissues [170].
TRAIL was significantly upregulated in the deceased donor group compared to
the living donor group. This would suggest that cells expressing TRAIL are
susceptible to apoptosis and would explain why its increased expression in the
deceased donor group is associated with a poorer outcome secondary to
increased rejection episodes, graft deterioration and loss. It therefore has a
potential as a biomarker for apoptosis and graft damage. Patients in whom
TRAIL was raised would require closer monitoring, possible biopsy to exclude
a reversible cause and consideration of change in immunosuppression.
iii. Proteolipid protein 2 (PLP2)
PLP2 was up-regulated 14.7 fold. It is a chemokine that binds to CCR1, which
plays important roles in immune and inflammatory responses. Over expression
of PLP2 stimulated a twofold increase in the agonist-induced migration of
Human osteogenic sarcoma (HOS)/CCR1 cells, implicating a functional role
for PLP2 in the chemotactic processes via CCR1 [171].
PLP2 may therefore have a role in the monitoring of the immune /
inflammatory response that follows transplantation or used to assess the
response at any time of graft dysfunction. It would therefore alert the physician
to closely monitor graft function and intervene at an earlier stage.
4.1.1.2 Down-regulated genes
A set of genes were down-regulated in the deceased donor group compared to
the living donor group. The amount of down-regulation was between -2.7 and -
235 times. The overall functions of these genes are the same as those functions
of the up-regulated genes. Gene ontology does not differentiate between up and
down-regulated; it merely identifies the differentially expressed process.
Therefore, at a cellular level the majority of genes functioned at the cell and
plasma membrane, within the cytoplasm, mitochondria and within the nucleus.
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Molecular functions involving binding, transporter and catalytic activity and
biological processes involving cellular physiological and communication
processes contained the majority of down-regulated genes.
The genes that were identified were down-regulated in the deceased donor
group; however, they could also potentially indicate processes that were not
changed in the deceased donor group but were expressed at higher levels in the
living donor group giving an overall negative value of different expression, If
this is the case then the processes identified could be seen as ‘protective’.
These genes may also represent genes that were up-regulated in the deceased
donors group, but to a lesser degree (equal to the fold change) compared to the
living donor group, hence have a negative differential value. As before the first
explanation is more likely, however, it is the identification of the process that
may be of potential clinical relevance.
The most negatively differentially expressed genes found in the dataset were:
i. Homo sapiens glutamine and serine rich 1 (QSER1), mRNA
This is a theoretical gene. It was negatively expressed in the deceased donor
group by 235 fold. No reports of its function are found in the literature. It is of
interest, however, and is an area of potential further research. Its use would be
as a surrogate marker of graft function.
ii. Homo nephrosis 1 homolog, nephrin (human) (NPHS1)
NPHS1 was negatively expressed by 160 times. This novel gene has been
found to be defective in patients with congenital nephrotic syndrome of the
Finnish type (CNF) leading to abnormal expression of the respective protein
product nephrin in glomerular cells [172]. CNF patients treated with
nephrectomy and renal transplantation have a 20% chance of recurrence of
nephrotic syndrome (NS). Wang et al found an increased antibody titre to
nephrin prior to the NS [172]. There results showed that a transplantation
induced production of autoantibodies occurred, pathogenic to the glomerular
filtration barrier function. This gene was significantly down-regulated in the
deceased group suggesting that down-regulation of the normal gene may lead
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in the long term to abnormal function of the glomerular membrane. Nephrin
therefore, could be used as a surrogate biomarker where reduced titres would
alert the physician to the potential development of nephrotic syndrome and
graft deterioration.
The recurrence of proteinuria following transplantation is associated with
allograft glomerular pathology[173], and gives a theoretical explanation of why
reduced expression of the normal gene leads to a pathological deterioration in
graft function.
iii. Homo sapiens cell division cycle 6 homolog (CDC6), mRNA.
CDC6 was down-regulated 92 fold. The protein encoded by this gene is
essential for the initiation of DNA replication[174]. It functions as a regulator
at the early steps of DNA replication and localizes in the cell nucleus during
cell cycle G1, but translocates to the cytoplasm at the start of S phase. Lau et al
showed that depletion of Cdc6 in synchronous G1 cells blocks G1 to S
transition, confirming the role of Cdc6 in the initiation of DNA replication. In
contrast, depletion of Cdc6 in synchronous S-phase cells slowed DNA
replication and led to mitotic lethality. These results show that Cdc6 is not only
required for G1 origin licensing (the initiation of DNA replication), but is also
crucial for proper S-phase DNA replication that is essential for DNA
segregation during mitosis.
Significant down-regulation in this gene in the deceased donor may reduce the
graft’s capacity to regenerate and repair leading to accelerated cell and hence
graft loss. It could therefore be used to alert the physician to a graft that is
potentially failing in order to institute supportive diagnostic and therapeutic
measures, including the modification of immunosuppression.
Hierarchical clustering of significantly differentially expressed genes identified
by SAM (FDR 0%) revealed two main groups of genes. Group A refers to
genes that were down-regulated in the deceased versus living donor group.
Group B refers to genes that were up-regulated in the deceased donor group. In
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order to look at these in a more biologically relevant way, pathway analysis
was performed with this dataset and correlated with a literature search for
transplantation and inflammation using the Medscan search tool within the
pathway studio program.
Gene Ontology found that significant data distributed to Cellular components
was mainly involved in processes incorporating the cell or plasma membrane
and within the cytoplasm and nucleus. Catalytic activity, signal transducer and
transcription regulator activity contained the majority of genes within the
molecular processes category. Signal transduction, cellular metabolism and
response to stimulus (including immune response) contained the majority of
genes within the category biological processes.
Gene ontology mapping is not specific enough to indicate which genes are
implicated in graft events; this specific data can be found using SAM. Gene
Ontology does, however, give a breakdown and visual representation of
microarray data and highlight the areas of interest from which we can go back
to the raw data to analyse in more detail and can suggest areas where further
research should be undertaken.
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Pathway analysis identified the following pathways that were significantly
differentially expressed between deceased and living donors.
A. Death Receptor Pathway, DR3 / DR4 Pathway , Inhibition of Apoptosis
B. Epidermal Growth Factor Signalling
C. IFN-ĮȕȖ(*)
Pathway A - Death Receptor Pathway, DR3 / DR4 Pathway and (Inhibition of)
Apoptosis Pathway.
Death receptors are cell surface receptors that transmit apoptosis signals
initiated by death ligands [175]. They play a central role in apoptosis.
Apoptosis is specifically induced via signalling through the tumour necrosis
factor (TNF) receptor gene superfamily which includes Fas, TNFR, DR3, 4 and
5. Death receptor ligands characteristically initiate signalling via receptor
oligomerization, recruitment of specialized adaptor proteins and activation of
caspase cascades [176].
Established death receptors are CD95 (also called Fas or Apo1) and TNFR1
[177] Additional death receptors include death receptor 3 (DR3) and DR4.
DR3 promotes apoptosis via the adaptor proteins TRADD/FADD and the
activation of caspase 8. The ligands that activate these receptors are structurally
related molecules that belong to the TNF gene superfamily [178]. Apo2 ligand
(Apo2L, also known as TRAIL) binds to DR4 [179].
Activated caspase 8 stimulates apoptosis via two parallel cascades: it cleaves
and activates caspase-3, and cleaves Bid (a Bcl-2 family protein) [180]. DR-3L
can deliver pro- or anti-apoptotic signals. DR-3 promotes apoptosis via the
adaptor proteins TRADD/FADD and the activation of caspase 8. Alternatively
apoptosis is inhibited via an adaptor protein complex including RIP which
activates NF-kB and induces survival genes including IAP.
TRAIL was a identified in this study and was fond to be up-regulated by 81.7
fold. The clinical implications are that if pro apoptotic signals such as TRAIL
are identified then the physician is alerted and is able to employ supportive
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measures should the transplanted graft develop dysfunction. If anti-apoptotic
signals are identified then this can be seen as a good prognostic indicator of
graft function and survival.
Pathway B – Pro-Epidermal Growth Factor Receptor signalling pathway.
This pathway contained significantly differentially expressed genes. Pro-
epidermal growth factor precursor (EGF) was one gene that was identified in
the SAM dataset (FDR 5%). It was downregulated by 2.5 fold. The epidermal
growth factor receptor (EGFR) signalling pathway regulates growth, survival,
proliferation and differentiation in the mammalian cell [181]. The epidermal
growth factor (EGF) peptide induces cellular proliferation through the EGF
receptor. The proliferative effects of EGF are signalled through several
pathways. The EGF receptor activates ras and the MAP kinase pathway,
ultimately causing phosphorylation of transcription factors such as c-Fos to
create AP-1 and ELK-1 that contribute to proliferation. Activation of STAT-1
and STAT-3 transcription factors by JAK kinases in response to EGF
contributes to proliferative signalling.
Smooth muscle proliferation along with lymphocyte proliferation is implicated
in chronic allograft nephropathy as a cause of graft deterioration [182].
Mycophenolate mofetil has been shown to reduce the rate of decline in renal
function in patients with established chronic allograft nephropathy [183].
The clinical implications of this would be that the detection of differentially
expressed genes such as Pro-epidermal growth factor precursor (EGF)
pathway would alert the physician to the possibility of the development or
progression of chronic allograft nephropathy. This may prompt a change in
immunosuppression to an agent such as mycophenolate mofetil or to the
reduction / cessation of calcineurin inhibitor.
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Pathway C - IFN-ĮȕȖand EGF Pathway.
Interferons have several effects in common. They are antiviral and possess
antioncogenic properties. They activate macrophage and natural killer T-
lymphocytes and through the major histocompatibility complex present foreign
peptides to T cells.
Interferon alpha plays a role in viral infections. Signalling takes place through
an IFN Receptor complex consisting of two alpha chains (Type I receptor)
complexed with Jak1 and Tyk2. These kinases phosphorylate STAT1 and
STAT 2 respectively.
STAT family members are phosphorylated in response to cytokines and growth
factors, by the receptor associated kinases, and then form heterodimers that
translocate to the cell nucleus where they act as transcription activators.
STAT1 can be activated by various ligands including interferon-alpha,
interferon-gamma, EGF, PDGF and IL6. The protein mediates the expression
of a variety of genes thought to be important for cell viability in response to
different cell stimuli and pathogens. Two transcript variants encoding distinct
isoforms have been described.[134, 184].
Interferon gamma is secreted from CD4+ Th1 cells, CD8 cells, gamma/delta T
cells and activated NK cells. It plays a role in activating lymphocytes to
enhance anti-microbial and anti-tumour effects. In addition it plays a role in
regulating the proliferation, differentiation, and response of lymphocyte
subsets. Signalling takes place through the IFN receptor complex.
The clinical significance of monitoring expression of the interferons is likely to
be limited. They play a complex role in the cytokine network and may
therefore have a more important role in the monitoring of the immune or
inflammatory responses but whose actions appear to be too generalised to be of
any specific monitoring or predictive value.
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4.1.2 Deceased Donors (Immediate function) versus all donors (Deceased
and Living), with Moderate / Poor / Non-function.
The purpose of this sub-analysis was to potentially identify genes or groups of
genes that were differentially expressed in deceased donor kidneys that
functioned well from the outset to all other kidneys from both sources that did
not. This analysis would potentially indicate processes that were present in the
graft at the time of biopsy prior to the process becoming apparent clinically.
Differential expressed processes may also be caused by the difference in donor
source.
Kidneys that did not function immediately or at all did so for a number of
clinical reasons:
Delayed graft function
Vascular thrombosis
Acute Rejection
Drug Toxicity
Unknown
This analysis would not be able to differentiate between the above clinical
scenarios as causes of graft dysfunction; to do so would create much smaller
groups, the sub-analysis of which highly unlikely to be of statistical or clinical
significance.
Supporting data was identified by SAM (FDR 5%) in the deceased donor
immediate function vs. non-immediately functioning kidneys. SAM detected
109 significantly differentially expressed genes. Hierarchical clustering of
these genes did not show any grouping of genes related to donor type
(deceased or living).
Gene ontology revealed identified genes to be involved in cell membrane,
nucleus and cytoplasm activities. The rest of the significantly differentially
expressed genes were spread over many processes. Many of the cellular
processes involved were happening in the cytoplasm. Binding and catalytic
processes were the predominant processes occurring under the term molecular
function. Cellular metabolism was represented with the most number of
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differentially expressed genes. These finding are not unexpected and represent
the fact that different processes were occurring in the cytoplasm of kidneys that
functioned well compared to those that did not.
Tumour necrosis factor type 1 receptor associated protein (TRAP 1) was down-
regulated by 2.2 fold. It has been found to be suppressed by beta-
Hydroxyisovalerylshikonin (beta-HIVS), a compound isolated from the
traditional oriental medicinal herb Lithospermum radix and VP-16 an inhibitor
of the enzyme topoisomerase II [185]. They are ATP non-competitive
inhibitors of protein-tyrosine kinases, such as EGFR, and induce apoptosis in
various lines of human tumour cells. The suppression of the level of TRAP1 by
beta-HIVS or VP16 was blocked by N-acetyl-cysteine, indicating the
involvement of reactive oxygen species (ROS) in the regulation of TRAP1
expression. These results suggest that suppression of TRAP1 expression in
mitochondria may have an important role in the induction of apoptosis caused
by the formation of reactive oxygen species [185].
Im et al found that deferoxamine (DFO) treatment to TRAP1-overexpressing
cells resulted in decreases in levels of ROS, Cav-1, glutathione peroxidase
(GPX), manganese superoxide dismutase (MnSOD) levels and senescence-
associated beta-galactosidase (SA beta-gal) activity. These results suggest that
TRAP1 may play a role in protecting mitochondria against damaging stimuli
via decrease of ROS generation [186] .
These finding are in keeping with the clinical scenario; possibly identifying
processes which explain a difference in kidneys that function well from the
outset (immediate function) to those that do not. Therefore TRAP-1 has the
potential to be a biomarker for apoptosis and/or mitochondrial damage. Also,
TRAP-1 expression has been shown to be suppressible by beta-HIVS, VP16
and DFO thus indicating a possible therapeutic role.
TRAP-1 was not recognised by Gene ontology mapping. The reason for this is
likely to be that although the record has had preliminary review of the
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sequence by NCBI Reference Sequences (RefSeq) it has not yet been subject to
final review.
The other main groups of genes belonged to cellular and biological processes
that are of unknown function. These genes are of interest as they may represent
novel genes that could have the potential to serve as biomarkers.
Pathway analysis identified a number of genes. One of those was the RET
(rearranged during transfection) proto-oncogene. This is a member of the
cadherin superfamily, which encodes one of the receptor tyrosine kinases cell-
surface molecules that transduce signals for cell growth and differentiation. It
is associated with the development of various tumours.
Another oncogene, BCL3 identified by pathway analysis has recently been
described by Kusaka et al. They performed global expression analysis on brain
dead rats (equivalent to deceased donors) and found BCL3 to be one of 22
upregulated genes. They postulated that the presence of these genes may pose
as novel target genes for treatment and prognosis of grafts from brain-dead
donors [187].
CD-63 has been used as a marker of response to treatment with the platelet
activation inhibitor Lipo PGE1 during acute rejection episodes. Zhang et al
randomly assigned forty patients with acute rejection after kidney
transplantation into groups treated with or without Lipo PGE1. Compared with
controls, the expression levels of CD61, CD63, and PAC-1 were lower among
acute rejection patients who received Lipo PGE1 therapy. Their 1-year patient
and graft survival rates were higher. They concluded that Lipo PGE1 therapy
in patients with acute rejection episodes may benefit graft functional recovery
via the inhibition of platelet activation [188].
Results found in this thesis corroborate other authors’ findings. Interestingly
CD-63 has been used as a biomarker that is measured in the peripheral blood.
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This adds evidence to suggest that novel genes identified by microarray
analysis may have a diagnostic and monitoring role in transplantation.
Prostaglandin D synthase also known as ß-Trace protein (BTP) was
downregulated by 1.4 fold. It is a 23- to 29-kDa enzyme that has been proposed
as an alternative marker for GFR in children and in people with diabetes or
various renal diseases [189], The protein encoded by this gene is a glutathione-
independent prostaglandin D synthase that catalyzes the conversion of
prostaglandin H2 (PGH2) to prostaglandin D2 (PGD2).
Based on the authors results, they believe that serum levels of Prostaglandin D
synthase may be a useful and reliable biomarker to estimate GFR[190]. The
implication here is that microarray analysis can identify biomarkers that can
also be measured in serum to estimate and monitor graft function.
.
SPP1 (also known as Osteopontin and early T-lymphocyte activation 1 (Eta-1))
has been shown to influence the type I immune response. Ashkar et al
identified Eta-1 as a key cytokine integral to efficient type-1 immune responses
through differential regulation of macrophage IL-12 and IL-10 cytokine
expression [191]. Cell-mediated immunity is necessary for immune protection
against most intracellular pathogens. When excessive it can mediate an organ-
specific autoimmune response. Autoimmunity has been implicated in the
development of chronic allograft nephropathy [192]. Sirolimus is an
immunosuppressant with potent antiproliferative actions and represents a
therapeutic option in the prevention of acute renal allograft rejection and
chronic allograft nephropathy [193].
The implications of these findings are, therefore, that SPP1 has the potential as
a biomarker to indicate the level of activity of the immune response and where
appropriate, the use of immunosuppression can modify this response in the
hope that acute rejection and chronic allograft nephropathy can be prevented or
reversed, so improving the function and longevity of the graft.
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4.1.3 Deceased Donors (Immediate function) vs. Deceased donors with
Moderate / Poor function / Non function
Being sourced from the same type of donor these kidneys should have, in
theory experienced similar events preceding transplantation. The difference
between this analysis and the analysis in scenario B is that all those factors that
could be explained by brain stem death and the autonomic insult are the same
for both groups. This should, therefore, highlight different processes unique to
one or other group that may explain why otherwise similar kidneys have very
different outcomes. Upregulated processes in the deceased donor group with
immediate function would be deemed ‘protective’, whereas downregulated
processes would be thought to be ‘damaging’. Conversely an upregulated
process in the deceased group with poor or non-function would be deemed as
‘damaging’ whereas a downregulated process may have a ‘protective’ role. The
mechanism behind this difference in clinical outcome may involve pre-existing
donor and recipient factors, environmental and unknown factors.
SAM analysis of the group DD (IF) vs. DD immediate / poor function /non
function (early and late) (FDR 0) produced two genes in common with the
analysis of the group DD (Immediate function) versus all donors (Deceased
and Living) with Moderate / Poor / Non-function. This finding is to be
expected as in the case of this analysis the same dataset is being analysed
minus data taken from living donor samples. Thus some of the pre-
transplantation factors are removed.
The genes prostaglandin D2 synthase and TNF receptor-associated protein 1
(TRAP1) were significantly differentially expressed in this analysis. As data
from the living donor group was removed it is likely, therefore, that these
genes were differentially expressed in deceased donors that had immediate
function and deceased donors that did not.
This suggests that TRAP1 suppression may lead to a reduction in reactive
oxygen species suppression and hence apoptosis in the deceased donor group
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causing graft dysfunction and loss. Whether or not changes in expression of
TRAP1 and its potential for monitoring and therapeutic options, are limited to
deceased donor recipients, is a further area for potential research. With regard
to Prostaglandin D synthase its role in monitoring renal function in living
donors would also be a subject for further research.
Homo sapiens transmembrane protein 29 is a novel protein that was down –
regulated by 10.5 fold. It’s function has not yet been described. Homo sapiens
NADH dehydrogenase (ubiquinone) was down-regulated 15.2 fold. It has been
associated with a systemic lupus erythematosus like disease (an autoimmune
disease) in the mouse. No human function has yet been described. The gene
sequence for the protein Homo sapiens cDNA FLJ13235 fis, clone
OVARC1000304, highly similar to PROTEIN MOV-10 has been described,
however no function has as yet been found. Homo sapiens hypothetical protein
FLJ10154 is another gene found to be differentially expressed in this dataset
that is awaiting confirmation of its gene sequence and has no known function.
These genes may therefore have a role as potential biomarkers that should be
investigated in future research.
4.1.4 Comparison of genes identified between groups
Comparison of Deceased Donors (Immediate function) versus Living Donors
(Immediate function) – Scenario A and Deceased Donors (Immediate function)
versus Deceased Donors (Moderate / Poor / Non-function) - Scenario C
It is interesting to observe that far fewer genes were found to be significantly
differentially expressed in this analysis of Scenario A than in the analysis of
Scenario C. The essential difference between the analyses was that the
comparison group in the first analysis were samples that were also functioning
well. The comparison group in Scenario C contained samples from donors
whose kidneys functioned poorly. It may be expected that many genes and
processes would be identified as being differentially expressed in these very
different groups. However, it may be the case that the small numbers of gene
identified reflects the possibility that the poor and non-functioning kidneys
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were damaged to such an extent that normal cellular processes were not
occurring and therefore not expressed. Another explanation is that the data
representing those genes that would account for the poor function of kidneys
was filtered out in the data processing stage.
4.1.5 Urinary Markers / Peripheral Blood Markers.
Although this study did not attempt to identify biomarkers using any methods
other that microarray, it did find upregulated pathways containing genes that
other authors have found can be used as non-invasive biomarkers. With regard
to predicting the presence of acute rejection there is accumulating evidence that
non-invasive immune monitoring may be useful in the early period after renal
transplant Muthukumar et al found that the measurement of FOXP3 mRNA in
urine could be used as a non-invasive means of improving the prediction of
outcome of acute rejection in renal transplants [194]. Mas et al measured
transforming growth factor (TGF), epidermal growth factor receptor (EGFR)
and angiotensinogen (AGT) in urine and peripheral blood samples from the
patients with chronic allograft nephropathy. They found that gene expression
levels of the studied markers in urine samples were more representative of the
gene expression in the kidney biopsies than in the peripheral blood samples.
Magee et al used flow cytometry to quantify cytokine production in peripheral
blood cells of renal transplant recipients [195]. The technique was sensitive
enough to detect differences between transplant recipients and healthy controls
but could not find differences between recipients with or without CAN.
Recently proteomics has been used in the development of urine biomarkers for
detection of renal allograft rejection [196].
This analysis has found many significantly differentially expressed genes
across many pathways, some of which have been investigated by other authors
and found to have a potential role as urinary biomarkers. Further consideration
of the results of this analysis should be made to assess the potential of
significant genes already identified as urinary biomarkers. Ideally further
studies should involve the use of microarray in conjunction with urine analysis.
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5 CONCLUSIONS AND FURTHER RESEARCH
It is usual that a patient experiencing acute graft dysfunction is subject to
hospitalisation, multiple blood tests and a transplant biopsy. The biopsy
procedure carries significant morbidity [197] and even mortality.
This study has identified potential biomarkers which may facilitate the
detection and monitoring of graft dysfunction and guide treatment strategies in
terms of modification of immunosuppression and other supportive measures.
A number of potential biomarkers were identified in this study. They may have
a role in monitoring the immune / inflammatory response central to the graft
/host response in transplantation. They include molecules which have been
shown to indicate graft dysfunction in terms of general (e.g. apoptosis)[179]
and specific (e.g. nephrotic syndrome) disease processes[172] . They may also
have a role in monitoring disease processes that have multiple aetiologies (e.g.
chronic allograft nephropathy)[183], or in monitoring the grafts capacity to
recover its function [188]. Many significantly differentially expressed genes
were identified that are not as yet fully described in terms of structure and
function but may have a role as potential biomarkers. There is also evidence to
suggest that the process underlying the expression of some potential
biomarkers identified can be influenced by pharmaceuticals [185, 186], thus
producing a change in its expression, and therefore, such biomarkers may find
application in monitoring therapeutic regimes.
It remains to be seen whether or not the use of biomarkers can fulfil these roles
and be used clinically to predict and monitor graft function, to inform patient
management and have a positive effect on the function and longevity of the
graft.
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Further Research
This study has found many interesting genes, some of which may have roles as
biomarkers. The realisation of these findings will clearly require validation and
warrant further investigation.
In addition, further genes of interest may be identified by the use of other
analysis methods. The microarray contained approximately 30,000 genes and
the dataset analysed contained 1802 genes, through the use of one or a
combination of user defined filters. Adjusting the filters would therefore give
different or larger datasets which may contain useful data.
Since the beginning of these studies, microarray technology has advanced
further. It is now possible to have a four-channel array i.e. one control and 3
test samples. This would allow the analysis of, for example, the pre-
transplantation biopsy, a biopsy taken at the time of acute rejection and a
protocol biopsy taken after 6 months. As there would be far less opportunity
for inter (or in this example, intra) experimental variation, the data would
require far less stringent filtering and normalisation and, therefore, maximise
the amount of data suitable for analysis.
One disadvantage of studying the gene expression of kidney allografts is that
the tissue samples that are obtained by biopsy may contain all or fewer
component parts of the kidney (e.g. capsule, cortex, medulla, collecting system
etc). It may be that the important processes only occur in specific areas. Laser
micro-dissection is a new technique that can dissect specific areas of tissue
such as the glomerulus for gene expression analysis [149].
In order to confirm and extend the findings of this study it would be necessary
to expand the sample set studied. The experimental design that is chosen
should be tried and tested. It should include other analyses such as real-time
PCR and Western Blotting to validate / quantify the results.
Immunohistochemistry and in-situ hybridisation have a role in identifying
where biomarkers are expressed at a cellular and tissue level. Laser micro-
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dissection could be used to obtain these specific tissues of interest. It would be
reasonable to include the use of a four channel microarray for the reasons
outlined above.
Proteomics is a developing technique that has been shown to be a valuable tool
for biomarker discovery [196]. There is currently much interest in the
development of urine biomarkers for detection of renal allograft rejection as an
alternative to needle biopsy. In comparison to microarray analysis (genomics),
proteomics is more complicated because the proteome is variable and
constantly changing. The apparent discrepancy between the number of genes in
the genome and number of proteins in the proteome (~30,000 vs. ~500,000)
can be explained by mechanisms such as alternative splicing, protein
modification and degradation. Hence products of transcription may give rise to
more than one protein or may experience a post-translational modification such
as phosphorylation or may interact with other protein molecules. Furthermore,
gene expression does not necessarily reflect the level of protein transcription
and vice versa.
The targeted use of proteomics in the development of urinary biomarkers has
recently been described [196, 198]. Its role in global molecular analyses would
appear to be more limited in its current stage of development. The
determination of biomarkers in transplantation probably requires a combination
of both approaches.
Once biomarkers have been identified and validated, further in vivo studies
using animal models would be required to further validate them prior to
commencing human studies. Human studies would need to be undertaken
ideally in the form of a randomised controlled clinical trial. The design of such
a trial would depend on the type of biomarkers identified and the way in which
they are to be measured. For example, the control group would have standard
care. The test group would have in addition, biomarker monitoring and its
predetermined changes to protocol based on biomarker expression, to see if the
use of measuring biomarkers in kidney transplantation has a real effect.
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Such a study should be co-ordinated by a central body or bodies such as the
British Transplantation Society, and should be performed in centres with a
proven track record in kidney transplantation and an established microarray
facility. There should be an agreed experimental protocol and standards set.
New legislation is currently going through Parliament making consent to organ
donation presumed unless a decision to opt out is actively made. This will go
some way to address the supply and demand mismatch however, it is hoped
that the results of these and future studies contribute to improving graft
survival.
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